
<html lang="en"     class="pb-page"  data-request-id="4a1d233d-fc40-48ce-ba3d-2bb4ecf7dc8e"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;issue:issue:10.1021/jmcmar.2014.57.issue-6;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/jm401958n;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Discovery of a Tetracyclic Quinoxaline Derivative as a Potent and Orally Active Multifunctional Drug Candidate for the Treatment of Neuropsychiatric and Neurological Disorders" /></meta><meta name="dc.Creator" content="Peng  Li" /></meta><meta name="dc.Creator" content="Qiang  Zhang" /></meta><meta name="dc.Creator" content="Albert J.  Robichaud" /></meta><meta name="dc.Creator" content="Taekyu  Lee" /></meta><meta name="dc.Creator" content="John  Tomesch" /></meta><meta name="dc.Creator" content="Wei  Yao" /></meta><meta name="dc.Creator" content="J. David  Beard" /></meta><meta name="dc.Creator" content="Gretchen L.  Snyder" /></meta><meta name="dc.Creator" content="Hongwen  Zhu" /></meta><meta name="dc.Creator" content="Youyi  Peng" /></meta><meta name="dc.Creator" content="Joseph P.  Hendrick" /></meta><meta name="dc.Creator" content="Kimberly E.  Vanover" /></meta><meta name="dc.Creator" content="Robert E.  Davis" /></meta><meta name="dc.Creator" content="Sharon  Mates" /></meta><meta name="dc.Creator" content="Lawrence P.  Wennogle" /></meta><meta name="dc.Description" content="We report the synthesis and structure–activity relationships of a class of tetracyclic butyrophenones that exhibit potent binding affinities to serotonin 5-HT2A and dopamine D2 receptors. This work..." /></meta><meta name="Description" content="We report the synthesis and structure–activity relationships of a class of tetracyclic butyrophenones that exhibit potent binding affinities to serotonin 5-HT2A and dopamine D2 receptors. This work..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="March 5, 2014" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm401958n" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2014 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm401958n" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm401958n" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm401958n" /></link>
        
    
    

<title>Discovery of a Tetracyclic Quinoxaline Derivative as a Potent and Orally Active Multifunctional Drug Candidate for the Treatment of Neuropsychiatric and Neurological Disorders | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm401958n" /></meta><meta property="og:title" content="Discovery of a Tetracyclic Quinoxaline Derivative as a Potent and Orally Active Multifunctional Drug Candidate for the Treatment of Neuropsychiatric and Neurological Disorders" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-6/jm401958n/production/images/large/jm-2013-01958n_0010.jpeg" /></meta><meta property="og:description" content="We report the synthesis and structure–activity relationships of a class of tetracyclic butyrophenones that exhibit potent binding affinities to serotonin 5-HT2A and dopamine D2 receptors. This work has led to the discovery of 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-1-(4-fluorophenyl)-butan-1-one 4-methylbenzenesulfonate (ITI-007), which is a potent 5-HT2A antagonist, postsynaptic D2 antagonist, and inhibitor of serotonin transporter. This multifunctional drug candidate is orally bioavailable and exhibits good antipsychotic efficacy in vivo. Currently, this investigational new drug is under clinical development for the treatment of neuropsychiatric and neurological disorders." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm401958n"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm401958n">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm401958n&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm401958n&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm401958n&amp;href=/doi/10.1021/jm401958n" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2014</span><span class="cit-fg-volume">, 57</span><span class="cit-fg-issue">, 6</span><span class="cit-fg-pageRange">, 2670-2682</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/57/6" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm401921j" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/jm401982j" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of a Tetracyclic Quinoxaline Derivative as a Potent and Orally Active Multifunctional Drug Candidate for the Treatment of Neuropsychiatric and Neurological Disorders</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Peng++Li">Peng Li</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Qiang++Zhang">Qiang Zhang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Albert+J.++Robichaud">Albert J. Robichaud</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Taekyu++Lee">Taekyu Lee</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=John++Tomesch">John Tomesch</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Wei++Yao">Wei Yao</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=J.+David++Beard">J. David Beard</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Gretchen+L.++Snyder">Gretchen L. Snyder</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hongwen++Zhu">Hongwen Zhu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Youyi++Peng">Youyi Peng</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Joseph+P.++Hendrick">Joseph P. Hendrick</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kimberly+E.++Vanover">Kimberly E. Vanover</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Robert+E.++Davis">Robert E. Davis</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sharon++Mates">Sharon Mates</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Lawrence+P.++Wennogle">Lawrence P. Wennogle</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">Intra-Cellular Therapies, Inc., 3960 Broadway, New York, New York 10032, United States</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">Medicinal Chemistry, Bristol-Myers Squibb Research and Development, Princeton, New Jersey 08543, United States</span></div><div class="aff-info" id="aff3"><span class="aff-symbol">§</span> <span class="aff-text">3D Pharmaceutical Consultants, Inc., 13272 Glencliff Way, San Diego, California 92130, United States</span></div><div class="corresp-info"><strong>*</strong>Phone: 212−923−3344. Fax: 212−923−3388. E-mail: <a href="/cdn-cgi/l/email-protection#e7978b8ea78e8993958684828b8b928b8695938f829586978e8294c984888a"><span class="__cf_email__" data-cfemail="cabaa6a38aa3a4beb8aba9afa6a6bfa6abb8be">[email protected]</span>herapies.com</a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm401958n&amp;href=/doi/10.1021%2Fjm401958n" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2014</span></span><span class="cit-volume">, 57</span><span class="cit-issue">, 6</span><span class="cit-pageRange">, 2670–2682</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">February 21, 2014</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>20 December 2013</li><li><span class="item_label"><b>Published</b> online</span>5 March 2014</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 27 March 2014</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm401958n" title="DOI URL">https://doi.org/10.1021/jm401958n</a></div><div class="article_header-article-copyright"><strong>Copyright © 2014 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D2670%26pageCount%3D13%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DPeng%2BLi%252C%2BQiang%2BZhang%252C%2BAlbert%2BJ.%2BRobichaud%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D57%26issueNum%3D6%26contentID%3Djm401958n%26title%3DDiscovery%2Bof%2Ba%2BTetracyclic%2BQuinoxaline%2BDerivative%2Bas%2Ba%2BPotent%2Band%2BOrally%2BActive%2BMultifunctional%2BDrug%2BCandidate%2Bfor%2Bthe%2BTreatment%2Bof%2BNeuropsychiatric%2Band%2BNeurological%2BDisorders%26numPages%3D13%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D2682%26publicationDate%3DMarch%2B2014">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm401958n"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">3346</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">33</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm401958n" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of a Tetracyclic Quinoxaline Derivative as a Potent and Orally Active Multifunctional Drug Candidate for the Treatment of Neuropsychiatric and Neurological Disorders&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Peng&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Qiang&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Albert&quot;,&quot;last_name&quot;:&quot;J. Robichaud&quot;},{&quot;first_name&quot;:&quot;Taekyu&quot;,&quot;last_name&quot;:&quot;Lee&quot;},{&quot;first_name&quot;:&quot;John&quot;,&quot;last_name&quot;:&quot;Tomesch&quot;},{&quot;first_name&quot;:&quot;Wei&quot;,&quot;last_name&quot;:&quot;Yao&quot;},{&quot;first_name&quot;:&quot;J.&quot;,&quot;last_name&quot;:&quot;David Beard&quot;},{&quot;first_name&quot;:&quot;Gretchen&quot;,&quot;last_name&quot;:&quot;L. Snyder&quot;},{&quot;first_name&quot;:&quot;Hongwen&quot;,&quot;last_name&quot;:&quot;Zhu&quot;},{&quot;first_name&quot;:&quot;Youyi&quot;,&quot;last_name&quot;:&quot;Peng&quot;},{&quot;first_name&quot;:&quot;Joseph&quot;,&quot;last_name&quot;:&quot;P. Hendrick&quot;},{&quot;first_name&quot;:&quot;Kimberly&quot;,&quot;last_name&quot;:&quot;E. Vanover&quot;},{&quot;first_name&quot;:&quot;Robert&quot;,&quot;last_name&quot;:&quot;E. Davis&quot;},{&quot;first_name&quot;:&quot;Sharon&quot;,&quot;last_name&quot;:&quot;Mates&quot;},{&quot;first_name&quot;:&quot;Lawrence&quot;,&quot;last_name&quot;:&quot;P. Wennogle&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2014&quot;,&quot;month&quot;:&quot;03&quot;,&quot;day&quot;:&quot;05&quot;,&quot;issue&quot;:&quot;6&quot;,&quot;volume&quot;:&quot;57&quot;,&quot;pages&quot;:&quot;2670-2682&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm401958n&quot;},&quot;abstract&quot;:&quot;We report the synthesis and structure–activity relationships of a class of tetracyclic butyrophenones that exhibit potent binding affinities to serotonin 5-HT2A and dopamine D2 receptors. This work has led to the discovery of 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-1-(4-fluorophenyl)-butan-1-one 4-methylbenzenesulfonate (ITI-007), which is a potent 5-HT2A antagonist, postsynaptic D2 antagonist, and inhibitor of serotonin transporter. This multifunctional drug candidate is orally bioavailable and exhibits good antipsychotic efficacy in vivo. Currently, this investigational new drug is under clinical development for the treatment of neuropsychiatric and neurological disorders.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm401958n&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm401958n" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm401958n&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm401958n" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm401958n&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm401958n" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm401958n&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm401958n&amp;href=/doi/10.1021/jm401958n" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm401958n" /></input><a href="/doi/pdf/10.1021/jm401958n" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (579 KB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm401958n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm401958n%26sid%3Dliteratum%253Aachs%26pmid%3D24559051%26genre%3Darticle%26aulast%3DLi%26date%3D2014%26atitle%3DDiscovery%2Bof%2Ba%2BTetracyclic%2BQuinoxaline%2BDerivative%2Bas%2Ba%2BPotent%2Band%2BOrally%2BActive%2BMultifunctional%2BDrug%2BCandidate%2Bfor%2Bthe%2BTreatment%2Bof%2BNeuropsychiatric%2Band%2BNeurological%2BDisorders%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D57%26issue%3D6%26spage%3D2670%26epage%3D2682%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291316" title="Mixtures">Mixtures</a>,</li><li><a href="/action/doSearch?ConceptID=291667" title="Vacuum">Vacuum</a>,</li><li><a href="/action/doSearch?ConceptID=292317" title="Ethyl groups">Ethyl groups</a>,</li><li><a href="/action/doSearch?ConceptID=291352" title="Screening assays">Screening assays</a>,</li><li><a href="/action/doSearch?ConceptID=292186" title="Receptors">Receptors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/57/6" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-6/jmcmar.2014.57.issue-6/production/jmcmar.2014.57.issue-6.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-6/jm401958n/production/images/medium/jm-2013-01958n_0010.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-6/jm401958n/production/images/large/jm-2013-01958n_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401958n&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">We report the synthesis and structure–activity relationships of a class of tetracyclic butyrophenones that exhibit potent binding affinities to serotonin 5-HT<sub>2A</sub> and dopamine D<sub>2</sub> receptors. This work has led to the discovery of 4-((6b<i>R</i>,10a<i>S</i>)-3-methyl-2,3,6b,9,10,10<i>a</i>-hexahydro-1<i>H</i>,7<i>H</i>-pyrido[3′,4′:4,5]pyrrolo[1,2,3-<i>de</i>]quinoxalin-8-yl)-1-(4-fluorophenyl)-butan-1-one 4-methylbenzenesulfonate (ITI-007), which is a potent 5-HT<sub>2A</sub> antagonist, postsynaptic D<sub>2</sub> antagonist, and inhibitor of serotonin transporter. This multifunctional drug candidate is orally bioavailable and exhibits good antipsychotic efficacy in vivo. Currently, this investigational new drug is under clinical development for the treatment of neuropsychiatric and neurological disorders.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_30270" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_30270" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Schizophrenia is a chronic neuropsychiatric illness affecting approximately 1% of the global population.<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1, 2)</a> This disorder is characterized principally by the appearance of hallucinations, delusions, agitation, and conceptual disorganization among other so-called positive symptoms. These positive symptoms can be accompanied by varying degrees of social withdrawal, blunted affect and emotion withdrawal, and asociality (negative symptoms) as well as reduction in working memory, attention, and verbal fluency (cognitive dysfunction).<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> The etiology and pathology of schizophrenia remain largely unresolved. Yet a disturbed and hyperactive dopaminergic signal transduction system clearly contributes to some symptoms in this disorder.<a onclick="showRef(event, 'ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref3 ref4">(3, 4)</a> Further, the relative potencies of antipsychotic drugs as dopamine receptor antagonists correlate with their clinical potencies. The first-generation antipsychotics, such as chlorpromazine and haloperidol (<b>1</b>), are potent D<sub>2</sub> receptor antagonists. Use of these agents caused extrapyramidal symptoms (EPS) including tardive dyskinesias and hyperprolactinemia.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> While effective in controlling some of the positive symptoms, these first-generation antipsychotic drugs are relatively ineffective and may exacerbate negative symptoms as well as cognitive dysfunction.</div><div class="NLM_p">The discovery of the dibenzodiazepine, clozapine (<b>2</b>),<a onclick="showRef(event, 'ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref6 ref7">(6, 7)</a> ushered in a new generation of potentially superior antipsychotic drugs. Clozapine was able to block dopamine mediated behavior in animals and exerted antipsychotic effects in humans without EPS or elevation of prolactin levels at efficacious doses. This profile was sufficiently different from the first-generation antipsychotic drugs such that clozapine was labeled “atypical”, and clozapine became the blueprint for the development of other newer so-called atypical antipsychotic drugs. It was later appreciated that clozapine exerted potent antagonist actions at 5-HT<sub>2A</sub> receptors, leading to the study of selective 5-HT<sub>2A</sub> antagonists as stand-alone antipsychotic agents.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> The potent and selective 5-HT<sub>2A</sub> antagonist, MDL-100907 (<b>3</b>), showed activity in several preclinical animal models of antipsychotic activity.<a onclick="showRef(event, 'ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref9 ref10">(9, 10)</a> However, it failed, like other selective 5-HT<sub>2A</sub> antagonists, to exhibit sufficient antipsychotic efficacy in clinical trials, and its development for this indication was discontinued.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a></div><div class="NLM_p">It is now apparent that these second-generation antipsychotics, including clozapine and olanzapine,<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> are antagonists at both serotonin 5-HT<sub>2A</sub> and dopamine D<sub>2</sub> receptors and activity at both of these receptors is necessary for the antipsychotic efficacy by this class of drugs. These atypical antipsychotics are efficacious in controlling the positive symptoms of schizophrenia while reducing the liability for EPS and hyperprolactinemia.<a onclick="showRef(event, 'ref13 ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref13 ref14 ref15">(13-15)</a> However, treatment with these antipsychotics is accompanied by various other side effects such as excessive weight gain, type II diabetes, hyperglycemia, and dyslipidemia,<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> which are primarily caused by high affinity binding to other off-target receptors such as serotonin 5-HT<sub>2C</sub> and histamine H<sub>1</sub> receptors.<a onclick="showRef(event, 'ref16 ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref16 ref17 ref18">(16-18)</a> Therefore, there are still urgent unmet medical needs to develop novel antipsychotics with good in vivo efficacy against a broad array of symptoms that accompany schizophrenia, improved pharmacological properties, and reduced side effect profiles.</div><div class="NLM_p">1,2,7,8,9,10-Hexahydropyrido[3′,4′:4,5]pyrrolo[1,2,3-<i>de</i>][1,4]benzoxazines<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> and 6,7,9,10,11,12-hexahydro-5<i>H</i>-pyrido[3′,4′:4,5]pyrrolo[1,2,3-<i>ef</i>][1,5]benzothiazepines<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> were reported to have antidepressant activity over three decades ago. The corresponding hydrogenated derivatives, (<i>cis</i>)/(<i>trans</i>)-octahydropyridopyrrolo-benzoxazines and benzothiazepines, were also documented.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> However, the biochemical mechanism of action of these compounds was not clear at that time. By linking this (<i>cis</i>)-octahydropyridopyrrolo-benzothiazepine core with 2′-aminobutyrophenone side chains, a series of potent 5-HT<sub>2A</sub> and D<sub>2</sub> antagonists were identified, as represented by compound <b>4</b>.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> In an effort to develop more efficacious and safer antipsychotics based upon these findings, we designed and evaluated a number of polycyclic cores linked with various side chains. By systematically varying ring sizes, heteroatoms, and stereochemistry at different parts of the heterocyclic cores as well as the ring systems and linker types of the side chains, we identified a novel scaffold, 2,3,6b,9,10,10a-hexahydro-1<i>H</i>,7<i>H</i>-pyrido[3′,4′:4,5]pyrrolo[1,2,3-<i>de</i>]quinoxaline and found compounds with this quinoxaline core generally exhibited better physicochemical and pharmacological properties and consequently showed better in vivo efficacy than compounds with other polycyclic cores. This work eventually led to the discovery of the quinoxaline-type compound <b>5</b>, a putative antipsychotic that has recently completed a large multicenter placebo controlled human clinical trial in patients with acutely exacerbated schizophrenia (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>). The synthesis and structure–activity relationships (SAR) of <b>5</b> and its tetracyclic analogues are described in this article, along with their unique receptor binding profiles and efficacy in animal behavioral models.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-6/jm401958n/production/images/medium/jm-2013-01958n_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-6/jm401958n/production/images/large/jm-2013-01958n_0002.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of representative antipsychotics and <b>5</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-6/jm401958n/production/images/large/jm-2013-01958n_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401958n&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_73273" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_73273" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The synthesis of these tetracyclic compounds with various cores and side chains is illustrated in Schemes <a class="ref internalNav" href="#sch1" aria-label="1">1</a>–<a class="ref internalNav" href="#sch3" aria-label="3">3</a>. The general synthetic route used for the preparation of compounds listed in Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a> is depicted in Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>. 3,4-Dihydroquinoxalin-2(1<i>H</i>)-one <b>6</b> was treated with sodium nitrite and acetic acid to give 4-nitroso-3,4-dihydro-quinoxalin-2(1<i>H</i>)-one <b>7</b>, which was reduced with zinc in acetic acid and 2-propanol to afford 4-amino-3,4-dihydroquinoxalin-2(1<i>H</i>)-one. The one-step construction of the tetracyclic core <b>8</b> was accomplished by Fisher-indole cyclization of 4-amino-3,4-dihydroquinoxalin-2(1<i>H</i>)-one with ethyl 4-oxopiperidine-1-carboxylate. Subsequent <i>cis</i>-reduction of <b>8</b> with sodium cyanoborohydride in trifluoroacetic acid afforded the indoline derivative (<i>cis</i>)-<b>9</b>, which was reacted with various alkyl or benzyl halides to give (<i>cis</i>)-<b>10</b>. The (<i>cis</i>)-2,3,6b,9,10,10a-hexahydro-1<i>H</i>,7<i>H</i>-pyrido[3′,4′:4,5]pyrrolo[1,2,3-<i>de</i>]quinoxaline core, (<i>cis</i>)-<b>12</b>, was produced by reduction of (<i>cis</i>)-<b>10</b> with borane in THF, followed by deprotection with potassium hydroxide in <i>n</i>-butanol. The <i>para</i>-fluoro butyrophenone side chain was introduced by <i>N-</i>alkylation under basic conditions to furnish the racemic (<i>cis</i>)-<b>13</b>, which was then resolved by chiral chromatograph to afford the (6b<i>R</i>,10a<i>S</i>)-<b>14</b> (entries <b>31</b>–<b>37</b> and <b>5</b>, Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>) and (6b<i>S</i>,10a<i>R</i>)-<b>15</b> (entries <b>51</b> and <b>54</b>, Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>).</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-6/jm401958n/production/images/medium/jm-2013-01958n_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-6/jm401958n/production/images/large/jm-2013-01958n_0003.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-6/jm401958n/production/images/large/jm-2013-01958n_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401958n&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) NaNO<sub>2</sub>, HOAc, 0–5 °C, 60–80%; (b) Zn, HOAc, 10 °C; (c) ethyl 4-oxopiperidine-1-carboxylate, HOAc, HCl, 100 °C, 40–60% (two steps); (d) NaBH<sub>3</sub>CN, TFA, rt, 85–95%; (e) R<sub>2</sub>X, K<sub>2</sub>CO<sub>3</sub> or NaH, 80–95%; (f) borane, THF, reflux, then 6N HCl, reflux, 85–95%; (g) KOH, <sup><i>n</i></sup>BuOH, reflux, 90–99%; (h) 4-chloro-1-(4-fluorophenyl)butan-1-one, NEt<sub>3</sub>, dioxane, toluene, reflux, 50–70%; (i) chiral HPLC separation, 30–45%.</p></p></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. SAR of Compounds with Variations of Substituents on A- and D-Ring</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-6/jm401958n/production/images/medium/jm-2013-01958n_0006.gif" alt="" id="fx1" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center" char="."><i>K</i><sub>i</sub> (nM)<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">ratio</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">R1</th><th class="colsep0 rowsep0" align="center">R<sub>2</sub></th><th class="colsep0 rowsep0" align="center" char=".">5-HT<sub>2A</sub></th><th class="colsep0 rowsep0" align="center" char=".">5-HT<sub>2C</sub></th><th class="colsep0 rowsep0" align="center">D<sub>2</sub></th><th class="colsep0 rowsep0" align="center" char=".">2C/2A<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">D<sub>2</sub>/2A<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="char" char=".">0.54</td><td class="colsep0 rowsep0" align="char" char=".">173</td><td class="colsep0 rowsep0" align="left">32</td><td class="colsep0 rowsep0" align="char" char=".">320</td><td class="colsep0 rowsep0" align="left">59</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>31</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">0.94</td><td class="colsep0 rowsep0" align="char" char=".">280</td><td class="colsep0 rowsep0" align="left">30</td><td class="colsep0 rowsep0" align="char" char=".">298</td><td class="colsep0 rowsep0" align="left">32</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>32</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">ethyl</td><td class="colsep0 rowsep0" align="char" char=".">2.1</td><td class="colsep0 rowsep0" align="char" char=".">287</td><td class="colsep0 rowsep0" align="left">66</td><td class="colsep0 rowsep0" align="char" char=".">137</td><td class="colsep0 rowsep0" align="left">31</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>33</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">isopropyl</td><td class="colsep0 rowsep0" align="char" char=".">7.5</td><td class="colsep0 rowsep0" align="char" char=".">498</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="char" char=".">66</td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>34</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left"><i>n</i>-butyl</td><td class="colsep0 rowsep0" align="char" char=".">14</td><td class="colsep0 rowsep0" align="char" char=".">240</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="char" char=".">17</td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>35</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">benzyl</td><td class="colsep0 rowsep0" align="char" char=".">4.7</td><td class="colsep0 rowsep0" align="char" char=".">385</td><td class="colsep0 rowsep0" align="left">86</td><td class="colsep0 rowsep0" align="char" char=".">82</td><td class="colsep0 rowsep0" align="left">18</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>36</b></td><td class="colsep0 rowsep0" align="left">Br</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="char" char=".">4.0</td><td class="colsep0 rowsep0" align="char" char=".">582</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="char" char=".">146</td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>37</b></td><td class="colsep0 rowsep0" align="left">MeO</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="char" char=".">3.5</td><td class="colsep0 rowsep0" align="char" char=".">1090</td><td class="colsep0 rowsep0" align="left">46</td><td class="colsep0 rowsep0" align="char" char=".">311</td><td class="colsep0 rowsep0" align="left">13</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>a</sup><p class="last"><i>K</i><sub>i</sub> values are the means of at least two experiments.</p></div><div class="footnote" id="t1fn2"><sup>b</sup><p class="last">Ratio of <i>K</i><sub>i</sub>(5-HT<sub>2C</sub>)/<i>K</i><sub>i</sub>(5-HT<sub>2A</sub>).</p></div><div class="footnote" id="t1fn3"><sup>c</sup><p class="last">Ratio of <i>K</i><sub>i</sub>(D<sub>2</sub>)/<i>K</i><sub>i</sub>(5-HT<sub>2A</sub>). ND stands for not determined.</p></div></div></div><div class="NLM_p">The synthetic route illustrated in Scheme <a class="ref internalNav" href="#sch2" aria-label="2">2</a> was developed to expedite the side chain SAR development at the piperidinyl ring. 2-Bromophenylhydrazine <b>16</b> was treated with 4-piperidone to produce the tricyclic indole derivative <b>17</b>, which upon treatment with triethylsilane in trifluoroacetic acid furnished the racemic indoline derivative (<i>cis</i>)-<b>18</b>. Reaction of (<i>cis</i>)-<b>18</b> with ethyl chloroformate afforded (<i>cis</i>)-<b>19</b>, which was coupled with benzophenone imine, employing Buchwald–Hartwig cross-coupling method,<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> to produce intermediate (<i>cis</i>)-<b>20</b>. <i>N</i>-Substitution of (<i>cis</i>)-<b>20</b> with ethyl bromoacetate and sodium carbonate, followed by acidic hydrolysis of the diphenylketimine moiety and spontaneous ring closure, furnished the tetracyclic intermediate (<i>cis</i>)-<b>21</b>. Subsequent <i>N</i>-methylation with methyl iodide and reduction with borane in THF afforded (<i>cis</i>)-<b>22</b>. Removal of the ethoxycarbonyl protective group from (<i>cis</i>)-<b>22</b> gave the tetracyclic core, which was used in subsequent alkylation reactions to introduce various side chains for SAR studies. The obtained racemic (<i>cis</i>)-<b>23</b> was resolved by chiral chromatography to produce the desired (6b<i>R</i>,10a<i>S</i>)-<b>24</b> (entries <b>38</b>–<b>50</b> (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>) and <b>5</b> (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>)) and other enantiomer (6b<i>S</i>,10a<i>R</i>)-<b>25</b> (entry <b>51</b>, Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>). Alternatively, racemic (<i>cis</i>)-<b>18</b> was resolved to give the desired (4a<i>S</i>,9b<i>R</i>)-<b>18</b> by forming a diastereomeric salt with (<i>S</i>)-mandelic acid with >99% enantiomeric excess. Absolute stereochemistry was determined by single crystal X-ray crystallography using (4a<i>R</i>,9b<i>S</i>)-<b>18</b> (<i>R</i>)-mandelate. The desired (4a<i>S</i>,9b<i>R</i>)-<b>18</b> was then converted to (6b<i>R</i>,10a<i>S</i>)-<b>22</b> using the same synthetic sequence. This route was easily scalable and used during the production of <b>5</b> and its analogues on large scales.</div><figure id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-6/jm401958n/production/images/medium/jm-2013-01958n_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-6/jm401958n/production/images/large/jm-2013-01958n_0004.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-6/jm401958n/production/images/large/jm-2013-01958n_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401958n&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) 4-piperidone monohydrate hydrochloride, HCl, EtOH, reflux, 6 h, 76%; (b) TFA, Et<sub>3</sub>SiH, rt, 19 h, 83%; (c) ethyl chloroformate, NEt<sub>3</sub>, THF, rt, 1 h, 84%; (d) benzophenone imine, Pd<sub>2</sub>(dba)<sub>3</sub>, NaOBu<sup><i>t</i></sup>, BINAP, toluene, 105 °C, 93%; (e) ethyl bromoacetate, Na<sub>2</sub>CO<sub>3</sub>, KI, acetone, reflux, 16 h; (f) 2N HCl, THF, rt, 1.5 h, 73% (two steps); (g) MeI, K<sub>2</sub>CO<sub>3</sub>, acetone, 109 °C, 6 h, 99%; (h) BH<sub>3</sub>-THF, THF, reflux, 3 h, 99%; (i) KOH, <sup><i>n</i></sup>BuOH, 120 °C, 3 h, 99%; (j) R<sub>3</sub>X, NEt<sub>3</sub>, dioxane, toluene, reflux, 50–70%; (k) chiral HPLC separation, 30–45%.</p></p></figure><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. SAR of Compounds with Variations of Substituents on the C-Ring</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-6/jm401958n/production/images/medium/jm-2013-01958n_0007.gif" alt="" id="fx2" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-6/jm401958n/production/images/medium/jm-2013-01958n_0008.gif" alt="" id="fx3" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>Table a</sup><p class="last"><i>K</i><sub>i</sub> values are the means of at least two experiments.</p></div><div class="footnote" id="t2fn2"><sup>Table b</sup><p class="last">Percent of inhibition at 100 nM.</p></div><div class="footnote" id="t2fn3"><sup>Table c</sup><p class="last">No inhibition at 100 nM. ND stands for not determined.</p></div></div><div></div></div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. SAR of Compounds with Variations of the Tetracyclic Cores</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-6/jm401958n/production/images/medium/jm-2013-01958n_0009.gif" alt="" id="fx4" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">chirality</th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center" char="."> </th><th class="colsep0 rowsep0" align="center" char="."> </th><th class="rowsep1 colsep0" colspan="3" align="center" char="."><i>K</i><sub>i</sub> (nM)<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></th><th class="rowsep1 colsep0" colspan="2" align="center">ratio</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">X</th><th class="colsep0 rowsep0" align="center">a</th><th class="colsep0 rowsep0" align="center">b</th><th class="colsep0 rowsep0" align="center">R<sub>4</sub></th><th class="colsep0 rowsep0" align="center">R<sub>5</sub></th><th class="colsep0 rowsep0" align="center" char=".">m</th><th class="colsep0 rowsep0" align="center" char=".">n</th><th class="colsep0 rowsep0" align="center" char=".">5-HT<sub>2A</sub></th><th class="colsep0 rowsep0" align="center" char=".">5-HT<sub>2C</sub></th><th class="colsep0 rowsep0" align="center">D<sub>2</sub></th><th class="colsep0 rowsep0" align="center">5-HT<sub>2C</sub>/5-HT<sub>2A</sub></th><th class="colsep0 rowsep0" align="center">D<sub>2</sub>/5-HT<sub>2A</sub></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5</b></td><td class="colsep0 rowsep0" align="left">N-Me</td><td class="colsep0 rowsep0" align="left">R</td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char=".">0.54</td><td class="colsep0 rowsep0" align="char" char=".">173</td><td class="colsep0 rowsep0" align="left">32</td><td class="colsep0 rowsep0" align="left">320</td><td class="colsep0 rowsep0" align="left">59</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>51</b></td><td class="colsep0 rowsep0" align="left">N-Me</td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left">R</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char=".">4.6</td><td class="colsep0 rowsep0" align="char" char=".">532</td><td class="colsep0 rowsep0" align="left">95</td><td class="colsep0 rowsep0" align="left">116</td><td class="colsep0 rowsep0" align="left">21</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>52</b><a class="ref internalNav" href="#t3fn2" aria-label="b">b</a>,<a class="ref internalNav" href="#t3fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">N-Me</td><td class="colsep0 rowsep0" align="left">rel-S</td><td class="colsep0 rowsep0" align="left">rel-S</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char=".">>1000</td><td class="colsep0 rowsep0" align="char" char=".">>1000</td><td class="colsep0 rowsep0" align="left">97</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left"><0.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>53</b><a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">N-Me</td><td class="colsep0 rowsep0" align="left">rel-R</td><td class="colsep0 rowsep0" align="left">rel-R</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char=".">324</td><td class="colsep0 rowsep0" align="char" char=".">>1000</td><td class="colsep0 rowsep0" align="left">52</td><td class="colsep0 rowsep0" align="left">>3</td><td class="colsep0 rowsep0" align="left">0.16</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>54</b></td><td class="colsep0 rowsep0" align="left">NH</td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left">R</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char=".">5.5</td><td class="colsep0 rowsep0" align="char" char=".">702</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">128</td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>55</b></td><td class="colsep0 rowsep0" align="left">N-Me</td><td class="colsep0 rowsep0" align="left">S<a class="ref internalNav" href="#t3fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char=".">1.7</td><td class="colsep0 rowsep0" align="char" char=".">503</td><td class="colsep0 rowsep0" align="left">148</td><td class="colsep0 rowsep0" align="left">296</td><td class="colsep0 rowsep0" align="left">87</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>56</b></td><td class="colsep0 rowsep0" align="left">N-Me</td><td class="colsep0 rowsep0" align="left">R<a class="ref internalNav" href="#t3fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">R</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char=".">17</td><td class="colsep0 rowsep0" align="char" char=".">1280</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">75</td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>57</b></td><td class="colsep0 rowsep0" align="left">N-Me</td><td class="colsep0 rowsep0" align="left">R</td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char=".">5.7</td><td class="colsep0 rowsep0" align="char" char=".">280</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">49</td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>58</b></td><td class="colsep0 rowsep0" align="left">N-Me</td><td class="colsep0 rowsep0" align="left">R</td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char=".">5.2</td><td class="colsep0 rowsep0" align="char" char=".">862</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">166</td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>59</b></td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">R</td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char=".">1.0</td><td class="colsep0 rowsep0" align="char" char=".">83</td><td class="colsep0 rowsep0" align="left">27</td><td class="colsep0 rowsep0" align="left">83</td><td class="colsep0 rowsep0" align="left">27</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>60</b></td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left">R</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char=".">7.7</td><td class="colsep0 rowsep0" align="char" char=".">110</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">14</td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>61</b></td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">R</td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">0</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char=".">2.9</td><td class="colsep0 rowsep0" align="char" char=".">507</td><td class="colsep0 rowsep0" align="left">71</td><td class="colsep0 rowsep0" align="left">175</td><td class="colsep0 rowsep0" align="left">24</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>62</b></td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">R</td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char=".">1.1</td><td class="colsep0 rowsep0" align="char" char=".">195</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">177</td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>63</b></td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left">R</td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char=".">1.3</td><td class="colsep0 rowsep0" align="char" char=".">150</td><td class="colsep0 rowsep0" align="left">50</td><td class="colsep0 rowsep0" align="left">115</td><td class="colsep0 rowsep0" align="left">38</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>64</b></td><td class="colsep0 rowsep0" align="left">O</td><td class="colsep0 rowsep0" align="left">R</td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char=".">0.89</td><td class="colsep0 rowsep0" align="char" char=".">520</td><td class="colsep0 rowsep0" align="left">41</td><td class="colsep0 rowsep0" align="left">584</td><td class="colsep0 rowsep0" align="left">46</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>65</b></td><td class="colsep0 rowsep0" align="left">O</td><td class="colsep0 rowsep0" align="left">S<a class="ref internalNav" href="#t3fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char=".">14</td><td class="colsep0 rowsep0" align="char" char=".">641</td><td class="colsep0 rowsep0" align="left">69</td><td class="colsep0 rowsep0" align="left">46</td><td class="colsep0 rowsep0" align="left">5</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>a</sup><p class="last"><i>K</i><sub>i</sub> values are the means of at least two experiments.</p></div><div class="footnote" id="t3fn2"><sup>b</sup><p class="last"><b>52</b> and <b>53</b> are a pair of <i>trans</i>-enantiomers resolved by chiral HPLC chromatography. The absolute stereochemistry of these enantiomers has not been determined yet.</p></div><div class="footnote" id="t3fn3"><sup>c</sup><p class="last">The <i>R</i>-/<i>S</i>-configuration at carbon-α of the compounds with seven-member C-ring is equivalent to <i>S</i>-/<i>R</i>-configuration at carbon-α of the analogues with 6-member C-ring.</p></div><div class="footnote" id="t3fn4"><sup>d</sup><p class="last"><i>K</i><sub>i</sub> for SERT is >1000 nM. ND stands for not determined.</p></div></div></div><div class="NLM_p">To delineate the SAR of compounds with various tetracyclic cores, we have developed a versatile synthetic route for producing the cores with different ring sizes, heteroatoms, and stereochemistry, as illustrated in Scheme <a class="ref internalNav" href="#sch3" aria-label="3">3</a>. Some of the synthetic methods have been described in a previous paper.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> In general, the tetracyclic indole derivatives <b>27a</b>–<b>27f</b> were synthesized by Fisher-indole cyclization of <b>26a</b>–<b>26e</b> with 4-piperidone or azepan-4-one. Cis-reduction of <b>27a</b>–<b>27f</b> with sodium cyanoborohydride or triethylsilane in trifluoroacetic acid, followed by Boc-protection, provided (<i>cis</i>)-<b>28a</b>–<b>28f</b>, which were separated by chiral chromatography, followed by Boc-deprotection to afford the optically pure tetracyclic cores <b>29a</b>–<b>29f</b> along with the corresponding enantiomers <b>30a</b>–<b>30f</b>. Reaction of these key intermediates with 4-chloro-1-(4-fluorophenyl)butan-1-one afforded compounds <b>59</b>–<b>65</b> in Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>. Compounds <b>52</b> and <b>53</b> are a pair of <i>trans</i>-enantiomers, which were synthesized using a method similar to the one described in Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a> except for the <i>trans</i>-indole reduction step, which was accomplished by employing the previously reported method utilizing borane and hydrochloric acid.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> The synthetic route for compounds <b>55</b> and <b>56</b> is similar to the route illustrated in Scheme <a class="ref internalNav" href="#sch2" aria-label="2">2</a>. Azepan-4-one was used in the Fisher-indole cyclization step to construct the core with a seven-membered C-ring. Compounds <b>57</b> and <b>58</b> were prepared using the synthetic method explicated in Scheme <a class="ref internalNav" href="#sch2" aria-label="2">2</a> as well. In step g, methyl iodide and sodium hydride were used to achieve the <i>N</i>-methylation and α-carbon methylation in one step. Mono- or dimethylation of the α-carbon can be controlled by controlling the equivalency of sodium hydride and reaction time.</div><figure id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-6/jm401958n/production/images/medium/jm-2013-01958n_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-6/jm401958n/production/images/large/jm-2013-01958n_0005.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 3. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-6/jm401958n/production/images/large/jm-2013-01958n_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401958n&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) 4-piperidone hydrochloride monohydrate or azepan-4-one, HCl, EtOH, reflux, 50–80%; (b) TFA, NaBH<sub>3</sub>CN or Et<sub>3</sub>SiH, 80–95%; (c) Boc<sub>2</sub>O, aq NaOH, dioxane, rt, 80–90%; (d) chiral HPLC separation, 30–45%; (e) TFA, CH<sub>2</sub>Cl<sub>2</sub>, rt, 90–99%.</p></p></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i6">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_47310" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_47310" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> In Vitro Activities and SAR</h3><div class="NLM_p">The binding affinities of synthesized compounds against the human full-length recombinant serotonin 5-HT<sub>2A</sub> and 5-HT<sub>2C</sub> receptors, expressed in HEK-293E cells, were determined by radioligand displacement methods. (±)-1-(2,5-Dimethoxy-4-[<sup>125</sup>I]iodophenyl)-2-aminopropane (<sup>125</sup>DOI) was used as a radioligand.<a onclick="showRef(event, 'ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref25 ref26">(25, 26)</a> Binding affinities of compounds against the rat recombinant dopamine D<sub>2</sub> short receptor, expressed in CHO cells, were determined with [<sup>3</sup>H]-<i>N</i>-methylspiperone as a radioligand.</div><div class="NLM_p">To delineate the SAR around the investigational new drug <b>5</b>, three representative sets of compounds were selected as summarized in Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>–<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>. The SAR of compounds with different substituents at position 3 of the D-ring and position 5 of the A-ring is summarized in Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>. <i>N</i>-Methylated compound <b>5</b> and its <i>des</i>-methyl analogue <b>31</b> exhibit the most potent binding affinities for 5-HT<sub>2A</sub> receptor and show greater than 200-fold selectivity against 5-HT<sub>2C</sub> receptor. As the size of the alkyl substituent increases, the binding activity for 5-HT<sub>2A</sub> decreases (<b>32</b>–<b>34</b> vs <b>5</b> and <b>31</b>). <i>N</i>-Benzyl substituted compound <b>35</b> binds to 5-HT<sub>2A</sub>, with a <i>K</i><sub>i</sub> of 4.7 nM, which is 9-fold weaker relative to <b>5</b>. We also prepared analogues of <b>35</b> containing various substituents on the benzyl group, and they did not show any improvement in 5-HT<sub>2A</sub> binding relative to the parent. In general, binding affinity for 5-HT<sub>2A</sub> decreases as the size and hydrophobicity of a substituent at the 3-position increases. Conversely, the affinity for 5-HT<sub>2C</sub> is relatively insensitive to the variation of substituents at the position. The high selectivity against 5-HT<sub>2C</sub> has been suggested to be crucial to minimize potential metabolic side effects associated with antagonizing the receptor. Compound <b>5</b> exhibits 320-fold higher affinity for 5-HT<sub>2A</sub> receptor relative to 5-HT<sub>2C</sub>. These results suggest that a small alkyl group, such as a methyl group, is optimal at the position for better 5-HT<sub>2A</sub> binding potency and selectivity against 5-HT<sub>2C</sub>. Substitution at position 5 of the A-ring is generally unfavorable for 5-HT<sub>2A</sub> binding (<b>36</b> and <b>37</b> vs <b>5</b>). Compounds with potent 5-HT<sub>2A</sub> binding affinity were also tested in dopamine D<sub>2</sub> binding assays, and they show comparable potency regardless of the substituents at positions 3 and 5. The SAR trends described above suggest that the 5-HT<sub>2A</sub> receptor subsite, where the position 3 and 5 region of the tetracyclic core unit binds, is the most restrictive among the receptors that were tested. Compound <b>5</b> exhibits the highest binding affinities for both 5-HT<sub>2A</sub> and D<sub>2</sub> receptors, with a D<sub>2</sub>/5-HT<sub>2A</sub> affinity ratio of 59.</div><div class="NLM_p">To explore the SAR of compounds with different side chains at position 8 of the C-ring, analogues <b>38</b>–<b>50</b> were synthesized, as listed in Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>. Comparing compound <b>5</b> with <b>38</b>, the 4′-fluoro group on the butyrophenone side chain increases the 5-HT<sub>2A</sub> binding potency by 11-fold and improves selectivity against 5-HT<sub>2C</sub> by 21-fold. Compound <b>39</b>, containing a 4-pyridyl headpiece on the side chain, maintains similar 5-HT<sub>2A</sub> potency while showing significantly improved selectivity over both 5-HT<sub>2C</sub> and D<sub>2</sub> receptors relative to analogue <b>38</b>. Compounds <b>40</b>, <b>49</b>, and <b>50</b>, containing nonaromatic side chain headpieces, exhibit total loss of binding affinities for all tested receptors. This observation suggests that an aromatic ring on the side chain is a critical component to maintain potent binding. According to a homology model of the human D<sub>2</sub> receptor in complex with compound <b>5</b>, the butyrophenone side chain has both π–π and hydrophobic interactions with hydrophobic residues, including Trp386, Phe389, Phe390, and Ile184. This model is shown in <a class="ref internalNav" href="#notes-1" aria-label="Figure S-2 of the Supporting Information">Figure S-2 of the Supporting Information</a>. According to this model, these interactions would be significantly weakened if the phenyl ring on the side chain was replaced with a cycloalkyl group, which is consistent with the observed SAR summarized in Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>. The linker unit between the tetracyclic quinoxaline core and the aromatic headpiece on the side chain also has a significant impact on receptor binding profiles. The butyryl linker maximizes binding potency for 5-HT<sub>2A</sub> and D<sub>2</sub> receptors and selectivity against 5-HT<sub>2C</sub> compared to other linkers (<b>5</b> vs <b>41</b>, <b>42</b>, and <b>46</b>). Remarkably, compound <b>5</b> with the butyryl linker exhibits 1200- and 24-fold superior binding for 5-HT<sub>2A</sub> and D<sub>2</sub> receptors over the ethylcarbamoyl linker containing compound <b>42</b>. Replacing the carbonyl group in the butyryl linker with oxygen or restraining the side chain flexibility by forming a dihydroisoxazole ring leads to weaker 5-HT<sub>2A</sub> binding (<b>41</b> and <b>46</b> vs <b>5</b>). Compounds <b>43</b>, <b>44</b>, and <b>45</b> contain bioisosteres of the phenone pharmacophore. Indeed, compound <b>43</b> shows similar potency for 5-HT<sub>2A</sub> compared to the parent <b>38</b>, while <b>44</b> is 5–6-fold weaker in both 5-HT<sub>2A</sub> and D<sub>2</sub> binding potency than <b>5</b>. Interestingly, the indazole analogue <b>45</b> exhibits 7-fold enhanced binding affinity to D<sub>2</sub> receptor but a similar degree of reduced 5-HT<sub>2A</sub> activity relative to benzoisoxazole <b>44</b> to become almost equipotent for both receptors.</div><div class="NLM_p">During the development of <b>5</b>, we found several of these pyrido[3′,4′:4,5]pyrrolo[1,2,3-<i>de</i>]quinoxalines also potently inhibited serotonin transporter (SERT), a major target for most antidepressant drugs. Depression is a prominent symptom that can be associated with schizophrenia. SERT inhibitory activity in antipsychotic drugs could add beneficial effects in the treatment of schizophrenia. The atypical antipsychotic drug aripiprazole, which has been approved by FDA as an adjunct to treat major depressive disorders, also has some SERT inhibitory activity.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> As shown in Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>, compound <b>5</b> has a <i>K</i><sub>i</sub> of 61 nM for SERT inhibition. The binding affinity against SERT in human platelet membranes was determined using [<sup>3</sup>H]-<i>N</i>-methyl-citalopram as a radioligand. The overall side chain SAR of these tetracyclic compounds for SERT is similar to that of the 5-HT<sub>2A</sub> receptor. Compounds with nonaromatic heterocycles did not show any SERT inhibitory activity (<b>40</b>, <b>49</b>, and <b>50</b>). Compound <b>5</b> exhibits more potent SERT inhibition than <b>42</b>, which contains the ethylcarbamoyl linker. However, the propoxy linker containing compound <b>41</b> demonstrates improved SERT inhibitory activity while showing reduced binding potency to 5-HT<sub>2A</sub> and D<sub>2</sub> receptors relative to <b>5</b>. The isosteric indazole analogue <b>45</b> exhibits comparable SERT and D<sub>2</sub> receptor binding potencies to phenone <b>5</b> but 33-fold weaker 5-HT<sub>2A</sub> binding affinity than <b>5</b>. As a result, <b>45</b> binds to the 5-HT<sub>2A</sub>, D<sub>2</sub>, and SERT with the double-digit nanomolar <i>K</i><sub>i</sub>’s. Intriguingly, we also identified potent and selective SERT inhibitors, <b>47</b> and <b>48</b>, by incorporating 6-chloro-indolin-2-one and 2,8-dimethyl-pyrido[1,2-<i>a</i>]pyrimidin-4-one headpieces using an ethyl linker. Compound <b>47</b> inhibits SERT with a <i>K</i><sub>i</sub> of 28 nM without significant binding to 5-HT<sub>2A</sub>, 5-HT<sub>2C</sub>, and D<sub>2</sub> receptors. These results suggest that binding affinity and selectivity profiles of these tetracyclic compounds among 5-HT<sub>2A</sub>, 5-HT<sub>2C</sub>, D<sub>2</sub>, and SERT can be customized by the side chains. To obtain a preferred binding profile, a butyryl linker and an aromatic pharmacophore on the side chain are required, as exemplified by compound <b>5</b>.</div><div class="NLM_p last">Effects on receptor binding profiles by structural modifications of the core unit were explored by varying ring size, heteroatoms, and stereochemistry at different parts of the tetracyclic core, as exemplified in Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>. Compound <b>5</b> has a quinoxaline core with absolute configuration of (6b<i>R</i>,10a<i>S</i>). Its enantiomer <b>51</b> is 9-fold weaker in 5-HT<sub>2A</sub> binding affinity and 3-fold weaker in D<sub>2</sub> binding potency. Similarly, the <i>des</i>-methyl analogue <b>31</b> with the preferred (6b<i>R</i>,10a<i>S</i>) stereochemistry is more potent than its enantiomer <b>54</b>. Compounds <b>52</b> and <b>53</b> are a pair of <i>trans</i>-stereoisomers of <b>5</b>. Both compounds exhibit significantly weaker 5-HT<sub>2A</sub> binding affinity relative to <b>5</b>. Notably, compound <b>52</b> selectively binds to D<sub>2</sub> receptor with a <i>K</i><sub>i</sub> of 97 nM, while its binding affinity to 5-HT<sub>2A</sub>, 5-HT<sub>2c</sub>, and SERT becomes insignificant. Expanding the C-ring of the tetracyclic core into a seven-membered ring decreases 5-HT<sub>2A</sub> and D<sub>2</sub> receptor binding potency by 3–5-fold (<b>55</b> vs <b>5</b>). <b>55</b>, with an equivalent configuration at the B/C ring junction as <b>5</b>, is also preferred by the 5-HT<sub>2A</sub> receptor and shows 10-fold tighter binding than its enantiomer <b>56</b>. Methylations at the position 1 of the D-ring weaken the 5-HT<sub>2A</sub> binding potency (<b>57</b> and <b>58</b> vs <b>5</b>). Replacement of the nitrogen at position 3 of the D-ring with a carbon leads to a tetracyclic quinoline scaffold. In comparison with the quinoxaline derivative <b>5</b>, the corresponding quinoline analogue <b>59</b> gives comparable 5-HT<sub>2A</sub> binding affinity but lower selectivity against 5-HT<sub>2C</sub> with no change of D<sub>2</sub> binding potency. Its enantiomer <b>60</b> is weaker in 5-HT<sub>2A</sub> binding and less selective against 5-HT<sub>2C</sub>, which is consistent with the SAR trends of the quinoxaline series. Shrinking or expanding the size of the D-ring has little effect on 5-HT<sub>2A</sub> binding potency while providing a marginal improvement in 5-HT<sub>2C</sub> selectivity (<b>61</b> and <b>62</b> vs <b>59</b>). Benzothiazine and benzoxazine derivatives, <b>63</b> and <b>64</b>, are slightly weaker in 5-HT<sub>2A</sub> and D<sub>2</sub> binding than the quinoxaline <b>5</b>. Finally, benzoxazine <b>65</b> with a seven-membered C-ring exhibits weaker 5-HT<sub>2A</sub> binding affinity with reduced 5-HT<sub>2C</sub> selectivity in comparison with <b>64</b>, while both compounds have similar D<sub>2</sub> binding potency. The SAR of these compounds suggests that the stereochemistry of the tetracyclic core has a profound impact on compound receptor binding profiles, and an absolute configuration of (6b<i>R</i>,10a<i>S</i>) at the junction of the B/C rings is preferred. Among different tetracyclic ring systems illustrated in Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>, the 2,3,6b,9,10,10a-hexahydro-1<i>H</i>,7<i>H</i>-pyrido[3′,4′:4,5]pyrrolo[1,2,3-<i>de</i>]quinoxaline core was found to provide compounds with potent 5-HT<sub>2A</sub> and D<sub>2</sub> binding affinity as well as good selectivity against 5-HT<sub>2C</sub>, as exemplified by <b>5</b>. By systematic optimization of the core and side chain, we have also identified selective SERT inhibitor <b>47</b> and compound <b>52</b> that selectively binds to D<sub>2</sub> receptor. Most importantly, this work led to the discovery of compound <b>5</b>, which exhibiting an optimal receptor binding profile as an antipsychotic drug candidate.</div></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> Receptor Profiling</h3><div class="NLM_p">Compound <b>5</b> and selected analogues were profiled against a panel of receptors, transporters, ion channels, and enzymes. Targets inhibited by more than 50% at 100 nM of <b>5</b> are included in the Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>. The complete list of targets and inhibition data are provided in the <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>. Histamine H<sub>1</sub> receptor binding data are also included in the table in order to compare with the representative atypical antipsychotics, clozapine and olanzapine. <b>5</b> and its close analogues have similar receptor binding profiles, with <b>5</b> possessing a relatively better overall profile. In comparison with clozapine and olanzapine, <b>5</b> and its analogues demonstrate much better selectivity against 5-HT<sub>2C</sub> and H<sub>1</sub> receptors. Binding to these targets are thought to contribute to metabolic side effects and weight gain.<a onclick="showRef(event, 'ref16 ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref16 ref17 ref18">(16-18)</a> Clozapine actually possesses higher binding affinity for H<sub>1</sub> and 5-HT<sub>2C</sub> receptors relative to the therapeutic targets, 5-HT<sub>2A</sub> and D<sub>2</sub> receptors. Olanzapine binds to H<sub>1</sub>, 5-HT<sub>2C</sub>, and 5-HT<sub>2A</sub> in similar potency, while <b>5</b> demonstrates >1800-fold selectivity against H<sub>1</sub> relative to 5-HT<sub>2A</sub> and 320-fold selectivity over 5-HT<sub>2C</sub>, which suggests <b>5</b> is expected to have a more favorable metabolic side effect profile than these antipsychotics. The ratio of affinity for adrenergic α<sub>1A</sub> and α<sub>1B</sub> receptors to that of serotonin 5-HT<sub>2A</sub> receptor for compound <b>5</b> (135 and 57, respectively) is far greater than the ratios for clozapine (2.0 and 1.3, respectively) and olanzapine (24 and 28, respectively). This indicates that compound <b>5</b> should interact with serotonin 5-HT<sub>2A</sub> receptor without significantly interacting with adrenergic α<sub>1A</sub> and α<sub>1B</sub> receptors, predicting less liability for potential side effects associated with adrenoceptors.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> Notably, the 5-HT<sub>2A</sub> binding affinity of <b>5</b> is 59-fold more potent relative to D<sub>2</sub> receptors. The high D<sub>2</sub>/5-HT<sub>2A</sub> ratio will result in differential dose-dependent engagement of 5-HT<sub>2A</sub> and D<sub>2</sub> receptors by compound <b>5</b> and should enable this putative antipsychotic to be used in the treatment of other disorders including insomnia, agitation, aggression, and depression at low doses.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> In keeping with this concept, we have shown that <b>5</b> exhibits differential pharmacology in humans depending on the dose administered. <b>5</b> rapidly penetrates into the brain and engages targets in human brain in a dose dependent manner as estimated by receptor occupancy studies using positron emission tomography, first saturating the 5-HT<sub>2A</sub> receptors at low doses and then occupying dopamine and serotonin transporters at higher doses. The details of receptor occupancy studies will be published elsewhere.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Receptor Profiling of Selected Compounds<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center" char=".">serotonin receptors</th><th class="rowsep1 colsep0" align="center" char=".">ratio</th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">adrenergic receptors</th><th class="rowsep1 colsep0" colspan="3" align="center">dopamine receptors</th><th class="rowsep1 colsep0" align="center" char=".">ratio</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char=".">5-HT<sub>2A</sub></th><th class="colsep0 rowsep0" align="center">5-HT<sub>1A</sub></th><th class="colsep0 rowsep0" align="center" char=".">5-HT<sub>2C</sub></th><th class="colsep0 rowsep0" align="center" char=".">2C/2A</th><th class="colsep0 rowsep0" align="center">SERT</th><th class="colsep0 rowsep0" align="center">H<sub>1</sub></th><th class="colsep0 rowsep0" align="center">α<sub>1A</sub></th><th class="colsep0 rowsep0" align="center">α<sub>1B</sub></th><th class="colsep0 rowsep0" align="center">D<sub>1</sub></th><th class="colsep0 rowsep0" align="center" char=".">D<sub>2</sub></th><th class="colsep0 rowsep0" align="center">D<sub>4</sub></th><th class="colsep0 rowsep0" align="center" char=".">D<sub>2</sub>/5-HT<sub>2A</sub></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5</b></td><td class="colsep0 rowsep0" align="char" char=".">0.54</td><td class="colsep0 rowsep0" align="left">1480</td><td class="colsep0 rowsep0" align="char" char=".">173</td><td class="colsep0 rowsep0" align="char" char=".">320</td><td class="colsep0 rowsep0" align="left">61</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">73</td><td class="colsep0 rowsep0" align="left">31</td><td class="colsep0 rowsep0" align="left">52</td><td class="colsep0 rowsep0" align="char" char=".">32</td><td class="colsep0 rowsep0" align="left">108</td><td class="colsep0 rowsep0" align="char" char=".">59</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>31</b></td><td class="colsep0 rowsep0" align="char" char=".">0.94</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="char" char=".">280</td><td class="colsep0 rowsep0" align="char" char=".">298</td><td class="colsep0 rowsep0" align="left">31–78</td><td class="colsep0 rowsep0" align="left">12%<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">110</td><td class="colsep0 rowsep0" align="char" char=".">30</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="char" char=".">32</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>43</b></td><td class="colsep0 rowsep0" align="char" char=".">3.3</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="char" char=".">287</td><td class="colsep0 rowsep0" align="char" char=".">87</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">314</td><td class="colsep0 rowsep0" align="left">294</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="char" char=".">174</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="char" char=".">53</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>44</b></td><td class="colsep0 rowsep0" align="char" char=".">2.5</td><td class="colsep0 rowsep0" align="left">364</td><td class="colsep0 rowsep0" align="char" char=".">300</td><td class="colsep0 rowsep0" align="char" char=".">120</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">66</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="char" char=".">192</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="char" char=".">77</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>59</b></td><td class="colsep0 rowsep0" align="char" char=".">1.0</td><td class="colsep0 rowsep0" align="left">206</td><td class="colsep0 rowsep0" align="char" char=".">83</td><td class="colsep0 rowsep0" align="char" char=".">83</td><td class="colsep0 rowsep0" align="left">98</td><td class="colsep0 rowsep0" align="left">9%<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="char" char=".">27</td><td class="colsep0 rowsep0" align="left">60</td><td class="colsep0 rowsep0" align="char" char=".">27</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>64</b></td><td class="colsep0 rowsep0" align="char" char=".">0.89</td><td class="colsep0 rowsep0" align="left">1330</td><td class="colsep0 rowsep0" align="char" char=".">520</td><td class="colsep0 rowsep0" align="char" char=".">584</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">262</td><td class="colsep0 rowsep0" align="left">104</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="char" char=".">41</td><td class="colsep0 rowsep0" align="left">320</td><td class="colsep0 rowsep0" align="char" char=".">46</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">clozapine</td><td class="colsep0 rowsep0" align="char" char=".">9.6</td><td class="colsep0 rowsep0" align="left">140</td><td class="colsep0 rowsep0" align="char" char=".">13</td><td class="colsep0 rowsep0" align="char" char=".">1.4</td><td class="colsep0 rowsep0" align="left">3900<a class="ref internalNav" href="#t4fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">1<a class="ref internalNav" href="#t4fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">19</td><td class="colsep0 rowsep0" align="left">12<a class="ref internalNav" href="#t4fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">290<a class="ref internalNav" href="#t4fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="char" char=".">190</td><td class="colsep0 rowsep0" align="left">40</td><td class="colsep0 rowsep0" align="char" char=".">20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">olanzapine</td><td class="colsep0 rowsep0" align="char" char=".">2.5</td><td class="colsep0 rowsep0" align="left">2720</td><td class="colsep0 rowsep0" align="char" char=".">7.1</td><td class="colsep0 rowsep0" align="char" char=".">3</td><td class="colsep0 rowsep0" align="left">>15000<a class="ref internalNav" href="#t4fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">2<a class="ref internalNav" href="#t4fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">60</td><td class="colsep0 rowsep0" align="left">69<a class="ref internalNav" href="#t4fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">52<a class="ref internalNav" href="#t4fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="char" char=".">31</td><td class="colsep0 rowsep0" align="left">28</td><td class="colsep0 rowsep0" align="char" char=".">12</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>a</sup><p class="last"><i>K</i><sub>i</sub> (nM) values are the means of at least two experiments.</p></div><div class="footnote" id="t4fn2"><sup>b</sup><p class="last">Percent of inhibition at 100 nM.</p></div><div class="footnote" id="t4fn3"><sup>c</sup><p class="last">Data from ref <a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">28</a>.</p></div><div class="footnote" id="t4fn4"><sup>d</sup><p class="last">Data from ref <a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">29</a>.</p></div><div class="footnote" id="t4fn5"><sup>e</sup><p class="last">Data from ref <a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">30</a>. ND stands for not determined.</p></div></div></div><div class="NLM_p last">In the HEK-293E cells expressing human recombinant 5-HT<sub>2A</sub> receptors, compound <b>5</b> was found to antagonize serotonin (30 nM) induced increase in calcium fluorescence with an IC<sub>50</sub> of approximately 7 nM.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> In the same cell system, but measuring serotonin induced [<sup>3</sup>H]-inositol phosphate accumulation,<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> compound <b>5</b> inhibited second messenger formation by right-shifting the serotonin dose–response curve. These assay results indicate compound <b>5</b> acts as a 5-HT<sub>2A</sub> antagonist. Compound <b>5</b> was found to block europium-labeled GTP analogue (Eu-GTP) binding to 10 nM 2-(<i>N</i>-phenethyl-<i>N</i>-propyl)amino-5-hydroxytetralin (PPHT)-activated G proteins in CHO cells expressing human recombinant D<sub>2</sub>-short dopamine receptors.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> 100% antagonism was observed at 10 μM of compound <b>5</b>. At this concentration, in the absence of dopamine, 0% activation of the system was seen with compound <b>5</b> alone at up to 1 μM concentration, indicating a pure antagonist nature of compound <b>5</b> in this system. Compound <b>5</b> was evaluated for inhibition of [<sup>3</sup>H]-serotonin uptake in whole human platelets cells, an indication of transport inhibition, and showed potent inhibition with a <i>K</i><sub>i</sub> of 72 nM. Overall, therefore, compound <b>5</b> displayed strong antagonist properties versus 5-HT<sub>2A</sub> and D<sub>2</sub> receptors as evaluated in these systems, as well as potent inhibition of SERT. By virtue of its unique pharmacological profile and superior selectivity against undesired targets, this putative antipsychotic <b>5</b> is being developed for multiple indications and is expected to have good tolerability.</div></div><div id="sec3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> In Vivo Studies</h3><div class="NLM_p">The in vivo efficacy of compound <b>5</b> and selected analogues was evaluated in the rat quipazine head twitch model. This model measures blockade of head twitches induced by quipazine which is a 5-HT<sub>2A</sub> agonist.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> As shown in Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a>, compounds <b>5</b> and <b>31</b> have ED<sub>50</sub> values of 0.12 and 0.08 mg/kg, respectively, which are more efficacious than their analogues and the reference compounds, clozapine and olanzapine. The relatively weaker efficacy of analogues is nicely correlated with in vitro 5-HT<sub>2A</sub> binding potency. Compound <b>5</b> was also evaluated in the rat conditioned avoidance response model<a onclick="showRef(event, 'ref37 ref38'); return false;" href="javascript:void(0);" class="ref ref37 ref38">(37, 38)</a> and was found to show good efficacy (ED<sub>50</sub> = 1.5 mg/kg). Inhibition of conditioned avoidance behavior without affecting escape behavior, as observed with compound <b>5</b>, predicts antipsychotic efficacy consistent with D<sub>2</sub> receptor antagonism. Tested up to a dose of 30 mg/kg, compound <b>5</b> never produced frank catalepsy as tested in a step-down latency model in rats.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> In contrast, the positive control, haloperidol, produced a full cataleptic response across a similar dose range where haloperidol showed efficacy in the conditioned avoidance response test. Compound <b>5</b> showed a wide separation between its antipsychotic ED<sub>50</sub> in conditioned avoidance and doses that increased step-down latency. These data predict antipsychotic efficacy with compound <b>5</b> and a low liability for extrapyramidal motor side effects.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. In Vivo Efficacy of Selected Compounds in the Rat Quipazine Head Twitch Model<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char=".">ED<sub>50</sub> (mg/kg)</th><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char=".">ED<sub>50</sub> (mg/kg)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5</b></td><td class="colsep0 rowsep0" align="char" char=".">0.12</td><td class="colsep0 rowsep0" align="left"><b>39</b></td><td class="colsep0 rowsep0" align="char" char=".">1.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>31</b></td><td class="colsep0 rowsep0" align="char" char=".">0.08</td><td class="colsep0 rowsep0" align="left"><b>41</b></td><td class="colsep0 rowsep0" align="char" char=".">1.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>32</b></td><td class="colsep0 rowsep0" align="char" char=".">0.99</td><td class="colsep0 rowsep0" align="left"><b>43</b></td><td class="colsep0 rowsep0" align="char" char=".">1.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>36</b></td><td class="colsep0 rowsep0" align="char" char=".">0.66</td><td class="colsep0 rowsep0" align="left"><b>64</b></td><td class="colsep0 rowsep0" align="char" char=".">0.25</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">clozapine</td><td class="colsep0 rowsep0" align="char" char=".">0.92</td><td class="colsep0 rowsep0" align="left">olanzapine</td><td class="colsep0 rowsep0" align="char" char=".">0.20</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup>a</sup><p class="last">Test compound suspended in 0.25% methylcellulose was dosed to animals orally by gavage. Assay protocol was described in the <a class="ref internalNav" href="#sec5" aria-label="Experimental Section">Experimental Section</a>.</p></div></div></div></div><div id="sec3_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Properties of <b>5</b></h3><div class="NLM_p">Compound <b>5</b> is being developed as a tosylate salt, displaying a plate-like crystalline material. This salt can be consistently produced as a nonhygroscopic, nonhydrated, and nonsolvated single polymorph and has demonstrated good stability under stressed conditions. Compound <b>5</b> has good physicochemical and biophysical properties, as summarized in Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a>. This compound is highly permeable and is not a p-glycoprotein substrate, as determined in the bidirectional permeability assays in the MDR1-trnsfected MDCK cells. Pharmacokinetic properties of <b>5</b> in rat, dog, and human subjects have been extensively studied, and good pharmacokinetic characteristic were demonstrated. Compound <b>5</b> is safe and well tolerated after wide range of single and multiple once daily doses in normal volunteers and patients with schizophrenia. Also, in phase II studies, low doses of <b>5</b>, predominantly occupying 5-HT<sub>2A</sub> receptors, have been shown to increase slow wave sleep and reduce waking after sleep onset while restoring normal sleep architecture in patients with sleep maintenance insomnia. At a higher dose, compound <b>5</b> demonstrated antipsychotic efficacy in a phase II clinical trial in patients with acutely exacerbated schizophrenia.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Properties of Compound <b>5</b></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col></colgroup><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Log <i>D</i> at pH 7.4</td><td class="colsep0 rowsep0" align="left">3.38</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Log <i>D</i> at pH 1.7</td><td class="colsep0 rowsep0" align="left">0.55</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">p<i>K</i><sub>a</sub> (free base)</td><td class="colsep0 rowsep0" align="left">6.5; 9.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">solubility in PBS at pH 7.4 (mg/mL)</td><td class="colsep0 rowsep0" align="left">0.33 </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">human plasma protein binding (%)</td><td class="colsep0 rowsep0" align="left">97.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">permeability, AB (× 10<sup>–6</sup> cm/s)<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">15.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">efflux ratio BA/AB<a class="ref internalNav" href="#t6fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">1.3</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup>a</sup><p class="last">Apical-to-basolateral permeability in MDR1-MDCK cells.</p></div><div class="footnote" id="t6fn2"><sup>b</sup><p class="last">Efflux ratio (<i>P</i><sub>app</sub> B→A)/(<i>P</i><sub>app</sub> A→B).</p></div></div></div></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_08041" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_08041" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">A new series of tetracyclic quinoxaline derivatives has been synthesized and selected candidates have been evaluated as potential new antipsychotic agents. Among this series, compound <b>5</b> is a potent serotonin 5-HT<sub>2A</sub> and dopamine D<sub>2</sub> antagonist with high affinity for SERT. This compound has a desirable selectivity profile against other receptors, such as serotonin 5-HT<sub>2C</sub>, histamine H<sub>1</sub>, and adrenergic α<sub>1A</sub> receptors, which are known to be associated with adverse effects of marketed antipsychotics. The high D<sub>2</sub>/5-HT<sub>2A</sub> ratio of <b>5</b> provides dose-dependent engagement of 5-HT<sub>2A</sub> and D<sub>2</sub> receptors and enables <b>5</b> to be used both in treating psychiatric illness such as schizophrenia at high doses and in treating other disorders, such as sleep or mood alterations, at low doses. <b>5</b> has suitable physicochemical, biophysical, and pharmacokinetic properties as a CNS-active drug candidate. The human clinical trials of <b>5</b> (ITI-007)<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> are ongoing, and the results will be reported in due course.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i15">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_54253" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_54253" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Chemistry</h3><div class="NLM_p last">Unless otherwise noted, all materials were obtained from commercial suppliers and used without further purification. All reactions involving air- or moisture-sensitive reagents were performed under an argon atmosphere. All microwave assisted reactions were conducted with an Initiator Eight EXP microwave system from Biotage, Charlotte, NC, USA. Silica gel or alumina column chromatography was performed with a CombiFlash Companion purification system from Teledyne ISCO, Lincoln, NE. Filtrations were generally performed with Waterman paper filters. All products, unless otherwise noted, were purified by column chromatography and/or preparative reverse-phase HPLC. A Waters preparative HPLC system equipped with a Delta 600EF pump, 2996 PDA detector, and WFCIII fraction collector was used for compound purification using the following general HPLC method. Column: Gemini, AXIA packed, 10 μm C18 110 Å, 250 mm × 21.2 mm; mobile phase A, 0.1% formic acid in water; mobile phase B, 0.1% formic acid in acetonitrile; gradient was adjusted and optimized based on compound polarity; HPLC run time was 22 min; flow rate was 24 mL/min; detection was at 210–350 nm. Purification of optically pure enantiomers was conducted on semipreparative Chiralpak AD-H or Chiralcel OD chiral columns with ethanol or 2-propanol–hexanes as an eluent. <sup>1</sup>H NMR spectra were determined in the cited solvent on a Bruker DRX 300 or Avance III (400 or 500 MHz) spectrometer. <sup>13</sup>C NMR spectra were recorded at 75 or 126 MHz. Chemical shifts are reported in delta (δ) units, parts per million (ppm) downfield from tetramethylsilane. Coupling constants are reported in hertz (Hz). Splitting patterns are designated as follows: s, singlet; br, broad singlet; d, doublet; t, triplet; q, quartet; m, multiplet. Purity of all final products was >95% as determined by reverse-phase UPLC/HPLC using method A and/or method B. Method A (UPLC): Waters ACQUITY UPLC system, ACQUITY HSS T3 column, 50 mm × 2.1 mm, 1.8 μm, 25 °C; mobile phase A, 0.1% formic acid in water/acetonitrile (95/5); mobile phase B, 0.1% formic acid in acetonitrile; gradient, 0.0–3.0 min, 5–95% B; 3.0–4.0 min, 95% B; 4.0–5.0 min, 95–5% B; flow rate 0.3 mL/min; detection at 210–400 nm. Method B (HPLC), Waters Alliance HT 2795 system, Ace 5 C18 column, 150 mm × 4.6 mm, 5 μm, 30 °C; mobile phase A, 0.1% HClO<sub>4</sub> in water/acetonitrile (95/5); mobile phase B, 0.1% HClO<sub>4</sub> in acetonitrile; gradient, 0.0–2.0 min, 0% B; 2.0–22 min, 0–100% B; 22–25 min, 100% B; flow rate 1.5 mL/min; detection at 254 nm and/or 280 nm. Chiral purity was determined by HPLC on a Daicel Chiralpak AD-H 4.6 mm × 250 mm chiral column; mobile phase, ethanol at 0.7 mL/min; UV detection at 250 and 280 nm. Mass spectral (MS) data were determined on a Micromass Quattro micro API or LCT Premier XE mass spectrometer from Waters. High-resolution mass spectral (HRMS) data were determined on the LCT Premier XE mass spectrometer. The chemical yields reported below are not optimized and correspond to specific examples of one preparation.</div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Representative Synthetic Procedures of the Tetracyclic Butyrophenone Derivatives Shown in Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a> via Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>. 4-((6b<i>R</i>,10a<i>S</i>)-3-Methyl-2,3,6b,9,10,10a-hexahydro-1<i>H</i>,7<i>H</i>-pyrido[3′,4′:4,5]pyrrolo[1,2,3-<i>de</i>]quinoxalin-8-yl)-1-(4-fluorophenyl)-butan-1-one 4-methylbenzenesulfonate (<b>5</b>)</h3><div id="sec5_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i18" class="anchor-spacer"></div><h4 class="article-section__title" id="_i18"> Step a: 4-Nitroso-3,4-dihydroquinoxalin-2(1<i>H</i>)-one (<b>7</b>; R<sub>1</sub> = H)</h4><div class="NLM_p last">A solution of 3,4-dihydroquinoxalin-2(1<i>H</i>)-one <b>6</b> (9.5 g, 64 mmol) in acetic acid (100 mL) and water (50 mL) was cooled to 5 °C, and then a solution of NaNO<sub>2</sub> (4.6 g, 67 mmol) in water (20 mL) was added dropwise. The reaction mixture was stirred at 0–5 °C for an hour and then filtered. The filter cake was washed with water and then dried under vacuum to give the title compound (7.6 g, 67% yield). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz) δ 10.96 (s, 1H), 7.94 (dd, <i>J</i> = 8.2, 1.3 Hz, 1H), 7.40–7.26 (m, 1H), 7.20–7.06 (m, 2H), 4.53 (s, 2H).</div></div><div id="sec5_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19"> Steps b and c: 2-Oxo-2,3,9,10-tetrahydro-1<i>H</i>,7<i>H</i>-pyrido-[3′,4′:4,5]pyrrolo[1,2,3-<i>de</i>]quinoxaline-8-carboxylic Acid Ethyl Ester (<b>8</b>; R<sub>1</sub> = H)</h4><div class="NLM_p last">A suspension of <b>7</b> (4.0 g, 23 mmol) in acetic acid (60 mL) was cooled to 5–10 °C, and then zinc powder (8.0 g, 122 mmol) was added in portions. The reaction mixture was stirred at 10–20 °C until all of the starting material had been consumed. Ethyl 4-oxopiperidine-1-carboxylate (3.4 mL, 22.6 mmol) was added to the reaction mixture, and then the mixture was filtered. The filter cake was rinsed with acetic acid (4 × 50 mL). The filtrate was combined, followed by adding 1.0 M HCl in ether (1 mL). The mixture was heated at 100 °C for an hour. Acetic acid was removed under reduced pressure, and the residue was treated with ethanol (20 mL). After filtration, the filter cake was washed with cold methanol (2 × 5 mL) to give the title compound (2.8 g, 42% yield) as a white solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz) δ 7.76 (s, 1H). 7.14 (d, <i>J</i> = 8.0 Hz, 1H), 7.02–6.92 (m, 1H), 6.52 (d, <i>J</i> = 7.4 Hz, 1H), 4.87 (s, 2H), 4.79–4.61 (m, 2H), 4.21(q, <i>J</i> = 7.1 Hz, 2H), 3.97–3.79 (m, 2H), 2.89–2.70 (m, 2H), 1.31 (t, <i>J</i> = 7.1 Hz, 3H). MS (ESI) <i>m</i>/<i>z</i> 300.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> Step d: (<i>cis</i>-)-2-Oxo-2,3,6b,9,10,10a-hexahydro-1<i>H</i>,7<i>H</i>-pyrido[3′,4′:4,5]pyrrolo[1,2,3-<i>de</i>]quinoxaline-8-carboxylic Acid Ethyl Ester (<i>cis</i>-<b>9</b>; R<sub>1</sub> = H)</h4><div class="NLM_p last">To a vigorously stirred solution of <b>8</b> (12 g, 40 mmol) in trifluoroacetic acid (125 mL) was added sodium cyanoborohydride (4.0 g, 65 mmol) in small portions at 0–5 °C. After the addition was complete, the reaction mixture was stirred at room temperature for 30 min and then poured slowly into ammonium hydroxide (300 mL) containing ice, followed by the addition of enough 1N NaOH to make the mixture basic. The mixture was extracted with CH<sub>2</sub>Cl<sub>2</sub> twice. The combined organic phase was washed with water, dried over MgSO<sub>4</sub>, concentrated, and dried under vacuum to give the title compound (10.9 g, 90% yield) as an off-white powder. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 500 MHz) δ 10.37 (s, 1H), 6.81 (d, <i>J</i> = 7.3 Hz, 1H), 6.65 (t, <i>J</i> = 7.5 Hz, 1H), 6.59 (d, <i>J</i> = 7.7 Hz, 1H), 4.09–3.98 (m, 2H), 3.97–3.85 (m, 1H), 3.84 (d, <i>J</i> = 14.6 Hz, 1H), 3.65 (dt, <i>J</i> = 13.2, 4.3 Hz, 1H), 3.51–3.42 (m, 1H), 3.38 (d, <i>J</i> = 14.5 Hz, 1H), 3.31–3.23 (m, 1H), 3.20–3.02 (m, 1H), 2.95–2.59 (m, 1H), 2.03–1.88 (m, 1H), 1.85–1.72 (m, 1H), 1.18 (t, <i>J</i> = 7.1 Hz, 3H). MS (ESI) <i>m</i>/<i>z</i> 302.2 [M + H]<sup>+</sup>.</div></div><div id="sec5_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> Step e: (<i>cis</i>)-3-Methyl-2-oxo-2,3,6b,9,10,10a-hexahydro-1<i>H</i>,7<i>H</i>-pyrido[3′,4′:4,5]pyrrolo[1,2,3-<i>de</i>]quinoxaline-8-carboxylic Acid Ethyl Ester (<i>cis</i>-<b>10</b>; R<sub>1</sub> = H, R<sub>2</sub> = Me)</h4><div class="NLM_p last">Sodium hydride (900 mg of 60% dispersion in mineral oil, 22.5 mmol) was washed with hexanes and suspended in anhydrous DMF (5 mL). The suspension was added to a stirred solution of <i>cis</i>-<b>9</b> (6.02 g, 20 mmol) in anhydrous DMF (50 mL) under nitrogen atmosphere. After gas evolution had subsided, the mixture was cooled in an ice–water bath and treated with methyl iodide (3.55 g, 25 mmol). The mixture was stirred at room temperature for an hour and then concentrated. The residue was treated with water and extracted with CH<sub>2</sub>Cl<sub>2</sub> twice. The combined organic phase was washed with brine, dried over MgSO<sub>4</sub>, and evaporated to dryness to give the title compound (5.48 g, 87% yield) as a tan solid. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 500 MHz,) δ 6.92 (d, <i>J</i> = 7.3 Hz, 1H), 6.86 (d, <i>J</i> = 7.9 Hz, 1H), 6.77 (t, <i>J</i> = 7.7 Hz, 1H), 4.09–3.85 (m, 4H), 3.67 (dt, <i>J</i> = 13.6, 4.2 Hz, 1H), 3.51–3.42 (m, 2H), 3.35–3.26 (m, 1H), 3.22 (s, 3H), 3.17–3.01 (m, 1H), 2.90–2.61 (m, 1H), 2.01–1.91 (m, 1H), 1.87–1.74 (m, 1H), 1.18 (t, <i>J</i> = 7.1 Hz, 3H). MS (ESI) <i>m</i>/<i>z</i> 316.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> Step f: (<i>cis</i>)-3-Methyl-2,3,6b,9,10,10a-hexahydro-1<i>H</i>,7<i>H</i>-pyrido[3′,4′:4,5]pyrrolo[1,2,3-<i>de</i>]quinoxaline-8-carboxylic Acid Ethyl Ester (<i>cis</i>-<b>11</b>; R<sub>1</sub> = H, R<sub>2</sub> = Me)</h4><div class="NLM_p last">A solution of borane in THF (1.0 M, 33 mL, 33 mmol) was added dropwise to a stirred solution of <i>cis</i>-<b>10</b> (5.24 g, 16.6 mmol) in anhydrous THF (25 mL) under nitrogen atmosphere. After the addition was complete, the mixture was stirred and heated at reflux for an hour and then cooled and treated with 6N HCl (15 mL). The mixture was then heated under reflux for 30 min, cooled, and evaporated to dryness under reduced pressure. The residue was dissolved in a minimum quantity of water, and the solution was basified with 1N NaOH and then extracted with CH<sub>2</sub>Cl<sub>2</sub> twice. The combined organic phase was washed with water, dried over MgSO<sub>4</sub>, concentrated, and dried under vacuum to give the title compound (4.65 g, 93% yield) as a viscous oil. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) δ 6.67 (t, <i>J</i> = 8.1 Hz, 1H), 6.61 (d, <i>J</i> = 8.1 Hz, 1H), 6.41 (d, <i>J</i> = 8.1 Hz, 1H), 4.16 (q, <i>J</i> = 7.0 Hz, 2H), 3.87–3.79 (m, 1H), 3.75–3.56 (m, 2H), 3.38–3.26 (m, 2H), 3.26–3.05 (m, 2H), 2.90–2.81 (m, 5H), 1.93–1.78 (m, 2H), 1.78–1.68 (m, 1H), 1.28 (t, <i>J</i> = 7.0 Hz, 3H). MS (ESI) <i>m</i>/<i>z</i> 302.3 [M + H]<sup>+</sup>.</div></div><div id="sec5_2_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> Step g: (<i>cis</i>)-3-Methyl-2,3,6b,7,8,9,10,10a-octahydro-1<i>H</i>-pyrido[3′,4′:4,5]pyrrolo[1,2,3-<i>de</i>]quinoxaline (<i>cis</i>-<b>12</b>; R<sub>1</sub> = H, R<sub>2</sub> = Me)</h4><div class="NLM_p last">To a stirred solution of <i>cis</i>-<b>11</b> (4.52 g, 15.0 mmol) in warm <i>n</i>-butanol (50 mL) was added powdered KOH (10.0 g, 178 mmol). The reaction mixture was heated under reflux for 5 h and then evaporated under reduced pressure. The residue was treated with water and extracted with CH<sub>2</sub>Cl<sub>2</sub> twice. The combined organic phase was washed with water, dried over MgSO<sub>4</sub>, concentrated, and dried under vacuum to give the title compound (3.27 g, 95% yield) as a viscous oil. <sup>1</sup>H NMR (CDC1<sub>3</sub>, 300 MHz) δ 6.65 (t, <i>J</i> = 7.3 Hz, 1H), 6.51 (d, <i>J</i> = 7.3 Hz, 1H), 6.41 (d, <i>J</i> = 7.3 Hz, 1H), 3.64–3.55 (m, 1H), 3.38–3.26 (m, 3H), 3.12–2.95 (m, 2H), 2.95–2.80 (m, 6H), 2.71–2.57 (m, 1H), 1.93–1.74 (m, 3H). MS (ESI) <i>m</i>/<i>z</i> 230.2 [M + H]<sup>+</sup>.</div></div><div id="sec5_2_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> Step h: (<i>cis</i>)-4-(3-Methyl-2,3,6b,9,10,10a-hexahydro-1<i>H</i>,7<i>H</i>-pyrido[3′,4′:4,5]pyrrolo[1,2,3-<i>de</i>]quinoxalin-8-yl)-1-(4-fluorophenyl)-butan-1-one (<i>cis</i>-<b>13</b>; R<sub>1</sub> = H, R<sub>2</sub> = Me)</h4><div class="NLM_p last">A suspension of <i>cis</i>-<b>12</b> (11.7 g, 51 mmol), 4-chloro-4′-fluoro-butyrophenone (15 g, 75 mmol), triethylamine (30 mL, 214 mmol), and KI (12.6 g, 76 mmol) in dioxane (65 mL) and toluene (65 mL) was refluxed for 7 h. After filtration and evaporation of the solvent, CH<sub>2</sub>Cl<sub>2</sub> (200 mL) was added to dissolve the residue. The CH<sub>2</sub>Cl<sub>2</sub> solution was washed with brine (2 × 200 mL), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated to ca. 55 mL and then added dropwise to a 0.5 N HCl ether solution (600 mL). The resulting brown solid was filtered, washed with ether, and then dissolved in water. The aqueous solution was basified with 2 N NaOH and extracted with CH<sub>2</sub>Cl<sub>2</sub> (2 × 100 mL). The combined organic phase was washed with brine (2 × 200 mL) and dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>. Evaporation of the solvent and chromatography of the residue through silica gel gave the title compound (11.5 g, 57% yield) as a brown oil. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) δ 8.01–7.98 (m, 2H). 7.14–7.10 (m, 2H), 6.64 (t, <i>J</i> = 7.6 Hz, 1H), 6.50 (d, <i>J</i> = 7.2 Hz, 1H), 6.40 (d, <i>J</i> = 7.6 Hz, 1H), 3.62–3.55 (m, 1H), 3.31–3.24 (m, 2H), 3.21–3.17 (m, 1H), 3.10–3.04 (m, 1H), 2.96–2.90 (m, 2H), 2.88–2.78 (m, 5H), 2.67–2.61 (m, 1H), 2.44–2.32 (m, 2H), 2.27–2.20 (m, 1H), 2.00–1.77 (m, 5H). MS (ESI) <i>m</i>/<i>z</i> 394.2 [M + H]<sup>+</sup>.</div></div><div id="sec5_2_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> Step i: 4-((6b<i>R</i>,10a<i>S</i>)-3-Methyl-2,3,6b,9,10,10a-hexahydro-1<i>H</i>,7<i>H</i>-pyrido[3′,4′:4,5]pyrrolo[1,2,3-<i>de</i>]quinoxalin-8-yl)-1-(4-fluorophenyl)-butan-1-one 4- methylbenzenesulfonate (<b>5</b>)</h4><div class="NLM_p last"><i>cis</i>-<b>13</b> (1.0 g, 2.5 mmol) was dissolved in ethanol (5 mL) and resolved by HPLC on a Chiral AD-H column (2.0 cm × 25 cm) eluting with ethanol. The early eluting peak was collected and concentrated to give the free base form of <b>5</b> (0.48 g, 48% yield) as a dense oil. The free base was dissolved in 2-propanol (2 mL), and then a solution of 4-methylbenzenesulfonic acid (200 mg, 1.16 mmol) in 2-propanol (1.0 mL) was added slowly at 0 °C. The mixture was stirred at room temperature overnight and then filtered. The filter cake was rinsed with 2-propanol and then dried under vacuum to give <b>5</b> (367 mg, 53% yield) as a gray solid. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 500 MHz) δ 9.10 (br, 1H), 8.10–8.01 (m, 2H), 7.48 (d, <i>J</i> = 8.0 Hz, 2H), 7.42–7.33 (m, 2H), 7.11 (d, <i>J</i> = 7.8 Hz, 2H), 6.65–6.57 (m, 1H), 6.51 (d, <i>J</i> = 7.3 Hz, 1H), 6.42 (d, <i>J</i> = 7.9 Hz, 1H), 3.59 (dd, <i>J</i> = 12.2, 6.5 Hz, 1H), 3.52–3.37 (m, 3H), 3.37–3.28 (m, 2H), 3.25–3.20 (m, 1H), 3.18–2.99 (m, 5H), 2.81 (s, 3H), 2.71 (td, <i>J</i> = 10.2, 3.0 Hz, 1H), 2.63–2.52 (m, 1H), 2.28 (s, 3H), 2.27–2.22 (m, 1H), 2.15–1.93 (m, 3H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>, 126 MHz) δ 197.2, 165.1 (d, <i>J</i><sub>CF</sub> = 252 Hz), 145.6, 137.6, 137.3, 135.2, 133.1, 130.9 (d, <i>J</i><sub>CF</sub> = 10 Hz), 128.1, 126.7, 125.5, 120.6, 115.7 (d, <i>J</i><sub>CF</sub> = 22 Hz), 112.5, 109.3, 62.2, 55.5, 52.5, 49.8, 47.8, 43.7, 38.6, 37.0, 34.9, 21.7, 20.8, 18.0. MS (ESI) <i>m</i>/<i>z</i> 394.2 [M + H]<sup>+</sup>. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>24</sub>H<sub>29</sub>FN<sub>3</sub>O [M + H]<sup>+</sup>, 394.2295; found, 394.2292. UPLC purity, 97.7%; retention time, 2.06 min (method A).</div></div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> Representative Synthetic Procedures of Tetracyclic Derivatives Shown in Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a> via Scheme <a class="ref internalNav" href="#sch2" aria-label="2">2</a>. (6b<i>R</i>,10a<i>S</i>)-8-[3-(4-Fluorophenoxy)propyl]-3-methyl-2,3,6b,7,8,9,10,10a-octahydro-1<i>H</i>-pyrido[3′,4′:4,5]pyrrolo[1,2,3-<i>de</i>]quinoxaline (<b>41</b>)</h3><div id="sec5_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> Step a: 6-Bromo-2,3,4,5-tetrahydro-1<i>H</i>-pyrido[4,3-<i>b</i>]indole Hydrochloride (<b>17</b>)</h4><div class="NLM_p last">A 1 L, three-neck flask was equipped with an overhead stirrer, a type-J Teflon covered thermocouple, and a reflux condenser with a N<sub>2</sub> inlet. The flask was charged with (2-bromophenyl) hydrazine hydrochloride (50.0 g, 224 mmol), 4-piperidone monohydrate hydrochloride (36 g, 234 mmol), ethanol (500 mL), and hydrochloric acid (50 mL). The resulting mixture was refluxed for 6 h and then cooled to room temperature. After filtration, the filter cake was washed with ethanol (3 × 50 mL) and then dried under vacuum to give the title compound (49.2 g, 76% yield) as a cream-colored solid. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 500 MHz) δ 11.3 (s, 1H), 9.21 (s, 2H),7.49 (d, <i>J</i> = 7.8 Hz, 1H), 7.32 (d, <i>J</i> = 7.6 Hz, 1H), 6.97 (t, <i>J</i> = 7.7 Hz, 1H), 4.31 (s, 2H), 3.48 (t, <i>J</i> = 6.2 Hz, 2H), 3.05 (t, <i>J</i> = 6.2 Hz, 2H). MS (ESI) <i>m</i>/<i>z</i> 251.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> Step b: (<i>cis</i>)-6-Bromo-2,3,4,4a,5,9b-hexahydro-1<i>H</i>-pyrido[4,3-<i>b</i>]indole (<i>cis</i>-<b>18</b>)</h4><div class="NLM_p last">To a suspension of <b>17</b> (49.2 g, 171 mmol) in TFA (630 mL) in a 1 L flask, triethylsilane (172 mL, 1.08 mol) was added. The resulting mixture was stirred at room temperature under nitrogen atmosphere for 19 h. TFA and triethylsilane were removed under vacuum. The remaining oil was treated with hexanes (550 mL), and the mixture was stirred at room temperature for an hour, after which time the hexanes was decanted. An additional 250 mL of hexanes was added, stirred for an hour, and then decanted. The remaining oil was basified with 2 N NaOH (ca. 360 mL) until it reached pH = 10, and then it was extracted with CH<sub>2</sub>Cl<sub>2</sub> (2 × 400 mL, 2 × 200 mL). The organic layers were combined and washed with brine (2 × 300 mL) and then dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>. Evaporation of the solvent gave the title compound (36 g, 83% yield). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz) δ 7.19 (d, <i>J</i> = 8.0 Hz, 1H), 7.01 (d, <i>J</i> = 7.2 Hz, 1H), 6.62 (dd, <i>J</i> = 8.1, 7.2 Hz, 1H), 3.98–3.96 (m, 2H), 3.22–3.16 (m, 1H), 3.06 (dd, <i>J</i> = 13.0, 5.8 Hz, 1H), 2.98 (ddd, <i>J</i> = 12.6, 9.0, 3.6 Hz, 1H), 2.89 (dd, <i>J</i> = 13.0, 7.7 Hz, 1H), 2.82–2.73 (m, 1H), 2.02–1.78 (m, 2H), 1.73–1.65 (m, 1H). MS (ESI) <i>m</i>/<i>z</i> 253.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_3_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> Step c: (<i>cis</i>)-Ethyl 6-Bromo-3,4,4a,5-tetrahydro-1<i>H</i>-pyrido[4,3-<i>b</i>]indole-2(9b<i>H</i>)-carboxylate (<i>cis</i>-<b>19</b>)</h4><div class="NLM_p last">A suspension of <i>cis</i>-<b>18</b> (36 g, 142 mmol) and triethylamine (24 mL, 171 mmol) in THF (300 mL) was cooled in an ice–water bath, and then ethyl chloroformate (13.5 mL, 142 mmol) was added dropwise via syringe pump over 30 min. The ice–water bath was removed, and the reaction mixture was stirred at room temperature for another hour. The reaction mixture was passed through a pad of Celite. Evaporation of solvent gave the title compound (39 g, 84% yield)) as a cream-colored solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) δ 7.20 (d, <i>J</i> = 8.1 Hz, 1H). 7.04 (d, <i>J</i> = 7.2 Hz, 1H), 6.60 (t, <i>J</i> = 7.7 Hz, 1H), 4.21–3.95 (m, 4H), 3.95–3.66 (br, 1H), 3.66–3.52 (m, 1H), 3.52–3.22 (m, 3H), 1.99–1.85 (m, 1H), 1.85–1.73 (m, 1H), 1.35–1.20 (m, 3H). MS (ESI) <i>m</i>/<i>z</i> 325.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_3_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> Step d: (<i>cis</i>)-Ethyl 6-(Diphenylmethyleneamino)-3,4,4a,5-tetrahydro-1<i>H</i>-pyrido[4,3-<i>b</i>]indole-2(9b<i>H</i>)-carboxylate (<i>cis</i>-<b>20</b>)</h4><div class="NLM_p last"><i>cis</i>-<b>19</b> (26 g, 80 mmol), benzophenone imine (16 g, 88 mmol), <i>t</i>-BuONa (15.1 g, 157 mmol), and BINAP (1.53 g, 2.5 mmol) were placed in a 1 L three-neck round-bottom flask equipped with a condenser and a Teflon covered thermocouple. Toluene (300 mL) was added, and nitrogen was bubbled into the suspension through a steel needle through a hole bored in the septum. The temperature was gradually raised to 60 °C via a heating mantle. The heating mantle was then removed, and the flask was cooled to ambient temperature with nitrogen bubbling. Pd<sub>2</sub>(dba)<sub>3</sub> (830 mg, 0.80 mmol) was added, and the flask was warmed up to 60 °C while nitrogen was bubbled through it. The reaction mixture was heated at 105 °C overnight under nitrogen atmosphere and then cooled and diluted with <i>t-</i>butyl methyl ether (1.25 L). The resulting suspension was passed through a pad of Celite and evaporated to dryness under vacuum to give the title compound (31.5 g, 93% yield) as a brown foamy solid. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 500 MHz) δ 7.68 (d, <i>J</i> = 7.4 Hz, 2H), 7.52 (m, 1H), 7.45 (m, 2H), 7.34–7.27 (m, 3H), 7.22–7.14 (m, 2H), 6.64 (d, <i>J</i> = 7.3 Hz, 1H), 6.29 (t, <i>J</i> = 7.5 Hz, 1H), 6.11 (d, <i>J</i> = 7.8 Hz, 1H), 5.23 (s, 1H), 4.04–3.97 (m, 2H), 3.82 (m, 1H), 3.63 (m, 1H), 3.42 (m, 1H), 3.23–3.12 (m, 2H), 2.97 (m, 1H), 1.81–1.74 (m, 1H), 1.70–1.64 (m, 1H), 1.15 (t, <i>J</i> = 7.0 Hz, 3H). MS (ESI) <i>m</i>/<i>z</i> 426.2 [M + H]<sup>+</sup>.</div></div><div id="sec5_3_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> Steps e and f: (<i>cis</i>)-2-Oxo-2,3,6b,9,10,10a-hexahydro-1<i>H</i>,7<i>H</i>-pyrido[3′,4′:4,5]pyrrolo[1,2,3-<i>de</i>]quinoxaline-8-carboxylic Acid Ethyl Ester (<i>cis</i>-<b>21</b>)</h4><div class="NLM_p last">A suspension of compound <i>cis</i>-<b>20</b> (63 g, 148 mmol), ethyl bromoacetate (22 mL, 198 mmol), Na<sub>2</sub>CO<sub>3</sub> (22.6 g, 213 mmol), and KI (30.9 g, 186 mmol) in acetone (1.5 L) was refluxed for 16 h. Acetone was removed under vacuum, and the residue was diluted with CH<sub>2</sub>Cl<sub>2</sub> (700 mL) and then washed with water (500 mL) and brine (200 mL) and dried over Na<sub>2</sub>SO<sub>4</sub>. Evaporation of the solvent gave an oil, which was then dissolved in THF (400 mL). Then 2 N HCl (140 mL) was added in portions at room temperature. After the reaction was completed (about 1.5 h), THF was removed under reduced pressure and the residue was treated with 1 N HCl (200 mL). After filtration, the resulting brown solid was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (250 mL), washed with brine (150 mL), and dried over Na<sub>2</sub>SO<sub>4</sub>. Evaporation of the solvent and flash chromatography of the residue on alumina eluting with a gradient of hexanes and ethyl acetate to CH<sub>2</sub>Cl<sub>2</sub> and methanol, gave the title compound (32.5 g, 73% yield). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) δ 9.46 (s, 1H), 6.85 (d, <i>J</i> = 7.0 Hz, 1H), 6.78–6.67 (m, 2H), 4.23–3.81 (m, 5H), 3.48–3.27 (m, 3H), 3.26–3.08 (m, 1H), 2.76 (br, 1H), 1.94 (br, 1H), 1.35–1.21 (m, 3H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 75 MHz) δ 167.6, 155.6, 138.0, 129.3, 123.3, 120.9, 119.2, 113.4, 66.5, 61.6, 52.1, 45.7, 41.4, 39.7, 24.5, 14.9. MS (ESI) <i>m</i>/<i>z</i> 302.3 [M + H]<sup>+</sup>.</div></div><div id="sec5_3_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> Steps g and h: (<i>cis</i>)-3-Methyl-2,3,6b,9,10,10a-hexahydro-1<i>H</i>,7<i>H</i>-pyrido[3′,4′:4,5]pyrrolo[1,2,3-<i>de</i>]quinoxaline-8-carboxylic Acid Ethyl Ester (<i>cis</i>- <b>22</b>)</h4><div class="NLM_p"><i>cis</i>-<b>21</b> (17.3 g, 57.5 mmol), K<sub>2</sub>CO<sub>3</sub> (15.8 g, 114 mmol), and methyl iodide (66 mL, 1.06 mol) were placed in a 2 L pressure bottle, and then acetone (500 mL) was added. The bottle was heated in an oil bath (109 °C) for 5.5 h and then cooled to room temperature. After solvents were removed under reduced pressure, the residue was treated with water (200 mL) and then extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 × 200 mL). The combined organic phase was washed with brine (2 × 200 mL), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and then evaporated to dryness to provide (<i>cis</i>)-3-methyl-2-oxo-2,3,6b,9,10,10a-hexahydro-1<i>H</i>,7<i>H</i>-pyrido[3′,4′:4,5]pyrrolo[1,2,3-<i>de</i>]quinoxaline-8-carboxylic acid ethyl ester (18 g, 99% crude yield), which was taken to the next step without further purification.</div><div class="NLM_p last">To a suspension of the above intermediate (18 g, 57 mmol) in THF (50 mL), BH<sub>3</sub>·THF (1.0 M in THF, 143 mL, 143 mmol) was added slowly at room temperature over 15 min. After the completion of the addition, the reaction mixture was refluxed for 3 h. The reaction mixture was then cooled with an ice–water bath and 6 N HCl (150 mL) was added dropwise. After the THF was removed under reduced pressure, 2 N NaOH was added to adjust the pH to 9. The mixture was extracted with CH<sub>2</sub>Cl<sub>2</sub> (500 mL). The CH<sub>2</sub>Cl<sub>2</sub> layer was washed with brine and water successively, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and then evaporated to dryness to give the title compound (17 g, 99% yield) as a dense oil. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) δ 6.66 (t, <i>J</i> = 7.7 Hz, 1H). 6.54 (d, <i>J</i> = 7.2 Hz, 1H), 6.41(d, <i>J</i> = 7.8 Hz, 1H), 4.24–3.78 (m, 4H), 3.64–3.54 (m, 1H), 3.38–3.22 (m, 3H), 3.22–3.02 (m, 2H), 2.92–2.74 (m, 5H), 1.95–1.79 (m, 2H), 1.28 (t, <i>J</i> = 7.0 Hz, 3H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 75 MHz) δ 155.6, 138.2, 135.1, 128.8, 120.6, 113.3, 109.3, 65.0, 61.4, 50.7, 45.8, 44.4, 41.4, 39.9, 37.7, 24.7, 14.9. MS (ESI) <i>m</i>/<i>z</i> 302.2 [M + H]<sup>+</sup>.</div></div><div id="sec5_3_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> Steps i and j: (<i>cis</i>)-8-[3-(4-Fluorophenoxy)propyl]-3-methyl-2,3,6b,7,8,9,10,10a-octahydro-1<i>H</i>-pyrido[3′,4′:4,5]pyrrolo[1,2,3-<i>de</i>]quinoxaline (<i>cis</i>-<b>23</b>, R<sub>3</sub> = 3-(4-fluorophenoxy)propyl)</h4><div class="NLM_p"><i>cis</i>-<b>22</b> (17 g, 56 mmol), KOH (12.7 g, 226 mmol), and <i>n</i>-butanol (90 mL) were placed in a 300 mL pressure bottle and heated in an oil bath at 120 °C for 3 h. After <i>n</i>-butanol was removed under vacuum, the residue was treated with water (300 mL) and then extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 × 100 mL). The combined organic phase was washed with brine (2 × 200 mL), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and then evaporated to dryness to give (<i>cis</i>)-3-methyl-2,3,6b,7,8,9,10,10a-octahydro-1<i>H</i>-pyrido[3′,4′:4,5]pyrrolo[1,2,3-<i>de</i>]quinoxaline (11.7 g, 91% yield) as a dense oil, which was taken to the next step without further purification.</div><div class="NLM_p last">A suspension of the above intermediate (1.2 g, 5.2 mmol), 1-(3-chloropropoxy)-4-fluorobenzene (1.4 g, 7.5 mmol), triethylamine (3.0 mL, 21 mmol), and KI (1.3 g, 7.8 mmol) in dioxane (6 mL) and toluene (6 mL) was refluxed for 7 h. The reaction mixture was cooled and then filtered. The filtrate was evaporated, and the residue was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (20 mL), washed with brine twice, dried over Na<sub>2</sub>SO<sub>4</sub>, and then filtered. The filtrate was concentrated to one-third of the volume and then added dropwise to a 0.5 N HCl ether solution. The formed solid was collected, washed with ether, and then dissolved in water. The aqueous solution was basified with 2 N NaOH and extracted with CH<sub>2</sub>Cl<sub>2</sub> three times. The combined organic phase was washed with brine twice, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and then concentrated. The residue was purified by silica-gel flash chromatography to give the title compound (1.1 g, 55% yield) as a dense oil. MS (ESI) <i>m</i>/<i>z</i> 382.2 [M + H]<sup>+</sup>.</div></div><div id="sec5_3_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> Step k: (6b<i>R</i>,10a<i>S</i>)-8-[3-(4-Fluorophenoxy)propyl]-3-methyl-2,3,6b,7,8,9,10,10a-octahydro-1<i>H</i>-pyrido[3′,4′:4,5]pyrrolo[1,2,3-<i>de</i>]quinoxaline (<b>41</b>)</h4><div class="NLM_p last"><i>cis</i>-<b>23</b> (100 mg, 0.26 mmol) was dissolved in ethanol and resolved by HPLC using a Chiral AD-H column (2.0 cm × 25 cm) eluting with ethanol containing 0.1% diethylamine. The corresponding peak was collected, concentrated, and dried under vacuum to give the title compound (35 mg, 35% yield) as a pale-yellow oil. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) δ 7.00−6.90 (m, 2H), 6.87−6.78 (m, 2H), 6.65 (t, <i>J</i> = 7.6 Hz, 1H), 6.51 (d, <i>J</i> = 7.3 Hz, 1H), 6.41 (dd, <i>J</i> = 8.0, 1.0 Hz, 1H), 3.97 (t, <i>J</i> = 6.4 Hz, 2H), 3.66−3.54 (m, 1H), 3.37−3.09 (m, 4H), 2.87 (s, 3H), 2.94−2.77 (m, 2H), 2.75−2.60 (m, 1H), 2.58−2.39 (m, 2H), 2.36−2.19 (m, 1H), 2.06−1.83 (m, 5H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>, 126 MHz) δ 156.4 (d, <i>J</i><sub>CF</sub> = 236 Hz), 155.0, 137.7, 134.8, 129.6, 119.7, 115.7 (d, <i>J</i><sub>CF</sub> = 23 Hz), 115.6 (d, <i>J</i><sub>CF</sub> = 8 Hz), 112.3, 108.6, 66.4, 64.1, 56.1, 54.5, 50.0, 48.8, 43.8, 41.1, 37.1, 26.4, 24.5. MS (ESI) <i>m</i>/<i>z</i> 382.2 [M + H]<sup>+</sup>. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>23</sub>H<sub>29</sub>FN<sub>3</sub>O [M + H]<sup>+</sup>, 382.2295; found, 382.2294. UPLC purity, 98.4%; retention time, 2.08 min (method A).</div></div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> Representative Synthetic Procedures of Tetracyclic Derivatives Shown in Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a> via Scheme <a class="ref internalNav" href="#sch3" aria-label="3">3</a>. 4-((8a<i>S</i>,12a<i>R</i>)-4,5,6,7,9,10,12,12a-Octahydroazepino[3,2,1-<i>hi</i>]pyrido[4,3-<i>b</i>]indol-11(8a<i>H</i>)-yl)-1-(4-fluorophenyl)-1-butanone (<b>62</b>, X = CH<sub>2</sub>, R<sub>4</sub> = R<sub>5</sub> = H, m = 2, n = 1, a = <i>R</i>, b = <i>S</i>)</h3><div id="sec5_4_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> Step a: 4,5,6,7,9,10,11,12-Octahydroazepino[3,2,1-<i>hi</i>]pyrido[4,3-<i>b</i>]indole (<b>27c</b>)</h4><div class="NLM_p">Sodium azide (1.95 g, 30 mmol) was added in small portions to a solution of 3,4-dihydro-(2<i>H</i>)-naphthalenone (2.92 g, 20 mmol) in CH<sub>3</sub>SO<sub>3</sub>H (50 mL) at 0 °C. The mixture was stirred at 0 °C for 15 min, then 1 h at room temperature and then poured into ice (400 mL). The mixture was basified until pH >8 with 1 N NaOH at 0 °C and extracted with ether (3 × 100 mL). The combined organic phase was dried over MgSO<sub>4</sub>, concentrated under vacuum, and then purified by silica gel flash column chromatography eluting with 50% ethyl acetate in hexanes to give 1,3,4,5-tetrahydro-2<i>H</i>-1-benzazepin-2-one (2.71 g, 84% yield) as a white solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) δ 8.10 (br, 1H), 7.22 (d, <i>J</i> = 7.0 Hz, 2H), 7.13 (td, <i>J</i> = 7.6, 1.5 Hz, 1H),), 6.99 (d, <i>J</i> = 8.1 Hz, 1H), 2.80 (t, <i>J</i> = 7.6 Hz, 2H), 2.36 (t, <i>J</i> = 7.1 Hz, 2H), 2.32–2.18 (m, 2H).</div><div class="NLM_p">A solution of 1,3,4,5-tetrahydro-2<i>H</i>-1-benzazepin-2-one (2.71 g, 16.8 mmol) in THF (40 mL) was added dropwise to a suspension of lithium aluminum hydride (1.27 g, 33.4 mmol) in ether (150 mL) at room temperature. The mixture was refluxed for 16 h. Saturated potassium sodium tartrate salt solution (15 mL) was added to the mixture which was cooled with an ice–water bath. The mixture was stirred for 2 h and the two layers were separated. The aqueous layer was extracted with ether (2 × 25 mL). The combined organic phase was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, concentrated in vacuum, and purified by flash column chromatography eluting with 30% ethyl acetate in hexanes to give 2,3,4,5-tetrahydro-1<i>H</i>-1-benzazepine (2.40 g, 97% yield) as a yellow liquid. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) δ 7.11 (d, <i>J</i> = 7.4 Hz, 1H). 7.04 (td, <i>J</i> = 7.5, 1.5 Hz, 1H), 6.82 (td, <i>J</i> = 7.3, 1.1 Hz, 1H), 6.74 (dd, <i>J</i> = 7.7, 1.1 Hz, 1H), 3.78 (br, 1H), 3.10–3.00 (m, 2H), 2.82– 2.72 (m, 2H), 1.86–1.72 (m, 2H), 1.70–1.58 (m, 2H).</div><div class="NLM_p">A solution of NaNO<sub>2</sub> (1.35 g, 19.6 mmol) in water (4.0 mL) was added dropwise to a solution of 2,3,4,5-tetrahydro-1<i>H</i>-1-benzazepine (2.40 g, 16.3 mmol) in acetic acid (10 mL) at 0–10 °C. The mixture was stirred at 5 °C for 10 min, then at room temperature for 1 h, and then extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 × 20 mL). The combined organic phase was dried over MgSO<sub>4</sub>, concentrated under vacuum, and then purified by silica gel flash column chromatography to give 1-nitroso-2,3,4,5-tetrahydro-1<i>H</i>-1-benzazepine (2.60 g, 91% yield) as a brown liquid. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) δ 7.48–7.40 (m, 1H), 7.40–7.32 (m, 2H), 7.32–7.25 (m, 1H), 3.92 (br, 2H), 2.82–2.70 (m, 2H), 1.85–1.70 (m, 4H).</div><div class="NLM_p">A solution of 1-nitroso-2,3,4,5-tetrahydro-1<i>H</i>-1-benzazepine (2.60 g, 14.7 mmol) in THF (40 mL) was added dropwise under nitrogen atmosphere to a suspension of lithium aluminum hydride (0.56 g, 14.7 mmol) in THF (10 mL) cooled with an ice-bath such that the temperature did not rise above 15 °C. The mixture was stirred at room temperature for an hour, quenched with saturated potassium sodium tartrate salt solution (15 mL), and extracted with ether (3 × 20 mL). The combined organic phase was dried over Na<sub>2</sub>SO<sub>4</sub>, concentrated under vacuum, and further purified by flash column chromatography using 25% ethyl acetate in hexanes to give 2,3,4,5-tetrahydro-1<i>H</i>-l-benzazepinamine <b>26c</b> (1.63 g, 68% yield) as a light-yellow solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) δ 7.28 (dd, <i>J</i> = 1.4, 8.0 Hz, 1H), 7.21 (td, <i>J</i> = 8.0, 1.4 Hz, 1H), 7.10 (dd, <i>J</i> = 1.1, 7.4 Hz, 1H), 6.91 (td, <i>J</i> = 7.3, 1.5 Hz, 1H), 3.78 (br, 2H), 3.22–3.18 (m, 2H), 2.82–2.70 (m, 2H), 1.92–1.78 (m, 2H), 1.72–1.50 (m, 2H).</div><div class="NLM_p last">A mixture of 4-piperidone hydrochloride monohydrate (1.54 g, 10 mmol) and <b>26c</b> (1.62 g, 10 mmol) in 2-propanol (50 mL) was refluxed for 2 h and then cooled to room temperature. Concentrated HCl (0.82 mL, 10 mmol) was added, and the resulting mixture was refluxed for 3 h before being cooled to room temperature. The solid was filtered, rinsed with cold 2-propanol (2 × 20 mL), and dried under vacuum to give the title compound (1.88 g, 71% yield) as a hydrochloride salt. A small amount (20 mg) of the hydrochloride salt was converted into free base form by basifying with 1N NaOH, followed by extraction with CHCl<sub>3</sub>, washing with brine, and drying under vacuum to give the title compound as a white foamy solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) δ 7.25 (dd, <i>J</i> = 1.0, 7.4 Hz, 1H), 6.98 (t, <i>J</i> = 7.4 Hz, 1H), 6.92 (d, <i>J</i> = 6.3 Hz, 1H), 4.05 (t, <i>J</i> = 1.6 Hz, 2H), 4.02–3.92 (m, 2H), 3.25 (t, <i>J</i> = 5.6 Hz, 2H), 3.20–3.05 (m, 2H), 2.72 (t, <i>J</i> = 5.7 Hz, 2H), 2.20–2.00 (m, 4H), 1.83 (m, 1H). MS (ESI) <i>m</i>/<i>z</i> 227.2 [M + H]<sup>+</sup>.</div></div><div id="sec5_4_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> Step b and c: (<i>cis</i>)-4,5,6,7,9,10,12,12a-Octahydro-pyrido[3′,4′:4,5]pyrrolo[3,2,1-<i>jk</i>][1]benzazepine-11(8a<i>H</i>)-carboxylic Acid, 1,1-Dimethylethyl Ester (<i>cis</i>-<b>28c</b>)</h4><div class="NLM_p">Sodium cyanoborohydride (0.94 g, 15 mmol) was added in small portions to a solution of <b>27c</b> hydrochloride salt (1.32 g, 5.0 mmol) in TFA (15 mL) at 0 °C. After stirring at room temperature for 2 h, the mixture was carefully treated with 6 N HCl (10 mL) and refluxed for 1 h. The mixture was basified with 50% NaOH and extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 × 20 mL). The combined organic phase was dried over MgSO<sub>4</sub> and concentrated under vacuum to give (<i>cis</i>)-4,5,6,7,8a,9,10,11,12,12a-decahydro-pyrido[3′,4′:4,5]pyrrolo[3,2,1-<i>jk</i>][1]benzazepine (1.0 g, 88% yield) as a yellow oil. MS (ESI) <i>m</i>/<i>z</i> 229.2 [M + H]<sup>+</sup>.</div><div class="NLM_p last">First, 1N NaOH (10 mL) was added to a solution of (<i>cis</i>)-4,5,6,7,8a,9,10,11,12,12a-decahydropyrido[3′,4′:4,5]pyrrolo[3,2,1-<i>jk</i>][1]benzazepine (1.0 g, 4.38 mmol) and di-<i>tert</i>-butyl dicarbonate (1.05 g, 4.8 mmol) in 1,4-dioxane (20 mL), and the mixture was then stirred for 2 h at room temperature. After the solvent was removed under reduced pressure, the residue was treated with ethyl acetate (30 mL). The solution was washed with brine (30 mL), dried over MgSO<sub>4</sub>, concentrated under vacuum, and then purified by flash column chromatography using 20% ethyl acetate in hexanes to give the title compound (1.2 g, 83% yield) as a white solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz) δ 6.95 (d, <i>J</i> = 7.2 Hz, 1H), 6.90 (d, <i>J</i> = 7.5 Hz, 1H), 6.68 (t, <i>J</i> = 7.4 Hz, 1H), 3.65–3.55 (m, 1H), 3.48–3.29 (m, 3H), 3.29–3.20 (m, 1H), 3.12–2.71 (m, 2H), 2.71–2.50 (m, 2H), 2.08–1.83 (m, 4H), 1.83–1.62 (m, 1H), 1.62–1.07 (m, 11H). MS (ESI) <i>m</i>/<i>z</i> 329.2 [M + H]<sup>+</sup>.</div></div><div id="sec5_4_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> Steps d and e: (8a<i>S</i>,12a<i>R</i>)-4,5,6,7,8a,9,10,11,12,12a-Decahydro-pyrido[3′,4′:4,5]pyrrolo[3,2,1-<i>jk</i>][1]benzazepine (<b>29c</b>)</h4><div class="NLM_p last">(8a<i>S</i>,12a<i>R</i>)-4,5,6,7,9,10,12,12a-Octahydro-pyrido[3′,4′:4,5]pyrrolo[3,2,1-<i>jk</i>][1]benzazepine-11(8a<i>H</i>)-carboxylic acid, 1,1-dimethylethyl ester (0.24 g, 0.73 mmol), which was obtained by chiral separation of <i>cis</i>-<b>28c</b> on a Chiracel OD column eluting with 2% 2-propanol in hexane, was stirred in 20% TFA in CH<sub>2</sub>Cl<sub>2</sub> (10 mL) at room temperature for 2 h before the solution was basified with saturated ammonium hydroxide until pH > 10. The layers were separated, and the aqueous layer was extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 × 20 mL). The combined organic phase was washed with brine (20 mL), dried over MgSO<sub>4</sub>, concentrated, and dried under vacuum to give the title compound (0.16 g, 94% yield) as a white foamy solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz) δ 6.96–6.87 (m, 2H), 6.69 (t, <i>J</i> = 7.4 Hz, 1H), 4.57–3.58 (br, 1H) 3.35–3.19 (m, 3H), 3.10 (dd, <i>J</i> = 12.7, 6.3 Hz, 1H), 3.03–2.78 (m, 3H), 2.71–2.59 (m, 1H), 2.58–2.44 (m, 2H), 2.10–1.67 (m, 5H), 1.65–1.40 (m, 1H). MS (ESI) <i>m</i>/<i>z</i> 229.2 [M + H]<sup>+</sup>.</div></div><div id="sec5_4_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> 4-((8a<i>S</i>,12a<i>R</i>)-4,5,6,7,9,10,12,12a-Octahydroazepino[3,2,1-<i>hi</i>]pyrido[4,3-<i>b</i>]indol-11(8a<i>H</i>)-yl)-1-(4-fluorophenyl)-1-butanone (<b>62</b>)</h4><div class="NLM_p last">To a solution of <b>29c</b> (0.23 g, 1.0 mmol) in 1,4-dioxane (7.0 mL) were added 4-chloro-4′-fluorobutyrophenone (0.4 g, 2.0 mmol), KI (83 mg, 0.5 mmol), and K<sub>2</sub>CO<sub>3</sub> (0.28 g, 2.0 mmol). The reaction mixture was heated at 100 °C for 48 h, cooled to 20 °C, and then diluted with CHCl<sub>3</sub>. The solution was filtered to remove excess K<sub>2</sub>CO<sub>3</sub>, and the filtrate was concentrated under vacuum. The residue was purified by silica gel flash column chromatography eluting with a gradient of 0–2% methanol in ethyl acetate to give the title compound (0.26 g, 66% yield) as a dense oil. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz) δ 8.04–7.95 (m, 2H), 7.16–7.08 (m, 2H), 6.95–6.85 (m, 2H), 6.67 (t, <i>J</i> = 7.4 Hz, 1H), 3.27–3.20 (m, 1H), 3.20–3.11 (m, 2H), 2.97 (t, <i>J</i> = 7.2 Hz, 2H), 2.94–2.84 (m, 1H), 2.75 (dd, <i>J</i> = 11.4, 5.1 Hz, 1H), 2.70–2.58 (m, 2H), 2.54–2.43 (m, 1H), 2.43–2.30 (m, 2H), 2.30–2.19 (m, 1H), 2.05–1.89 (m, 5H), 1.89–1.68 (m, 3H), 1.61–1.48 (m, 1H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>, 126 MHz,) δ 198.4, 164.8 (d, <i>J</i><sub>CF</sub> = 251 Hz), 152.4, 133.8 (d, <i>J</i><sub>CF</sub> = 3 Hz), 133.4, 130.8 (d, <i>J</i><sub>CF</sub> = 9 Hz), 129.0, 126.3, 120.9, 118.9, 115.6 (d, <i>J</i><sub>CF</sub> = 22 Hz), 63.7, 57.1, 56.9, 51.4, 48.8, 40.2, 35.7, 34.7, 29.6, 26.9, 25.1, 21.6. MS (ESI) <i>m</i>/<i>z</i> 393.2 [M + H]<sup>+</sup>. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>25</sub>H<sub>30</sub>FN<sub>2</sub>O [M + H]<sup>+</sup>, 393.2342; found, 393.2332. UPLC purity, 99.0%; retention time, 2.29 min (method A).</div></div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> Rat Quipazine Head Twitch</h3><div class="NLM_p last">Different groups of male rats (<i>N</i> = 6 rats/dose/test substance) were fasted overnight and then placed in individual cells of a clear Lucite box. Varying concentrations of a test substance were administered by oral gavage to each rat 30 min prior to behavioral testing and 25 min prior to intraperitoneal injection of a standard dose (2.5 mg/kg) of quipazine maleate. Behavioral observations were begun 5 min after quipazine treatment. The number of stereotyped head twitch movements was counted for each rat by a trained observer over a 15 min period after quipazine treatment. The 50% effective dose (ED<sub>50</sub> value) for the inhibition of quipazine-induced head twitch was calculated for each test substance. At least two independent dose–response tests were conducted for each test substance, and the average ED<sub>50</sub> values were reported.</div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> Protocol for the Rat Conditioned Avoidance Response (CAR) Animal Model<a onclick="showRef(event, 'ref37 ref38'); return false;" href="javascript:void(0);" class="ref ref37 ref38">(37, 38)</a></h3><div class="NLM_p last">Adult, male Sprague–Dawley rats were trained to consistently escape an electric foot shock (0.75 mA pulsed current, 250 ms on, 750 ms off) delivered to the grid floor of the test chamber. Animals were allowed to escape the shock delivery by climbing onto a pole suspended from the ceiling of the test chamber. Different groups of rats (<i>N</i> = 5–6 rats/dose/test substance) were administered different concentrations of the test substance in a 0.5% methylcellulose vehicle solution or vehicle alone (10 mL/kg volume) by oral gavage. Compound <b>5</b> was administered to individual rats at doses ranging from 0.1 to 10 mg/kg. Haloperidol, an antipsychotic medication, was administered to rats at a dose of 2 mg/kg as a positive control. The ability of <b>5</b> or haloperidol to inhibit the CAR response was evaluated in rats at 2 h after PO drug administration. The 50% effective dose (ED<sub>50</sub>) for inhibition of CAR by compound <b>5</b> at 2 h postdosing was determined to be 1.5 mg/kg.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i42"><a href="/doi/suppl/10.1021/jm401958n">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_24334" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_24334" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Synthesis and analytical data of intermediates and final compounds not listed in the <a class="ref internalNav" href="#sec5" aria-label="Experimental Section">Experimental Section</a>, receptor profiling results, in vitro binding assays, and homology modeling and docking studies. This material is available free of charge via the Internet at <a href="http://pubs.acs.org" class="extLink">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm401958n/suppl_file/jm401958n_si_001.pdf">jm401958n_si_001.pdf (575.34 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/jm401958n" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_74640" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_74640" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Peng Li</span> - <span class="hlFld-Affiliation affiliation">Intra-Cellular
Therapies, Inc., 3960
Broadway, New York, New York 10032, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#26564a4f664f4852544745434a4a534a4754524e435447564f43550845494b"><span class="__cf_email__" data-cfemail="1c6c70755c7572686e7d7f79707069707d6e6874796e7d6c75796f327f7371">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Qiang Zhang</span> - <span class="hlFld-Affiliation affiliation">Intra-Cellular
Therapies, Inc., 3960
Broadway, New York, New York 10032, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Albert J. Robichaud</span> - <span class="hlFld-Affiliation affiliation">Medicinal
Chemistry, Bristol-Myers Squibb Research
and Development, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Taekyu Lee</span> - <span class="hlFld-Affiliation affiliation">Medicinal
Chemistry, Bristol-Myers Squibb Research
and Development, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">John Tomesch</span> - <span class="hlFld-Affiliation affiliation">Intra-Cellular
Therapies, Inc., 3960
Broadway, New York, New York 10032, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wei Yao</span> - <span class="hlFld-Affiliation affiliation">Intra-Cellular
Therapies, Inc., 3960
Broadway, New York, New York 10032, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">J. David Beard</span> - <span class="hlFld-Affiliation affiliation">Intra-Cellular
Therapies, Inc., 3960
Broadway, New York, New York 10032, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gretchen L. Snyder</span> - <span class="hlFld-Affiliation affiliation">Intra-Cellular
Therapies, Inc., 3960
Broadway, New York, New York 10032, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hongwen Zhu</span> - <span class="hlFld-Affiliation affiliation">Intra-Cellular
Therapies, Inc., 3960
Broadway, New York, New York 10032, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Youyi Peng</span> - <span class="hlFld-Affiliation affiliation">Intra-Cellular
Therapies, Inc., 3960
Broadway, New York, New York 10032, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Joseph P. Hendrick</span> - <span class="hlFld-Affiliation affiliation">Intra-Cellular
Therapies, Inc., 3960
Broadway, New York, New York 10032, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kimberly E. Vanover</span> - <span class="hlFld-Affiliation affiliation">Intra-Cellular
Therapies, Inc., 3960
Broadway, New York, New York 10032, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Robert E. Davis</span> - <span class="hlFld-Affiliation affiliation">3D
Pharmaceutical Consultants, Inc., 13272 Glencliff Way, San Diego, California 92130, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sharon Mates</span> - <span class="hlFld-Affiliation affiliation">Intra-Cellular
Therapies, Inc., 3960
Broadway, New York, New York 10032, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lawrence P. Wennogle</span> - <span class="hlFld-Affiliation affiliation">Intra-Cellular
Therapies, Inc., 3960
Broadway, New York, New York 10032, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare the following competing financial interest(s): Peng Li, Qiang Zhang, Wei Yao, J. David Beard, Gretchen L. Snyder, Youyi Peng, Joseph P. Hendrick, Kimberly E. Vanover, Sharon Mates and Lawrence P. Wennogle are full-time employees of Intra-Cellular Therapies, Inc. (ITI). John Tomesch is a retired employee of ITI. Hongwen Zhu is a former employee of ITI. Albert J. Robichaud and Taekyu Lee are former employees of Bristol-Myers Squibb. Robert E. Davis is a paid consultant to ITI.<br /></br></div></li></ul></div><div class="ack" id="ACK-d839e5881-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i46">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_43500" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_43500" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The authors wish to thank all team members from Intra-Cellular Therapies, Inc., Bristol-Myers Squibb Company and DuPont Pharmaceutical Company for their contributions to this project. We thank Dr. Richard Lerner at the Scripps Research Institute for his thoughtful comments on the manuscript.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i47" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i47"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i48" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i48"> Abbreviations Used</h2><tr><td class="NLM_term">BINAP</td><td class="NLM_def"><p class="first last">2,2′-bis(diphenylphosphino)-1,1′-binaphthyl</p></td></tr><tr><td class="NLM_term">CHO cells</td><td class="NLM_def"><p class="first last">Chinese hamster ovary cells</p></td></tr><tr><td class="NLM_term">CNS</td><td class="NLM_def"><p class="first last">central nervous system</p></td></tr><tr><td class="NLM_term">EPS</td><td class="NLM_def"><p class="first last">extrapyramidal symptoms</p></td></tr><tr><td class="NLM_term">Eu-GTP</td><td class="NLM_def"><p class="first last">europium-labeled GTP analogue</p></td></tr><tr><td class="NLM_term">5-HT</td><td class="NLM_def"><p class="first last">serotonin or 5-hydroxytryptamine</p></td></tr><tr><td class="NLM_term">MDCK</td><td class="NLM_def"><p class="first last">Madin–Darby canine kidney</p></td></tr><tr><td class="NLM_term">MDR1</td><td class="NLM_def"><p class="first last">multidrug resistance protein 1</p></td></tr><tr><td class="NLM_term">Pd<sub>2</sub>(dba)<sub>3</sub></td><td class="NLM_def"><p class="first last">tris(dibenzylideneacetone)-dipalladium(0)</p></td></tr><tr><td class="NLM_term">PPHT</td><td class="NLM_def"><p class="first last">2-(<i>N</i>-phenethyl-<i>N</i>-propyl)amino-5-hydroxytetralin</p></td></tr><tr><td class="NLM_term">SERT</td><td class="NLM_def"><p class="first last">serotonin transporter</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationships</p></td></tr><tr><td class="NLM_term">TFA</td><td class="NLM_def"><p class="first last">trifluoroacetic acid</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i49">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_40020" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_40020" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 40 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Wickelgren, I.</span><span> </span><span class="NLM_article-title">A new route to treating schizophrenia?</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">281</span><span class="NLM_x">, </span> <span class="NLM_fpage">1264</span><span class="NLM_x">–</span> <span class="NLM_lpage">1265</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=281&publication_year=1998&pages=1264-1265&author=I.+Wickelgren&title=A+new+route+to+treating+schizophrenia%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWickelgren%26aufirst%3DI.%26atitle%3DA%2520new%2520route%2520to%2520treating%2520schizophrenia%253F%26jtitle%3DScience%26date%3D1998%26volume%3D281%26spage%3D1264%26epage%3D1265" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Marino, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knutsen, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, M.</span><span> </span><span class="NLM_article-title">Emerging opportunities for antipsychotic drug discovery in the postgenomic era</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">1077</span><span class="NLM_x">–</span> <span class="NLM_lpage">1107</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm701094q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=1077-1107&author=M.+J.+Marinoauthor=L.+J.+Knutsenauthor=M.+Williams&title=Emerging+opportunities+for+antipsychotic+drug+discovery+in+the+postgenomic+era"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1021%2Fjm701094q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm701094q%26sid%3Dliteratum%253Aachs%26aulast%3DMarino%26aufirst%3DM.%2BJ.%26aulast%3DKnutsen%26aufirst%3DL.%2BJ.%26aulast%3DWilliams%26aufirst%3DM.%26atitle%3DEmerging%2520opportunities%2520for%2520antipsychotic%2520drug%2520discovery%2520in%2520the%2520postgenomic%2520era%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D1077%26epage%3D1107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Remington, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agid, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foussias, G.</span><span> </span><span class="NLM_article-title">Schizophrenia as a disorder of too little dopamine: implications for symptoms and treatment</span> <span class="citation_source-journal">Expert Rev. Neurother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">589</span><span class="NLM_x">–</span> <span class="NLM_lpage">607</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm401958n&amp;key=10.1586%2Fern.10.191" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm401958n&amp;key=21469931" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm401958n&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktlyqtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=589-607&author=G.+Remingtonauthor=O.+Agidauthor=G.+Foussias&title=Schizophrenia+as+a+disorder+of+too+little+dopamine%3A+implications+for+symptoms+and+treatment"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Schizophrenia as a disorder of too little dopamine: implications for symptoms and treatment</span></div><div class="casAuthors">Remington, Gary; Agid, Ofer; Foussias, George</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Neurotherapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">589-607</span>CODEN:
                <span class="NLM_cas:coden">ERNXAR</span>;
        ISSN:<span class="NLM_cas:issn">1473-7175</span>.
    
            (<span class="NLM_cas:orgname">Expert Reviews Ltd.</span>)
        </div><div class="casAbstract">A review.  Antipsychotics represent the first effective therapy for schizophrenia, with their benefits linked to dopamine D2 blockade.  Schizophrenia was soon identified as a hyperdopaminergic disorder, and antipsychotics proved to be reasonably effective in controlling pos. symptoms.  However, over the years, schizophrenia has been reconceptualized more broadly, now defined as a heterogeneous disorder with multiple symptom domains.  Neg. and cognitive features, not particularly responsive to antipsychotic therapy, have taken on increased importance -- current thinking suggests that these domains predate the onset of pos. symptoms and are more closely tied to functional outcome.  That they are better understood in the context of decreased dopamine activity suggests that schizophrenia may fundamentally represent a hypodopaminergic disorder.  This shift in thinking has important theor. implications from the standpoint of etiol. and pathophysiol., but also clin. in terms of treatment and drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKxDPNplr2yrVg90H21EOLACvtfcHk0lg747xPW6-Dtw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktlyqtbo%253D&md5=65a8003827406d9e7ba57f1a60222940</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1586%2Fern.10.191&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252Fern.10.191%26sid%3Dliteratum%253Aachs%26aulast%3DRemington%26aufirst%3DG.%26aulast%3DAgid%26aufirst%3DO.%26aulast%3DFoussias%26aufirst%3DG.%26atitle%3DSchizophrenia%2520as%2520a%2520disorder%2520of%2520too%2520little%2520dopamine%253A%2520implications%2520for%2520symptoms%2520and%2520treatment%26jtitle%3DExpert%2520Rev.%2520Neurother.%26date%3D2011%26volume%3D11%26spage%3D589%26epage%3D607" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Kim, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maneen, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stahl, S. M.</span><span> </span><span class="NLM_article-title">Building a better antipsychotic: receptor targets for the treatment of multiple symptom dimensions of schizophrenia</span> <span class="citation_source-journal">Neurotherapeutics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">78</span><span class="NLM_x">–</span> <span class="NLM_lpage">85</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2009&pages=78-85&author=D.+H.+Kimauthor=M.+J.+Maneenauthor=S.+M.+Stahl&title=Building+a+better+antipsychotic%3A+receptor+targets+for+the+treatment+of+multiple+symptom+dimensions+of+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DD.%2BH.%26aulast%3DManeen%26aufirst%3DM.%2BJ.%26aulast%3DStahl%26aufirst%3DS.%2BM.%26atitle%3DBuilding%2520a%2520better%2520antipsychotic%253A%2520receptor%2520targets%2520for%2520the%2520treatment%2520of%2520multiple%2520symptom%2520dimensions%2520of%2520schizophrenia%26jtitle%3DNeurotherapeutics%26date%3D2009%26volume%3D6%26spage%3D78%26epage%3D85" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Muench, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamer, A. M.</span><span> </span><span class="NLM_article-title">Adverse effects of antipsychotic medications</span> <span class="citation_source-journal">Am. Fam. Physician</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">81</span><span class="NLM_x">, </span> <span class="NLM_fpage">617</span><span class="NLM_x">–</span> <span class="NLM_lpage">622</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm401958n&amp;key=20187598" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm401958n&amp;key=1%3ACAS%3A280%3ADC%252BC3c7ktlynsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2010&pages=617-622&author=J.+Muenchauthor=A.+M.+Hamer&title=Adverse+effects+of+antipsychotic+medications"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Adverse effects of antipsychotic medications</span></div><div class="casAuthors">Muench John; Hamer Ann M</div><div class="citationInfo"><span class="NLM_cas:title">American family physician</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">617-22</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The use of antipsychotic medications entails a difficult trade-off between the benefit of alleviating psychotic symptoms and the risk of troubling, sometimes life-shortening adverse effects.  There is more variability among specific antipsychotic medications than there is between the first- and second-generation antipsychotic classes.  The newer second-generation antipsychotics, especially clozapine and olanzapine, generally tend to cause more problems relating to metabolic syndrome, such as obesity and type 2 diabetes mellitus.  Also, as a class, the older first-generation antipsychotics are more likely to be associated with movement disorders, but this is primarily true of medications that bind tightly to dopaminergic neuroreceptors, such as haloperidol, and less true of medications that bind weakly, such as chlorpromazine.  Anticholinergic effects are especially prominent with weaker-binding first-generation antipsychotics, as well as with the second-generation antipsychotic clozapine.  All antipsychotic medications are associated with an increased likelihood of sedation, sexual dysfunction, postural hypotension, cardiac arrhythmia, and sudden cardiac death.  Primary care physicians should understand the individual adverse effect profiles of these medications.  They should be vigilant for the occurrence of adverse effects, be willing to adjust or change medications as needed (or work with psychiatric colleagues to do so), and be prepared to treat any resulting medical sequelae.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTKTaXFsO12OOIHSmpohpd0fW6udTcc2eaLxeFRgwzEMrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3c7ktlynsQ%253D%253D&md5=2bac8b3c75c7610f7d59f5a34b296723</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMuench%26aufirst%3DJ.%26aulast%3DHamer%26aufirst%3DA.%2BM.%26atitle%3DAdverse%2520effects%2520of%2520antipsychotic%2520medications%26jtitle%3DAm.%2520Fam.%2520Physician%26date%3D2010%26volume%3D81%26spage%3D617%26epage%3D622" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Meltzer, H. Y.</span><span> </span><span class="NLM_article-title">Clozapine: balancing safety with superior antipsychotic efficacy</span> <span class="citation_source-journal">Clin. Schizophrenia Relat. Psychoses</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">134</span><span class="NLM_x">–</span> <span class="NLM_lpage">144</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Fjm401958n&amp;key=10.3371%2FCSRP.6.3.5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm401958n&amp;key=1%3ACAS%3A280%3ADC%252BC38bps1Ghsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2012&pages=134-144&author=H.+Y.+Meltzer&title=Clozapine%3A+balancing+safety+with+superior+antipsychotic+efficacy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Clozapine: balancing safety with superior antipsychotic efficacy</span></div><div class="casAuthors">Meltzer Herbert Y</div><div class="citationInfo"><span class="NLM_cas:title">Clinical schizophrenia & related psychoses</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">134-44</span>
        ISSN:<span class="NLM_cas:issn">1935-1232</span>.
    </div><div class="casAbstract">Clozapine is often referred to as the gold standard for the treatment of schizophrenia and yet has also been described as the most underutilized treatment for schizophrenia supported by solid evidence-based medicine.  In 2008, it was used to treat only 4.4% of patients with schizophrenia in the U.S., which is ~10-20% of those with approved indications for clozapine for which there is no alternative of equal efficacy.  Its use is much higher in Scandinavian countries and China.  The primary indications for clozapine are: 1) treatment-resistant schizophrenia or schizoaffective disorder, defined as persistent moderate to severe delusions or hallucinations despite two or more clinical trials with other antipsychotic drugs; and, 2) patients with schizophrenia or schizoaffective disorder who are at high risk for suicide.  Concerns over a number of safety considerations are responsible for much of the underutilization of clozapine: 1) agranulocytosis; 2) metabolic side effects; and, 3) myocarditis.  These side effects can be detected, prevented, minimized and treated, but there will be a very small number of fatalities.  Nevertheless, clozapine has been found in two large epidemiologic studies to have the lowest mortality of any antipsychotic drug, mainly due to its very large effect to reduce the risk for suicide.  Other reasons for limited use of clozapine include the extra effort entailed in monitoring white blood cell counts to detect granulocytopenia or agranulocytosis and, possibly, minimal efforts to market it now that it is largely generic.  Awareness of the benefits and risks of clozapine is essential for increasing the use of this lifesaving agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRaC8eLy6C7ZGmbXvSEQle5fW6udTcc2eaLxeFRgwzEMrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38bps1Ghsw%253D%253D&md5=ea71630fe3a2fae86f0c2a18180e0cb5</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.3371%2FCSRP.6.3.5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3371%252FCSRP.6.3.5%26sid%3Dliteratum%253Aachs%26aulast%3DMeltzer%26aufirst%3DH.%2BY.%26atitle%3DClozapine%253A%2520balancing%2520safety%2520with%2520superior%2520antipsychotic%2520efficacy%26jtitle%3DClin.%2520Schizophrenia%2520Relat.%2520Psychoses%26date%3D2012%26volume%3D6%26spage%3D134%26epage%3D144" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Fakra, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azorin, J. M.</span><span> </span><span class="NLM_article-title">Clozapine for the treatment of schizophrenia</span> <span class="citation_source-journal">Expert Opin. Pharmacother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">1923</span><span class="NLM_x">–</span> <span class="NLM_lpage">1935</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm401958n&amp;key=10.1517%2F14656566.2012.709235" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm401958n&amp;key=22803789" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm401958n&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1WltbnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=1923-1935&author=E.+Fakraauthor=J.+M.+Azorin&title=Clozapine+for+the+treatment+of+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">for the treatment of schizophrenia</span></div><div class="casAuthors">Fakra, Eric; Azorin, Jean-Michel</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Pharmacotherapy</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1923-1935</span>CODEN:
                <span class="NLM_cas:coden">EOPHF7</span>;
        ISSN:<span class="NLM_cas:issn">1465-6566</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Despite considerable progress in the pharmacol. treatment of schizophrenia, about 30% of patients are minimally responsive to antipsychotics and there is still an excessively high rate of mortality in schizophrenia patients. , a D2-5HT2 antagonist, was the first antipsychotic to demonstrate efficacy in treatment-resistant patients, and to be assocd. with the lowest risk of death.Areas covered: The pharmacodynamics, pharmacokinetics, clin. efficacy, safety and cost-effectiveness of clozapine are covered in this article, based on a literature review (PubMed) from 1975 to 2012.  Pivotal, as well as supporting, randomized controlled trials are reviewed, along with observational and/or naturalistic safety studies.  This review of clozapine will allow the reader to det. the place for clozapine in the schizophrenia treatment landscape.  Expert opinion: Studies conducted so far suggest that clozapine is the treatment of choice for schizophrenic patients who are refractory to treatment, display violent behaviors, or who are at high risk of suicide.  However, it is also the antipsychotic with the worst side effect profile, the highest risk of complications, and the most difficult to prescribe.  Experience with clozapine should therefore be included in the education of future physicians.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-DXVoDDm74LVg90H21EOLACvtfcHk0ljQC6kCRQFKcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1WltbnM&md5=c1b548b4020dae15d89d48cec36b9cc8</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1517%2F14656566.2012.709235&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14656566.2012.709235%26sid%3Dliteratum%253Aachs%26aulast%3DFakra%26aufirst%3DE.%26aulast%3DAzorin%26aufirst%3DJ.%2BM.%26atitle%3DClozapine%2520for%2520the%2520treatment%2520of%2520schizophrenia%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2012%26volume%3D13%26spage%3D1923%26epage%3D1935" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Schmidt, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sorensen, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kehne, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carr, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palfreyman, M. G.</span><span> </span><span class="NLM_article-title">The role of 5-HT<sub>2A</sub> receptors in antipsychotic activity</span> <span class="citation_source-journal">Life Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">2209</span><span class="NLM_x">–</span> <span class="NLM_lpage">2222</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=1995&pages=2209-2222&author=C.+J.+Schmidtauthor=S.+M.+Sorensenauthor=J.+H.+Kehneauthor=A.+A.+Carrauthor=M.+G.+Palfreyman&title=The+role+of+5-HT2A+receptors+in+antipsychotic+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSchmidt%26aufirst%3DC.%2BJ.%26aulast%3DSorensen%26aufirst%3DS.%2BM.%26aulast%3DKehne%26aufirst%3DJ.%2BH.%26aulast%3DCarr%26aufirst%3DA.%2BA.%26aulast%3DPalfreyman%26aufirst%3DM.%2BG.%26atitle%3DThe%2520role%2520of%25205-HT2A%2520receptors%2520in%2520antipsychotic%2520activity%26jtitle%3DLife%2520Sci.%26date%3D1995%26volume%3D56%26spage%3D2209%26epage%3D2222" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Sorensen, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kehne, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fadayel, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Humphreys, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sullivan, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, V. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, C. J.</span><span> </span><span class="NLM_article-title">Characterization of the 5-HT2 receptor antagonist MDL 100907 as a putative atypical antipsychotic: behavioral, electrophysiological and neurochemical studies</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">266</span><span class="NLM_x">, </span> <span class="NLM_fpage">684</span><span class="NLM_x">–</span> <span class="NLM_lpage">691</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Fjm401958n&amp;key=8102646" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Fjm401958n&amp;key=1%3ACAS%3A528%3ADyaK2cXitlelug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=266&publication_year=1993&pages=684-691&author=S.+M.+Sorensenauthor=J.+H.+Kehneauthor=G.+M.+Fadayelauthor=T.+M.+Humphreysauthor=C.+K.+Sullivanauthor=V.+L.+Taylorauthor=C.+J.+Schmidt&title=Characterization+of+the+5-HT2+receptor+antagonist+MDL+100907+as+a+putative+atypical+antipsychotic%3A+behavioral%2C+electrophysiological+and+neurochemical+studies"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of the 5-HT2 receptor antagonist MDL 100907 as a putative atypical antipsychotic: Behavioral, electrophysiological and neurochemical studies</span></div><div class="casAuthors">Sorensen, Stephen M.; Kehne, John H.; Fadayel, Gina M.; Humphreys, Teresa M.; Ketteler, Herbert J.; Sullivan, Christine K.; Taylor, Vicki L.; Schmidt, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">266</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">684-91</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    </div><div class="casAbstract">Progress toward understanding the role of the 5-hydroxytryptamine (5-HT)2 receptor in the therapy for schizophrenia has been hampered by the lack of high selective antagonists.  The authors now report on the effects of MDL 100,907 [R(+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenylethyl)]-4-piperidinemethanol], a highly selective and potent 5-HT2 receptor antagonist, in behavioral, electrophysiol. and neurochem. models of antipsychotic activity and extrapyramidal side-effect liability.  In mice, MDL 100,907 blocked amphetamine-stimulated locomotion at doses that did not significantly affect apomorphine-stimulated climbing behavior.  Neither MDL 100,907 nor clozapine reduced apomorphine-induced stereotypies or produced catalepsy in rats.  MDL 100,907 blocked the slowing of ventral tegmental area (A10) dopaminergic neurons by amphetamine but, like clozapine, produced only small increases in the no. of active substantia nigra zona compacta (A9) and A10 dopamine neurons after acute administration.  When administered chronically, MDL 100,907 and clozapine selectively reduced the no. of spontaneously active A10 neurons, whereas haloperidol reduced activity in both the A9 and A10 regions.  Consistent with their acute effect on A9 and A10 activity, neither MDL 100,907 nor clozapine increased dopamine metab. in the striatum or nucleus accumbens, whereas acute haloperidol accelerated dopamine turnover in both regions.  The administration of the dopamine uptake blocker amfonelic acid with haloperidol produced a massive increase in DA metab. characteristic of typical antipsychotics.  In contrast, MDL 100,907 and clozapine were without effect on dopamine turnover when given in the presence of amfonelic acid.  These data indicate that MDL 100,907 has a clozapine-like profile of potential antipsychotic activity with low extrapyramidal side-effect liability.  The receptor selectivity of MDL 100,907 and the proposed regulation of dopaminergic function by 5-HT2 receptors support the conclusion that further clin. evaluation of selective 5-HT2 antagonists as antipsychotic agents is warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwBFqMWvGTiLVg90H21EOLACvtfcHk0lgfmPOm_MptSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXitlelug%253D%253D&md5=5519667c5d7e79ee2132247738de91a7</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSorensen%26aufirst%3DS.%2BM.%26aulast%3DKehne%26aufirst%3DJ.%2BH.%26aulast%3DFadayel%26aufirst%3DG.%2BM.%26aulast%3DHumphreys%26aufirst%3DT.%2BM.%26aulast%3DSullivan%26aufirst%3DC.%2BK.%26aulast%3DTaylor%26aufirst%3DV.%2BL.%26aulast%3DSchmidt%26aufirst%3DC.%2BJ.%26atitle%3DCharacterization%2520of%2520the%25205-HT2%2520receptor%2520antagonist%2520MDL%2520100907%2520as%2520a%2520putative%2520atypical%2520antipsychotic%253A%2520behavioral%252C%2520electrophysiological%2520and%2520neurochemical%2520studies%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1993%26volume%3D266%26spage%3D684%26epage%3D691" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Kehne, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baron, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carr, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaney, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elands, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feldman, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frrank, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Giersbergen, P. L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mccloskey, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mccarty, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poirot, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Senyah, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siegel, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Widmaier, C.</span><span> </span><span class="NLM_article-title">Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100907 as a potent 5-HT<sub>2A</sub> antagonist with a favorable CNS safety profile</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">277</span><span class="NLM_x">, </span> <span class="NLM_fpage">968</span><span class="NLM_x">–</span> <span class="NLM_lpage">981</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Fjm401958n&amp;key=8627580" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm401958n&amp;key=1%3ACAS%3A528%3ADyaK28XivFeht7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=1996&pages=968-981&author=J.+H.+Kehneauthor=B.+M.+Baronauthor=A.+A.+Carrauthor=S.+F.+Chaneyauthor=J.+Elandsauthor=D.+J.+Feldmanauthor=R.+A.+Frrankauthor=P.+L.+M.+van+Giersbergenauthor=T.+C.+Mccloskeyauthor=M.+P.+Johnsonauthor=D.+R.+Mccartyauthor=M.+Poirotauthor=Y.+Senyahauthor=B.+W.+Siegelauthor=C.+Widmaier&title=Preclinical+characterization+of+the+potential+of+the+putative+atypical+antipsychotic+MDL+100907+as+a+potent+5-HT2A+antagonist+with+a+favorable+CNS+safety+profile"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100,907 as a potent 5-HT2A antagonist with a favorable CNS safety profile</span></div><div class="casAuthors">Kehne, John H.; Baron, Bruce M.; Carr, Albert A.; Chaney, Stephen F.; Elands, Jack; Feldman, Daniel J.; Frank, Robert A.; Van Giersbergen, Paul L. M.; McCloskey, Timothy C.; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">277</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">968-981</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">In preclin. studies, [R-(+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol] (MDL 100,907), a putative atypical antipsychotic, was characterized in vitro as a potent and selective ligand for the serotonin2A (5-HT2A) receptor and was evaluated in vitro and in vivo as a potent 5-HT2A receptor antagonist.  Furthermore, MDL 100,907's potential CNS safety profile and selectivity as a potential antipsychotic agent were evaluated and compared with benchmark compds.  MDL 100,907 demonstrated low nanomolar or subnanomolar binding in vitro at the 5-HT2A receptor and showed a > 100-fold sepn. from all other receptors measured.  MDL 100,907 has subnanomolar potency as a 5-HT2A antagonist in vitro in reversing 5-HT-stimulated inositol phosphate accumulation in NIH 3T3 cells transfected with the rat 5-HT2A receptor.  In vivo, MDL 100,907 potently inhibited 5-methoxy-N,N-dimethyltryptamine-induced head twitches in mice or 5-hydroxytrypophan-induced head twitched in rats.  In vivo functional tests in mice revealed a > 500-fold sepn. between doses that produced 5-HT2A antagonism and doses that produced α1-adrenergic or striatal D2 antagonism.  Using inhibition of D-amphetamine-stimulated locomotion in mice as a measure of potential antipsychotic efficacy, MDL 100,907 showed a superior CNS safety index relative to the ref. compds., haloperidol, clozapine, risperidone,ritanserin, and amperozide, in each of five tests for side effect potential, including measures of ataxia, general depressant effects, α1-adrenergic antagonism, striatal D2 receptor antagonism, and muscle relaxation.  MDL 100,907 did not antagonize apomorphine-induced stereotypies in rats, suggesting that it potentially lacks extrapyramidal side effect liability.  MDL 100,907 showed selectivity as a potential antipsychotic in that it lacked consistent activity in selected rodent models of anticonvulsant, anti-depressant, analgesic, or anxiolytic activity.  In summary, these preclin. data indicate that MDL 100,907 is a potent and selective ligand at the 5-HT2A receptor.  MDL 100,907's potent 5-HT2A antagonist activity might account for its activity in preclin. models of antipsychotic potential.  Ongoing clin. evaluation with MDL 100,907 will test the hypothesis that 5-HT2A receptor antagonism is sufficient for antipsychotic activity in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqravKtRD4ZLbVg90H21EOLACvtfcHk0lgfmPOm_MptSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XivFeht7s%253D&md5=01a7031bf3ef86ac47fe60ac14493a64</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKehne%26aufirst%3DJ.%2BH.%26aulast%3DBaron%26aufirst%3DB.%2BM.%26aulast%3DCarr%26aufirst%3DA.%2BA.%26aulast%3DChaney%26aufirst%3DS.%2BF.%26aulast%3DElands%26aufirst%3DJ.%26aulast%3DFeldman%26aufirst%3DD.%2BJ.%26aulast%3DFrrank%26aufirst%3DR.%2BA.%26aulast%3Dvan%2BGiersbergen%26aufirst%3DP.%2BL.%2BM.%26aulast%3DMccloskey%26aufirst%3DT.%2BC.%26aulast%3DJohnson%26aufirst%3DM.%2BP.%26aulast%3DMccarty%26aufirst%3DD.%2BR.%26aulast%3DPoirot%26aufirst%3DM.%26aulast%3DSenyah%26aufirst%3DY.%26aulast%3DSiegel%26aufirst%3DB.%2BW.%26aulast%3DWidmaier%26aufirst%3DC.%26atitle%3DPreclinical%2520characterization%2520of%2520the%2520potential%2520of%2520the%2520putative%2520atypical%2520antipsychotic%2520MDL%2520100907%2520as%2520a%2520potent%25205-HT2A%2520antagonist%2520with%2520a%2520favorable%2520CNS%2520safety%2520profile%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1996%26volume%3D277%26spage%3D968%26epage%3D981" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">De Paulis, T.</span><span> </span><span class="NLM_article-title">M-100907 (Aventis)</span> <span class="citation_source-journal">Curr. Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">123</span><span class="NLM_x">–</span> <span class="NLM_lpage">132</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2001&pages=123-132&author=T.+De+Paulis&title=M-100907+%28Aventis%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BPaulis%26aufirst%3DT.%26atitle%3DM-100907%2520%2528Aventis%2529%26jtitle%3DCurr.%2520Opin.%2520Invest.%2520Drugs%26date%3D2001%26volume%3D2%26spage%3D123%26epage%3D132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Buckley, P. F.</span><span> </span><span class="NLM_article-title">Olanzapine: a critical review of recent literature</span> <span class="citation_source-journal">Expert Opin. Pharmacother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">2077</span><span class="NLM_x">–</span> <span class="NLM_lpage">2089</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Fjm401958n&amp;key=10.1517%2F14656566.6.12.2077" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Fjm401958n&amp;key=16197360" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Fjm401958n&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFCjsbjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2005&pages=2077-2089&author=P.+F.+Buckley&title=Olanzapine%3A+a+critical+review+of+recent+literature"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Olanzapine: a critical review of recent literature</span></div><div class="casAuthors">Buckley, Peter F.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Pharmacotherapy</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2077-2089</span>CODEN:
                <span class="NLM_cas:coden">EOPHF7</span>;
        ISSN:<span class="NLM_cas:issn">1465-6566</span>.
    
            (<span class="NLM_cas:orgname">Ashley Publications Ltd.</span>)
        </div><div class="casAbstract">The purpose of this review is to critically review the current literature on olanzapine with an emphasis on emergent themes and key findings in the use of this agent for the treatment of mood disorders and schizophrenia.  New information continues to emerge on the impact of olanzapine on schizo-phrenia and on aspects of the course of mood disorders.  There are also continued efforts to understand, predict and manage the side-effect risk with olanzapine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquFaBBxEa2sbVg90H21EOLACvtfcHk0lgfmPOm_MptSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFCjsbjL&md5=7a8d254ff01b11854b8af9e93acb80a5</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1517%2F14656566.6.12.2077&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14656566.6.12.2077%26sid%3Dliteratum%253Aachs%26aulast%3DBuckley%26aufirst%3DP.%2BF.%26atitle%3DOlanzapine%253A%2520a%2520critical%2520review%2520of%2520recent%2520literature%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2005%26volume%3D6%26spage%3D2077%26epage%3D2089" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Worrel, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marken, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beckman, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruehter, V. L.</span><span> </span><span class="NLM_article-title">Atypical antipsychotic agents: a critical review</span> <span class="citation_source-journal">Am. J. Health Syst. Pharm.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">238</span><span class="NLM_x">–</span> <span class="NLM_lpage">255</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2000&pages=238-255&author=J.+A.+Worrelauthor=P.+A.+Markenauthor=S.+E.+Beckmanauthor=V.+L.+Ruehter&title=Atypical+antipsychotic+agents%3A+a+critical+review"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWorrel%26aufirst%3DJ.%2BA.%26aulast%3DMarken%26aufirst%3DP.%2BA.%26aulast%3DBeckman%26aufirst%3DS.%2BE.%26aulast%3DRuehter%26aufirst%3DV.%2BL.%26atitle%3DAtypical%2520antipsychotic%2520agents%253A%2520a%2520critical%2520review%26jtitle%3DAm.%2520J.%2520Health%2520Syst.%2520Pharm.%26date%3D2000%26volume%3D57%26spage%3D238%26epage%3D255" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Meltzer, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsubara, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. C.</span><span> </span><span class="NLM_article-title">The ratios of serotonin2 and dopamine2 affinities differentiate atypical antipsychotic drugs</span> <span class="citation_source-journal">Psychopharmacol. Bull.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">390</span><span class="NLM_x">–</span> <span class="NLM_lpage">392</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Fjm401958n&amp;key=2576319" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm401958n&amp;key=1%3ACAS%3A528%3ADyaK3cXhsFWmu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=1989&pages=390-392&author=H.+Y.+Meltzerauthor=S.+Matsubaraauthor=J.+C.+Lee&title=The+ratios+of+serotonin2+and+dopamine2+affinities+differentiate+atypical+antipsychotic+drugs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs</span></div><div class="casAuthors">Meltzer, Herbert Y.; Matsubara, Shigehiro; Lee, Jar Chi</div><div class="citationInfo"><span class="NLM_cas:title">Psychopharmacology Bulletin</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">390-2</span>CODEN:
                <span class="NLM_cas:coden">PSYBB9</span>;
        ISSN:<span class="NLM_cas:issn">0048-5764</span>.
    </div><div class="casAbstract">Atypical antipsychotic drugs such as clozapine, fluperlapine, and melperone produce weak catalepsy in rodents, and minimal extrapyramidal symptoms and serum prolactin elevations in humans, compared to typical antipsychotic drugs such as haloperidol.  The biol. basis for these differences has been attributed to relatively weak blockade at D2 dopamine (DA) receptors, various effects at D1 receptors, or potent serotonin2 (5-HT2) antagonism, although other possibilities exist.  To clarify the relative importance of actions of D1, D2, and 5-HT2 receptors for identification of candidate typical and atypical drugs, the authors detd. the neg. log of the Ki (pKi) value of 21 typical and 17 atypical antipsychotic drugs for the striatal D1 and D2 and frontal cortex 5-HT2 receptors of rodent brain.  Cluster anal. identified that the 5-HT2/D2 ratio was the most successful means of utilizing this data to classify typical and atypical antipsychotic drugs correctly.  A 92% accuracy was achieved.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGos0Xqr2TSGcLVg90H21EOLACvtfcHk0lhXvLOskIS_pQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXhsFWmu7Y%253D&md5=3f5c199f61ada18f6210532b086b0e13</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMeltzer%26aufirst%3DH.%2BY.%26aulast%3DMatsubara%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DJ.%2BC.%26atitle%3DThe%2520ratios%2520of%2520serotonin2%2520and%2520dopamine2%2520affinities%2520differentiate%2520atypical%2520antipsychotic%2520drugs%26jtitle%3DPsychopharmacol.%2520Bull.%26date%3D1989%26volume%3D25%26spage%3D390%26epage%3D392" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Oakley, N. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayes, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheehan, M. J.</span><span> </span><span class="NLM_article-title">Effect of typical and atypical neuroleptics on the behavioural consequences of activation by muscimol of mesolimbic and nigro-striatal dopaminergic pathways in the rat</span> <span class="citation_source-journal">Psychopharmocology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">204</span><span class="NLM_x">–</span> <span class="NLM_lpage">208</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Fjm401958n&amp;key=10.1007%2FBF02244310" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Fjm401958n&amp;key=1686655" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=1991&pages=204-208&author=N.+R.+Oakleyauthor=A.+G.+Hayesauthor=M.+J.+Sheehan&title=Effect+of+typical+and+atypical+neuroleptics+on+the+behavioural+consequences+of+activation+by+muscimol+of+mesolimbic+and+nigro-striatal+dopaminergic+pathways+in+the+rat"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1007%2FBF02244310&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF02244310%26sid%3Dliteratum%253Aachs%26aulast%3DOakley%26aufirst%3DN.%2BR.%26aulast%3DHayes%26aufirst%3DA.%2BG.%26aulast%3DSheehan%26aufirst%3DM.%2BJ.%26atitle%3DEffect%2520of%2520typical%2520and%2520atypical%2520neuroleptics%2520on%2520the%2520behavioural%2520consequences%2520of%2520activation%2520by%2520muscimol%2520of%2520mesolimbic%2520and%2520nigro-striatal%2520dopaminergic%2520pathways%2520in%2520the%2520rat%26jtitle%3DPsychopharmocology%26date%3D1991%26volume%3D105%26spage%3D204%26epage%3D208" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Reynolds, G. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirk, S. L.</span><span> </span><span class="NLM_article-title">Metabolic side effects of antipsychotic drug treatment—pharmacological mechanisms</span> <span class="citation_source-journal">Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">125</span><span class="NLM_x">, </span> <span class="NLM_fpage">169</span><span class="NLM_x">–</span> <span class="NLM_lpage">179</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Fjm401958n&amp;key=10.1016%2Fj.pharmthera.2009.10.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Fjm401958n&amp;key=19931306" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Fjm401958n&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFyiu77E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2010&pages=169-179&author=G.+P.+Reynoldsauthor=S.+L.+Kirk&title=Metabolic+side+effects+of+antipsychotic+drug+treatment%E2%80%94pharmacological+mechanisms"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolic side effects of antipsychotic drug treatment - pharmacological mechanisms</span></div><div class="casAuthors">Reynolds, Gavin P.; Kirk, Shona L.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">169-179</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Obesity and metabolic syndrome, with increased risk of eventual cardiovascular disease and type II diabetes, are significant problems for patients receiving antipsychotic drugs and are likely contribute to their decreased life expectancy.  Several drug-related mechanisms may contribute to these problems, including effects both influencing food intake and on glucose and lipid metab.  The metabolic consequences of different antipsychotic drugs vary substantially; these variations reflect differences in receptor pharmacol. and provide clues as to the underlying pharmacol. mechanisms.  The two drugs with the greatest effects on body wt., olanzapine and clozapine, also have high affinity for the 5-HT2C and histamine H1 receptors, which implicate these receptors in antipsychotic-induced wt. gain, while peripheral M3 muscarinic receptor antagonism as well as central 5-HT2C effects may contribute to obesity-independent diabetes.  Other receptor mechanisms may have additive or synergistic effects; dopamine D2 receptor antagonism can enhance 5-HT2C-mediated effects on food intake, as well as influencing lipid and glucose metab. via disinhibition of prolactin secretion.  Pharmacogenetic assocns. of drug-induced wt. gain with 5-HT2C receptor and leptin gene polymorphisms, among others, have provided further clues.  Elevated leptin secretion in the absence of a decrease in food intake indicates drug-induced leptin insensitivity in the hypothalamus.  The minimal wt. gain seen with ziprasidone and aripiprazole may reflect their having further pharmacol. effects that protect against changes in food intake and related metabolic factors.  Understanding the pharmacol. of metabolic consequences of current antipsychotic drug treatment is clearly the key to developing improved pharmacotherapies that avoid these problematic and limiting adverse effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqt7JyuRcCdILVg90H21EOLACvtfcHk0lhXvLOskIS_pQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFyiu77E&md5=548d49d2cca697e4405549be6ba0dd6f</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2009.10.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2009.10.010%26sid%3Dliteratum%253Aachs%26aulast%3DReynolds%26aufirst%3DG.%2BP.%26aulast%3DKirk%26aufirst%3DS.%2BL.%26atitle%3DMetabolic%2520side%2520effects%2520of%2520antipsychotic%2520drug%2520treatment%25E2%2580%2594pharmacological%2520mechanisms%26jtitle%3DPharmacol.%2520Ther.%26date%3D2010%26volume%3D125%26spage%3D169%26epage%3D179" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Deng, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weston-Green, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, X. F.</span><span> </span><span class="NLM_article-title">The role of histaminergic H1 and H3 receptors in food intake: a mechanism for atypical antipsychotic-induced weight gain?</span> <span class="citation_source-journal">Prog. Neuro-Psychopharmacol. Biol. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">4</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Fjm401958n&amp;key=10.1016%2Fj.pnpbp.2009.11.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Fjm401958n&amp;key=19922755" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm401958n&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjsl2kuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2010&pages=1-4&author=C.+Dengauthor=K.+Weston-Greenauthor=X.+F.+Huang&title=The+role+of+histaminergic+H1+and+H3+receptors+in+food+intake%3A+a+mechanism+for+atypical+antipsychotic-induced+weight+gain%3F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">The role of histaminergic H1 and H3 receptors in food intake: A mechanism for atypical antipsychotic-induced weight gain?</span></div><div class="casAuthors">Deng, Chao; Weston-Green, Katrina; Huang, Xu-Feng</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Neuro-Psychopharmacology & Biological Psychiatry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-4</span>CODEN:
                <span class="NLM_cas:coden">PNPPD7</span>;
        ISSN:<span class="NLM_cas:issn">0278-5846</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Atypical antipsychotics such as olanzapine and clozapine are effective at treating the multiple domains of schizophrenia, with a low risk of extra-pyramidal side-effects.  However a major downfall to their use is metabolic side-effects particularly wt. gain/obesity, which occurs by unknown mechanisms.  The present paper explores the potential candidature of histaminergic neurotransmission in the mechanisms of atypical antipsychotic-induced wt. gain, with a focus on the histaminergic H1 and H3 receptors.  Olanzapine and clozapine have a high affinity for the H1 receptor, and meta-analyses show a strong correlation between risk of wt. gain and H1 receptor affinity.  In addn., olanzapine treatment decreases H1 receptor binding and mRNA expression in the rat hypothalamus.  Furthermore, a complex role is emerging for the histamine H3 receptor in the control of hunger.  The H3 receptor is a pre-synaptic autoreceptor that inhibits the synthesis and release of histamine, and a heteroreceptor that inhibits other neurotransmitters such as serotonin (5-HT), noradrenaline (NA) and acetylcholine (ACh), which are also implicated in the regulation of food intake.  Thus, the H3 receptor is in a prime position to regulate food intake, both through its control of histamine and its influence on other feeding pathways.  We proposed that a mechanism for atypical antipsychotic-induced wt. gain may be partly through the H3 receptor, as a drug-induced decrease in H1 receptor activity may decrease histamine tone through the H3 autoreceptors, compounding the wt. gain problem.  In addn., atypical antipsychotics may affect food intake by influencing 5-HT, NA and ACh release via interactions with the H3 heteroreceptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRPtyjEiBxobVg90H21EOLACvtfcHk0lhXvLOskIS_pQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjsl2kuw%253D%253D&md5=8ee52c313f7e12534d2cf4016f06b6b4</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.pnpbp.2009.11.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pnpbp.2009.11.009%26sid%3Dliteratum%253Aachs%26aulast%3DDeng%26aufirst%3DC.%26aulast%3DWeston-Green%26aufirst%3DK.%26aulast%3DHuang%26aufirst%3DX.%2BF.%26atitle%3DThe%2520role%2520of%2520histaminergic%2520H1%2520and%2520H3%2520receptors%2520in%2520food%2520intake%253A%2520a%2520mechanism%2520for%2520atypical%2520antipsychotic-induced%2520weight%2520gain%253F%26jtitle%3DProg.%2520Neuro-Psychopharmacol.%2520Biol.%2520Psychiatry%26date%3D2010%26volume%3D34%26spage%3D1%26epage%3D4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Kirk, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glazebrook, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grayson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neill, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reynolds, G. P.</span><span> </span><span class="NLM_article-title">Olanzapine-induced weight gain in the rat: role of 5-HT<sub>2C</sub> and histamine H<sub>1</sub> receptors</span> <span class="citation_source-journal">Psychopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">207</span><span class="NLM_x">, </span> <span class="NLM_fpage">119</span><span class="NLM_x">–</span> <span class="NLM_lpage">125</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=207&publication_year=2009&pages=119-125&author=S.+L.+Kirkauthor=J.+Glazebrookauthor=B.+Graysonauthor=J.+C.+Neillauthor=G.+P.+Reynolds&title=Olanzapine-induced+weight+gain+in+the+rat%3A+role+of+5-HT2C+and+histamine+H1+receptors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKirk%26aufirst%3DS.%2BL.%26aulast%3DGlazebrook%26aufirst%3DJ.%26aulast%3DGrayson%26aufirst%3DB.%26aulast%3DNeill%26aufirst%3DJ.%2BC.%26aulast%3DReynolds%26aufirst%3DG.%2BP.%26atitle%3DOlanzapine-induced%2520weight%2520gain%2520in%2520the%2520rat%253A%2520role%2520of%25205-HT2C%2520and%2520histamine%2520H1%2520receptors%26jtitle%3DPsychopharmacology%26date%3D2009%26volume%3D207%26spage%3D119%26epage%3D125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Rajagopalan, P.</span><span> </span><span class="NLM_article-title">Pyridopyrrolobenzoxazine</span>. (Endo Laboratories, Inc.). U.S. Patent 4,013,652, <span class="NLM_month">March</span><span class="NLM_day">22</span>,<span class="NLM_x"> </span><span class="NLM_year">1977</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1977&author=P.+Rajagopalan&title=Pyridopyrrolobenzoxazine"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DRajagopalan%26aufirst%3DP.%26atitle%3DPyridopyrrolobenzoxazine%26date%3D1977" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Rajagopalan, P.</span><span> </span><span class="NLM_article-title"> Pyridopyrrolobenzheterocycles for combating depression</span>. (Endo Laboratories, Inc.). U.S. Patent 3,914,421, <span class="NLM_month">October</span><span class="NLM_day">21</span>,<span class="NLM_x"> </span><span class="NLM_year">1975</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1975&author=P.+Rajagopalan&title=+Pyridopyrrolobenzheterocycles+for+combating+depression"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DRajagopalan%26aufirst%3DP.%26atitle%3D%2520Pyridopyrrolobenzheterocycles%2520for%2520combating%2520depression%26date%3D1975" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Rajagopalan, P.</span><span> </span><span class="NLM_article-title"><i>cis</i>- and <i>trans</i>-Octahydropyridopyrrolobenzheterocycles</span>. (E. I. Du Pont De Nemours and Co.). U.S. Patent 4,219,550, <span class="NLM_month">August</span><span class="NLM_day">26</span>,<span class="NLM_x"> </span><span class="NLM_year">1980</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1980&author=P.+Rajagopalan&title=cis-+and+trans-Octahydropyridopyrrolobenzheterocycles"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DRajagopalan%26aufirst%3DP.%26atitle%3Dcis-%2520and%2520trans-Octahydropyridopyrrolobenzheterocycles%26date%3D1980" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Lee, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robichaud, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boyle, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robertson, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fitzgerald, L. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McElroy, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Largent, B. L.</span><span> </span><span class="NLM_article-title">Novel, highly potent, selective 5-HT<sub>2A</sub>/D<sub>2</sub> receptor antagonists as potential atypical antipsychotics</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">767</span><span class="NLM_x">–</span> <span class="NLM_lpage">770</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2003&pages=767-770&author=T.+Leeauthor=A.+J.+Robichaudauthor=K.+E.+Boyleauthor=Y.+Luauthor=D.+W.+Robertsonauthor=K.+J.+Millerauthor=L.+W.+Fitzgeraldauthor=J.+F.+McElroyauthor=B.+L.+Largent&title=Novel%2C+highly+potent%2C+selective+5-HT2A%2FD2+receptor+antagonists+as+potential+atypical+antipsychotics"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DT.%26aulast%3DRobichaud%26aufirst%3DA.%2BJ.%26aulast%3DBoyle%26aufirst%3DK.%2BE.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DRobertson%26aufirst%3DD.%2BW.%26aulast%3DMiller%26aufirst%3DK.%2BJ.%26aulast%3DFitzgerald%26aufirst%3DL.%2BW.%26aulast%3DMcElroy%26aufirst%3DJ.%2BF.%26aulast%3DLargent%26aufirst%3DB.%2BL.%26atitle%3DNovel%252C%2520highly%2520potent%252C%2520selective%25205-HT2A%252FD2%2520receptor%2520antagonists%2520as%2520potential%2520atypical%2520antipsychotics%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2003%26volume%3D13%26spage%3D767%26epage%3D770" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Wolfe, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sadighi, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singer, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchwald, S. L.</span><span> </span><span class="NLM_article-title">An ammonia equivalent for the palladium-catalyzed amination of aryl halides and triflates</span> <span class="citation_source-journal">Tetrahedron. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">6367</span><span class="NLM_x">–</span> <span class="NLM_lpage">6370</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Fjm401958n&amp;key=10.1016%2FS0040-4039%2897%2901465-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Fjm401958n&amp;key=1%3ACAS%3A528%3ADyaK2sXlvFGns7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=1997&pages=6367-6370&author=J.+P.+Wolfeauthor=J.+Ahmanauthor=J.+P.+Sadighiauthor=R.+A.+Singerauthor=S.+L.+Buchwald&title=An+ammonia+equivalent+for+the+palladium-catalyzed+amination+of+aryl+halides+and+triflates"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">An ammonia equivalent for the palladium-catalyzed amination of aryl halides and triflates</span></div><div class="casAuthors">Wolfe, John P.; Ahman, Jens; Sadighi, Joseph P.; Singer, Robert A.; Buchwald, Stephen L.</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron Letters</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">6367-6370</span>CODEN:
                <span class="NLM_cas:coden">TELEAY</span>;
        ISSN:<span class="NLM_cas:issn">0040-4039</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Com. available benzophenone imine serves as a convenient NH3 equiv. in the Pd-catalyzed amination of aryl halides and triflates.  The benzophenone imine adducts can be cleaved directly to the corresponding primary anilines by catalytic hydrogenation or treatment with hydroxylamine hydrochloride or a catalytic amt. of HCl in wet THF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXMgy_yfX_ubVg90H21EOLACvtfcHk0liwK-0PYpHlzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXlvFGns7k%253D&md5=a460a4291911fcf3da1c7f6f61a1c38b</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2FS0040-4039%2897%2901465-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0040-4039%252897%252901465-2%26sid%3Dliteratum%253Aachs%26aulast%3DWolfe%26aufirst%3DJ.%2BP.%26aulast%3DAhman%26aufirst%3DJ.%26aulast%3DSadighi%26aufirst%3DJ.%2BP.%26aulast%3DSinger%26aufirst%3DR.%2BA.%26aulast%3DBuchwald%26aufirst%3DS.%2BL.%26atitle%3DAn%2520ammonia%2520equivalent%2520for%2520the%2520palladium-catalyzed%2520amination%2520of%2520aryl%2520halides%2520and%2520triflates%26jtitle%3DTetrahedron.%2520Lett.%26date%3D1997%26volume%3D38%26spage%3D6367%26epage%3D6370" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Welch, W. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harbert, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weissman, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koe, B. K.</span><span> </span><span class="NLM_article-title">Neuroleptics from the 4a, 9b-<i>cis</i>- and 4a, 9b-<i>trans</i>-2,3,4,4a,5,9b-hexahydro-1<i>H</i>-pyrido[4,3-<i>b</i>]indole series. 2</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1986</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">2093</span><span class="NLM_x">–</span> <span class="NLM_lpage">2099</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm00160a050" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=1986&pages=2093-2099&author=W.+M.+Welchauthor=C.+A.+Harbertauthor=A.+Weissmanauthor=B.+K.+Koe&title=Neuroleptics+from+the+4a%2C+9b-cis-+and+4a%2C+9b-trans-2%2C3%2C4%2C4a%2C5%2C9b-hexahydro-1H-pyrido%5B4%2C3-b%5Dindole+series.+2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fjm00160a050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00160a050%26sid%3Dliteratum%253Aachs%26aulast%3DWelch%26aufirst%3DW.%2BM.%26aulast%3DHarbert%26aufirst%3DC.%2BA.%26aulast%3DWeissman%26aufirst%3DA.%26aulast%3DKoe%26aufirst%3DB.%2BK.%26atitle%3DNeuroleptics%2520from%2520the%25204a%252C%25209b-cis-%2520and%25204a%252C%25209b-trans-2%252C3%252C4%252C4a%252C5%252C9b-hexahydro-1H-pyrido%255B4%252C3-b%255Dindole%2520series.%25202%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1986%26volume%3D29%26spage%3D2093%26epage%3D2099" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Fitzgerald, L. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conklin, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krause, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patterson, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iyer, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kostich, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Largent, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartig, P. R.</span><span> </span><span class="NLM_article-title">High-affinity agonist binding correlates with efficacy (intrinsic activity) at the human serotonin 5-HT<sub>2A</sub> and 5-HT<sub>2C</sub> receptors: evidence favoring the ternary complex and two-state models of agonist action</span> <span class="citation_source-journal">J. Neurochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">2127</span><span class="NLM_x">–</span> <span class="NLM_lpage">2134</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Fjm401958n&amp;key=10.1046%2Fj.1471-4159.1999.0722127.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Fjm401958n&amp;key=10217294" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Fjm401958n&amp;key=1%3ACAS%3A528%3ADyaK1MXis12ltLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=1999&pages=2127-2134&author=L.+W.+Fitzgeraldauthor=D.+S.+Conklinauthor=C.+M.+Krauseauthor=A.+P.+Marshallauthor=J.+P.+Pattersonauthor=D.+P.+Tranauthor=G.+Iyerauthor=W.+A.+Kostichauthor=B.+L.+Largentauthor=P.+R.+Hartig&title=High-affinity+agonist+binding+correlates+with+efficacy+%28intrinsic+activity%29+at+the+human+serotonin+5-HT2A+and+5-HT2C+receptors%3A+evidence+favoring+the+ternary+complex+and+two-state+models+of+agonist+action"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">High-affinity agonist binding correlates with efficacy (intrinsic activity) at the human serotonin 5-HT2A and 5-HT2C receptors: evidence favoring the ternary complex and two-state models of agonist action</span></div><div class="casAuthors">Fitzgerald, Lawrence W.; Conklin, Deborah S.; Krause, Carol M.; Marshall, Anne P.; Patterson, John P.; Tran, David P.; Iyer, Geeta; Kostich, Walter A.; Largent, Brian L.; Hartig, Paul R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2127-2134</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Many modern models of receptor-G protein function assume that there is a direct relationship between high-affinity agonist binding and efficacy.  The validity of this assumption has been recently questioned for the serotonin 5-HT2A receptor.  The authors examd. the intrinsic activities of various ligands in activating phosphoinositide hydrolysis and measured their resp. binding affinities to the high- and low-affinity states of the 5-HT2C (VNV isoform) and 5-HT2A receptors.  Ligand binding affinities for the high-affinity state of the receptors were detd. using 1-(4-[125I]iodo-2,5-dimethoxyphenyl)-2-aminopropane, whereas [3H]mesulergine and N-[3H]-methylspiperone were used, in the presence of excess guanine nucleotide [guanosine 5'-O-(3-thiotriphosphate)], to define binding to the low-affinity state of the 5-HT2C and 5-HT2A receptors, resp.  Antagonists labeled the high- and low-affinity states of each receptor with comparable affinities.  Previously identified inverse agonists of the 5-HT2C receptor behaved as silent antagonists in the authors' systems even when the receptor was over-expressed at a relatively high d.  In contrast, the ability of agonists to bind differentially to the high- and low-affinity states of the 5-HT2A and 5-HT2C receptors was highly correlated (R2 = 0.86 and 0.96, resp.) with their intrinsic activities.  These data suggest that high-affinity agonist states can account for agonist efficacy at human 5-HT2A or 5-HT2C receptors without the need for considering addnl. transition or active states of the receptor-ligand complex.  The procedure described herein may expedite drug discovery efforts by predicting intrinsic activities of ligands solely from ligand binding assays.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozA61mRFBtzbVg90H21EOLACvtfcHk0lgNC3zsFOLReQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXis12ltLg%253D&md5=76a7600ee51a0dff38298d091640ffd7</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1046%2Fj.1471-4159.1999.0722127.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1471-4159.1999.0722127.x%26sid%3Dliteratum%253Aachs%26aulast%3DFitzgerald%26aufirst%3DL.%2BW.%26aulast%3DConklin%26aufirst%3DD.%2BS.%26aulast%3DKrause%26aufirst%3DC.%2BM.%26aulast%3DMarshall%26aufirst%3DA.%2BP.%26aulast%3DPatterson%26aufirst%3DJ.%2BP.%26aulast%3DTran%26aufirst%3DD.%2BP.%26aulast%3DIyer%26aufirst%3DG.%26aulast%3DKostich%26aufirst%3DW.%2BA.%26aulast%3DLargent%26aufirst%3DB.%2BL.%26aulast%3DHartig%26aufirst%3DP.%2BR.%26atitle%3DHigh-affinity%2520agonist%2520binding%2520correlates%2520with%2520efficacy%2520%2528intrinsic%2520activity%2529%2520at%2520the%2520human%2520serotonin%25205-HT2A%2520and%25205-HT2C%2520receptors%253A%2520evidence%2520favoring%2520the%2520ternary%2520complex%2520and%2520two-state%2520models%2520of%2520agonist%2520action%26jtitle%3DJ.%2520Neurochem.%26date%3D1999%26volume%3D72%26spage%3D2127%26epage%3D2134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Nelson, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucaites, V. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wainscott, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glennon, R. A.</span><span> </span><span class="NLM_article-title">Comparisons of hallucinogenic phenylisopropylamine binding affinities at cloned human 5-HT<sub>2A</sub>, 5-HT<sub>2B</sub> and 5-HT<sub>2C</sub> receptors</span> <span class="citation_source-journal">Naunyn-Schmiedeberg’s Arch. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">359</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">6</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Fjm401958n&amp;key=10.1007%2FPL00005315" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Fjm401958n&amp;key=9933142" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Fjm401958n&amp;key=1%3ACAS%3A528%3ADyaK1cXnvFalu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=359&publication_year=1999&pages=1-6&author=D.+L.+Nelsonauthor=V.+L.+Lucaitesauthor=D.+B.+Wainscottauthor=R.+A.+Glennon&title=Comparisons+of+hallucinogenic+phenylisopropylamine+binding+affinities+at+cloned+human+5-HT2A%2C+5-HT2B+and+5-HT2C+receptors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Comparisons of hallucinogenic phenylisopropylamine binding affinities at cloned human 5-HT2A, 5-HT2B and 5-HT2C receptors</span></div><div class="casAuthors">Nelson, D. L.; Lucaites, V. L.; Wainscott, D. B.; Glennon, R. A.</div><div class="citationInfo"><span class="NLM_cas:title">Naunyn-Schmiedeberg's Archives of Pharmacology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">359</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-6</span>CODEN:
                <span class="NLM_cas:coden">NSAPCC</span>;
        ISSN:<span class="NLM_cas:issn">0028-1298</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag</span>)
        </div><div class="casAbstract">Since the classical hallucinogens were initially reported to produce their behavioral effects via a 5-HT2 agonist mechanism (i.e., the 5-HT2 hypothesis of hallucinogen action), 5-HT2 receptors have been demonstrated to represent a family of receptors that consists of three distinct subpopulations: 5-HT2A, 5-HT2B, and 5-HT2C receptors.  Today, there is greater support for 5-HT2A than for 5-HT2C receptor involvement in the behavioral effects evoked by these agents.  However, with the recent discovery of 5-HT2B receptors, a new question arises: do classical hallucinogens bind at 5-HT2B receptors.  In the present study, the authors examd. and compared the binding of 17 phenylisopropylamines at human 5-HT2A, 5-HT2B, and 5-HT2C receptors.  Although there was a notable pos. correlation (r>0.9) between the affinities of the agents at all three populations of 5-HT2 receptors, structural modification resulted only in small differences in 5-HT2B receptor affinity such that the range of affinities was only about 50-fold.  As with 5-HT2A and 5-HT2C receptor affinity, there is a significant correlation (r>0.9) between 5-HT2B receptor affinity and human hallucinogenic potency.  Nevertheless, given that 5-HT2A and 5-HT2A/2C antagonists - antagonists with low affinity for 5-HT2B receptors - have been previously shown to block the stimulus effects of phenylisopropylamine hallucinogens, it is likely that 5-HT2A receptors play a more prominent role than 5-HT2B and 5-HT2C receptors in mediating such effects despite the affinity of these agents for all three 5-HT2 receptor subpopulations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvcUJ72-JQ2LVg90H21EOLACvtfcHk0lgNC3zsFOLReQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXnvFalu7k%253D&md5=0aa21959353f624601097271883a49de</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1007%2FPL00005315&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FPL00005315%26sid%3Dliteratum%253Aachs%26aulast%3DNelson%26aufirst%3DD.%2BL.%26aulast%3DLucaites%26aufirst%3DV.%2BL.%26aulast%3DWainscott%26aufirst%3DD.%2BB.%26aulast%3DGlennon%26aufirst%3DR.%2BA.%26atitle%3DComparisons%2520of%2520hallucinogenic%2520phenylisopropylamine%2520binding%2520affinities%2520at%2520cloned%2520human%25205-HT2A%252C%25205-HT2B%2520and%25205-HT2C%2520receptors%26jtitle%3DNaunyn-Schmiedeberg%25E2%2580%2599s%2520Arch.%2520Pharmacol.%26date%3D1999%26volume%3D359%26spage%3D1%26epage%3D6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Seo, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jung, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Son, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, W. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J.</span><span> </span><span class="NLM_article-title">Design and synthesis of novel arylpiperazine derivatives containing the imidazole core targeting 5-HT<sub>2A</sub> receptor and 5-HT transporter</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">6305</span><span class="NLM_x">–</span> <span class="NLM_lpage">6318</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm200682b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=6305-6318&author=H.+J.+Seoauthor=E.+J.+Parkauthor=M.+J.+Kimauthor=S.+Y.+Kangauthor=S.+H.+Leeauthor=H.+J.+Kimauthor=K.+N.+Leeauthor=M.+E.+Jungauthor=M.+Leeauthor=M.+S.+Kimauthor=E.+J.+Sonauthor=W.+K.+Parkauthor=J.+Kimauthor=J.+Lee&title=Design+and+synthesis+of+novel+arylpiperazine+derivatives+containing+the+imidazole+core+targeting+5-HT2A+receptor+and+5-HT+transporter"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fjm200682b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200682b%26sid%3Dliteratum%253Aachs%26aulast%3DSeo%26aufirst%3DH.%2BJ.%26aulast%3DPark%26aufirst%3DE.%2BJ.%26aulast%3DKim%26aufirst%3DM.%2BJ.%26aulast%3DKang%26aufirst%3DS.%2BY.%26aulast%3DLee%26aufirst%3DS.%2BH.%26aulast%3DKim%26aufirst%3DH.%2BJ.%26aulast%3DLee%26aufirst%3DK.%2BN.%26aulast%3DJung%26aufirst%3DM.%2BE.%26aulast%3DLee%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DM.%2BS.%26aulast%3DSon%26aufirst%3DE.%2BJ.%26aulast%3DPark%26aufirst%3DW.%2BK.%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DJ.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520novel%2520arylpiperazine%2520derivatives%2520containing%2520the%2520imidazole%2520core%2520targeting%25205-HT2A%2520receptor%2520and%25205-HT%2520transporter%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D6305%26epage%3D6318" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Ablordeppey, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Altundas, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bricker, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, X. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eyunni, S. E. V. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rothb, B. L.</span><span> </span><span class="NLM_article-title">Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">7291</span><span class="NLM_x">–</span> <span class="NLM_lpage">7301</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2008&pages=7291-7301&author=S.+Y.+Ablordeppeyauthor=R.+Altundasauthor=B.+Brickerauthor=X.+Y.+Zhuauthor=S.+E.+V.+K.+Eyunniauthor=T.+Jacksonauthor=A.+Khanauthor=B.+L.+Rothb&title=Identification+of+a+butyrophenone+analog+as+a+potential+atypical+antipsychotic+agent%3A+4-%5B4-%284-chlorophenyl%29-1%2C4-diazepan-1-yl%5D-1-%284-fluorophenyl%29butan-1-one"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAblordeppey%26aufirst%3DS.%2BY.%26aulast%3DAltundas%26aufirst%3DR.%26aulast%3DBricker%26aufirst%3DB.%26aulast%3DZhu%26aufirst%3DX.%2BY.%26aulast%3DEyunni%26aufirst%3DS.%2BE.%2BV.%2BK.%26aulast%3DJackson%26aufirst%3DT.%26aulast%3DKhan%26aufirst%3DA.%26aulast%3DRothb%26aufirst%3DB.%2BL.%26atitle%3DIdentification%2520of%2520a%2520butyrophenone%2520analog%2520as%2520a%2520potential%2520atypical%2520antipsychotic%2520agent%253A%25204-%255B4-%25284-chlorophenyl%2529-1%252C4-diazepan-1-yl%255D-1-%25284-fluorophenyl%2529butan-1-one%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2008%26volume%3D16%26spage%3D7291%26epage%3D7301" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Kroeze, W. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hufeisen, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Popadak, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Renock, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinberg, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ernsberger, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayathilake, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meltzer, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B. L.</span><span> </span><span class="NLM_article-title">H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs</span> <span class="citation_source-journal">Neuropsychopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">519</span><span class="NLM_x">–</span> <span class="NLM_lpage">526</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2003&pages=519-526&author=W.+K.+Kroezeauthor=S.+J.+Hufeisenauthor=B.+A.+Popadakauthor=S.+M.+Renockauthor=S.+Steinbergauthor=P.+Ernsbergerauthor=K.+Jayathilakeauthor=H.+Y.+Meltzerauthor=B.+L.+Roth&title=H1-histamine+receptor+affinity+predicts+short-term+weight+gain+for+typical+and+atypical+antipsychotic+drugs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKroeze%26aufirst%3DW.%2BK.%26aulast%3DHufeisen%26aufirst%3DS.%2BJ.%26aulast%3DPopadak%26aufirst%3DB.%2BA.%26aulast%3DRenock%26aufirst%3DS.%2BM.%26aulast%3DSteinberg%26aufirst%3DS.%26aulast%3DErnsberger%26aufirst%3DP.%26aulast%3DJayathilake%26aufirst%3DK.%26aulast%3DMeltzer%26aufirst%3DH.%2BY.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26atitle%3DH1-histamine%2520receptor%2520affinity%2520predicts%2520short-term%2520weight%2520gain%2520for%2520typical%2520and%2520atypical%2520antipsychotic%2520drugs%26jtitle%3DNeuropsychopharmacology%26date%3D2003%26volume%3D28%26spage%3D519%26epage%3D526" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Cahir, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">King, D. J.</span><span> </span><span class="NLM_article-title">Antipsychotics lack <i>α</i><sub>1A/B</sub> adrenoceptor subtype selectivity in the rat</span> <span class="citation_source-journal">Eur. Neuropsychopharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">231</span><span class="NLM_x">–</span> <span class="NLM_lpage">234</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Fjm401958n&amp;key=10.1016%2Fj.euroneuro.2004.10.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Fjm401958n&amp;key=15695070" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Fjm401958n&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVOqtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2005&pages=231-234&author=M.+Cahirauthor=D.+J.+King&title=Antipsychotics+lack+%CE%B11A%2FB+adrenoceptor+subtype+selectivity+in+the+rat"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Antipsychotics lack α1A/B adrenoceptor subtype selectivity in the rat</span></div><div class="casAuthors">Cahir, Marie; King, David J.</div><div class="citationInfo"><span class="NLM_cas:title">European Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">231-234</span>CODEN:
                <span class="NLM_cas:coden">EURNE8</span>;
        ISSN:<span class="NLM_cas:issn">0924-977X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The α1A- and α1B-adrenoceptor affinity of the typical (chlorpromazine, haloperidol, pimozide, thioridazine and trifluoperazine) and atypical (clozapine, olanzapine, quetiapine, risperidone and sertindole) antipsychotics was detd. by competition binding at α1A- and α1B-adrenoceptors in rat submaxillary gland and liver.  Although all antipsychotics bound to both subtypes with relatively high affinity (Kis<74 nM), none were selective (>10-fold).  Comparison with published dopamine D2 receptor affinities suggests that antipsychotic blockade of α1A- and/or α1B-adrenoceptors may contribute to the antipsychotic activity of all the atypical and several of the typical antipsychotics examd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodcoj8da0IV7Vg90H21EOLACvtfcHk0ljnCq-DYLxCEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVOqtLs%253D&md5=3c07837debd93eca7c671ae4d732e08d</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.euroneuro.2004.10.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.euroneuro.2004.10.002%26sid%3Dliteratum%253Aachs%26aulast%3DCahir%26aufirst%3DM.%26aulast%3DKing%26aufirst%3DD.%2BJ.%26atitle%3DAntipsychotics%2520lack%2520%25CE%25B11A%252FB%2520adrenoceptor%2520subtype%2520selectivity%2520in%2520the%2520rat%26jtitle%3DEur.%2520Neuropsychopharmacol.%26date%3D2005%26volume%3D15%26spage%3D231%26epage%3D234" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Nourian, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mow, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muftic, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burek, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pedersen, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matz, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mulvany, M. J.</span><span> </span><span class="NLM_article-title">Orthostatic hypotensive effect of antipsychotic drugs in Wistar rats by in vivo and in vitro studies of alpha1-adrenoceptor function</span> <span class="citation_source-journal">Psychopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">199</span><span class="NLM_x">, </span> <span class="NLM_fpage">15</span><span class="NLM_x">–</span> <span class="NLM_lpage">27</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=199&publication_year=2008&pages=15-27&author=Z.+Nourianauthor=T.+Mowauthor=D.+Mufticauthor=S.+Burekauthor=M.+L.+Pedersenauthor=J.+Matzauthor=M.+J.+Mulvany&title=Orthostatic+hypotensive+effect+of+antipsychotic+drugs+in+Wistar+rats+by+in+vivo+and+in+vitro+studies+of+alpha1-adrenoceptor+function"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNourian%26aufirst%3DZ.%26aulast%3DMow%26aufirst%3DT.%26aulast%3DMuftic%26aufirst%3DD.%26aulast%3DBurek%26aufirst%3DS.%26aulast%3DPedersen%26aufirst%3DM.%2BL.%26aulast%3DMatz%26aufirst%3DJ.%26aulast%3DMulvany%26aufirst%3DM.%2BJ.%26atitle%3DOrthostatic%2520hypotensive%2520effect%2520of%2520antipsychotic%2520drugs%2520in%2520Wistar%2520rats%2520by%2520in%2520vivo%2520and%2520in%2520vitro%2520studies%2520of%2520alpha1-adrenoceptor%2520function%26jtitle%3DPsychopharmacology%26date%3D2008%26volume%3D199%26spage%3D15%26epage%3D27" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Ancoli-Israel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vanover, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiner, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Kammen, D. P.</span><span> </span><span class="NLM_article-title">Pimavanserin tartrate, a 5-HT<sub>2A</sub> receptor inverse agonist, increases slow wave sleep as measured by polysomnography in healthy adult volunteers</span> <span class="citation_source-journal">Sleep Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">134</span><span class="NLM_x">–</span> <span class="NLM_lpage">141</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Fjm401958n&amp;key=10.1016%2Fj.sleep.2010.10.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Fjm401958n&amp;key=21256805" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Fjm401958n&amp;key=1%3ACAS%3A280%3ADC%252BC3M7msVSgsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2011&pages=134-141&author=S.+Ancoli-Israelauthor=K.+E.+Vanoverauthor=D.+M.+Weinerauthor=R.+E.+Davisauthor=D.+P.+van+Kammen&title=Pimavanserin+tartrate%2C+a+5-HT2A+receptor+inverse+agonist%2C+increases+slow+wave+sleep+as+measured+by+polysomnography+in+healthy+adult+volunteers"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Pimavanserin tartrate, a 5-HT(2A) receptor inverse agonist, increases slow wave sleep as measured by polysomnography in healthy adult volunteers</span></div><div class="casAuthors">Ancoli-Israel Sonia; Vanover Kimberly E; Weiner David M; Davis Robert E; van Kammen Daniel P</div><div class="citationInfo"><span class="NLM_cas:title">Sleep medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">134-41</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVE:  Determine the effects of pimavanserin tartrate [ACP-103; N-(4-flurophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl)carbamide], a selective serotonin 5-HT(2A) receptor inverse agonist, on slow wave sleep (SWS), other sleep parameters, and attention/vigilance.  METHODS:  Forty-five healthy adults were randomized to pimavanserin (1, 2.5, 5, or 20 mg) or placebo in a double-blind fashion (n=9/group).  Pimavanserin or placebo was administered once daily in the morning for 13 consecutive days.  The effects of pimavanserin were measured after the first dose and again after 13 days.  Sleep parameters were measured by polysomnography.  Effects on attention/vigilance were measured by a continuous performance task.  RESULTS:  Compared to placebo, pimavanserin significantly increased SWS following single and multiple dose administration.  Pimavanserin also decreased number of awakenings.  PSG variables not affected by pimavanserin included sleep period time, total sleep time, sleep onset latency, number of stage shifts, total time awake, early morning wake, and microarousal index.  Changes in sleep architecture parameters, sleep profile parameters, and spectral power density parameters were consistent with a selective increase in SWS.  Pimavanserin did not adversely affect performance on the continuous performance test measured in the evening before or morning after polysomnography.  CONCLUSIONS:  These data suggest that pimavanserin selectively increases slow wave sleep and decreases awakenings, an effect that does not diminish with repeated administration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSDDABm1ytk_xpyrDyM_m9cfW6udTcc2eah0_aK40PIQbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3M7msVSgsA%253D%253D&md5=0d59959b886b750a8fd987595ebfbe29</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.sleep.2010.10.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.sleep.2010.10.004%26sid%3Dliteratum%253Aachs%26aulast%3DAncoli-Israel%26aufirst%3DS.%26aulast%3DVanover%26aufirst%3DK.%2BE.%26aulast%3DWeiner%26aufirst%3DD.%2BM.%26aulast%3DDavis%26aufirst%3DR.%2BE.%26aulast%3Dvan%2BKammen%26aufirst%3DD.%2BP.%26atitle%3DPimavanserin%2520tartrate%252C%2520a%25205-HT2A%2520receptor%2520inverse%2520agonist%252C%2520increases%2520slow%2520wave%2520sleep%2520as%2520measured%2520by%2520polysomnography%2520in%2520healthy%2520adult%2520volunteers%26jtitle%3DSleep%2520Med.%26date%3D2011%26volume%3D12%26spage%3D134%26epage%3D141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Porter, R. H. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benwell, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malcolm, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allen, N. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Revell, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheardown, M. J.</span><span> </span><span class="NLM_article-title">Functional characterization of agonists at recombinant human 5-HT<sub>2A</sub>, 5-HT<sub>2B</sub> and 5-HT<sub>2C</sub> receptors in CHO-K1 cells</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">128</span><span class="NLM_x">, </span> <span class="NLM_fpage">13</span><span class="NLM_x">–</span> <span class="NLM_lpage">20</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Fjm401958n&amp;key=10.1038%2Fsj.bjp.0702751" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Fjm401958n&amp;key=10498829" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Fjm401958n&amp;key=1%3ACAS%3A528%3ADyaK1MXmt1Squrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=1999&pages=13-20&author=R.+H.+P.+Porterauthor=K.+R.+Benwellauthor=H.+Lamauthor=C.+S.+Malcolmauthor=N.+H.+Allenauthor=D.+F.+Revellauthor=D.+R.+Adamsauthor=M.+J.+Sheardown&title=Functional+characterization+of+agonists+at+recombinant+human+5-HT2A%2C+5-HT2B+and+5-HT2C+receptors+in+CHO-K1+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Functional characterization of agonists at recombinant human 5-HT2A, 5-HT2B and 5-HT2C receptors in CHO-K1 cells</span></div><div class="casAuthors">Porter, R. H. P.; Benwell, K. R.; Lamb, H.; Malcolm, C. S.; Allen, N. H.; Revell, D. F.; Adams, D. R.; Sheardown, M. J.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">128</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">13-20</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Stockton Press</span>)
        </div><div class="casAbstract">The goal of this study was to characterize the agonist pharmacol. of human 5-HT2A, 5-HT2B and 5-HT2C (VSV) receptors expressed in CHO-K1 (Chinese hamster ovary) cells.  We used a fluorometric imaging plate reader (FLIPR) which allows rapid detection of rises in intracellular calcium levels upon the addn. of agonists.  Stimulation of all three receptors by 5-HT caused a robust concn. dependent increase in intracellular calcium levels.  No such effect was obsd. from non-transfected control CHO-K1 cells.  The rank order of potency of agonists at the different receptor subtypes varied.  Tryptamines, BW-723C86, d-norfenfluramine, Ro 60-0175 and LSD exhibited the following rank order of potency; 5-HT2B>5-HT2C>5-HT2A.  Piperazines such as m-chlorophenylpiperazine (mCPP), ORG-12962, MK-212 and also ORG-37684 exhibited a rank order of potency of 5-HT2C>5-HT2B>5-HT2A.  The phenylisopropylamines DOI and DOB had a rank order of 5-HT2A>5-HT2B>5-HT2C.  Many agonists tested had partial agonist actions when compared to 5-HT, and a wide range of relative efficacies were exhibited, which was cell line dependent.  For example, mCPP had a relative efficacy of 65% at 5-HT2C receptors but <25% at either 5-HT2A or 5-HT2B receptors.  Interpretation of literature values of functional assays using different cell lines, different receptor expression levels and different receptor isoforms, is complex.  Species differences and the previous use of antagonist radioligands to characterize agonist potency in binding assays emphasizes the importance of studying agonists in the same expt. using the same assay conditions and parental cell lines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgNDFqRrlEtbVg90H21EOLACvtfcHk0ljyNBwHz6B2JA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXmt1Squrg%253D&md5=ff33f4122999f10960865e75161179ca</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjp.0702751&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjp.0702751%26sid%3Dliteratum%253Aachs%26aulast%3DPorter%26aufirst%3DR.%2BH.%2BP.%26aulast%3DBenwell%26aufirst%3DK.%2BR.%26aulast%3DLam%26aufirst%3DH.%26aulast%3DMalcolm%26aufirst%3DC.%2BS.%26aulast%3DAllen%26aufirst%3DN.%2BH.%26aulast%3DRevell%26aufirst%3DD.%2BF.%26aulast%3DAdams%26aufirst%3DD.%2BR.%26aulast%3DSheardown%26aufirst%3DM.%2BJ.%26atitle%3DFunctional%2520characterization%2520of%2520agonists%2520at%2520recombinant%2520human%25205-HT2A%252C%25205-HT2B%2520and%25205-HT2C%2520receptors%2520in%2520CHO-K1%2520cells%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D1999%26volume%3D128%26spage%3D13%26epage%3D20" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Conn, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanders-Bush, E.</span><span> </span><span class="NLM_article-title">Selective 5-HT-2 antagonists inhibit serotonin stimulated phosphatidylinositol metabolism in cerebral cortex</span> <span class="citation_source-journal">Neuropharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1984</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">993</span><span class="NLM_x">–</span> <span class="NLM_lpage">996</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=1984&pages=993-996&author=P.+J.+Connauthor=E.+Sanders-Bush&title=Selective+5-HT-2+antagonists+inhibit+serotonin+stimulated+phosphatidylinositol+metabolism+in+cerebral+cortex"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DConn%26aufirst%3DP.%2BJ.%26aulast%3DSanders-Bush%26aufirst%3DE.%26atitle%3DSelective%25205-HT-2%2520antagonists%2520inhibit%2520serotonin%2520stimulated%2520phosphatidylinositol%2520metabolism%2520in%2520cerebral%2520cortex%26jtitle%3DNeuropharmacology%26date%3D1984%26volume%3D23%26spage%3D993%26epage%3D996" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Koval, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kopein, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Purvanov, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katanaev, V. L.</span><span> </span><span class="NLM_article-title">Europium-labeled GTP as a general nonradioactive substitute for [<sup>35</sup>S]GTPγS in high-throughput G protein studies</span> <span class="citation_source-journal">Anal. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">397</span><span class="NLM_x">, </span> <span class="NLM_fpage">202</span><span class="NLM_x">–</span> <span class="NLM_lpage">207</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=397&publication_year=2010&pages=202-207&author=A.+Kovalauthor=D.+Kopeinauthor=V.+Purvanovauthor=V.+L.+Katanaev&title=Europium-labeled+GTP+as+a+general+nonradioactive+substitute+for+%5B35S%5DGTP%CE%B3S+in+high-throughput+G+protein+studies"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKoval%26aufirst%3DA.%26aulast%3DKopein%26aufirst%3DD.%26aulast%3DPurvanov%26aufirst%3DV.%26aulast%3DKatanaev%26aufirst%3DV.%2BL.%26atitle%3DEuropium-labeled%2520GTP%2520as%2520a%2520general%2520nonradioactive%2520substitute%2520for%2520%255B35S%255DGTP%25CE%25B3S%2520in%2520high-throughput%2520G%2520protein%2520studies%26jtitle%3DAnal.%2520Biochem.%26date%3D2010%26volume%3D397%26spage%3D202%26epage%3D207" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Malick, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doren, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barnett, A.</span><span> </span><span class="NLM_article-title">Quipazine-induced head-twitch in mice</span> <span class="citation_source-journal">Pharmacol., Biochem. Behav.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1977</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">325</span><span class="NLM_x">–</span> <span class="NLM_lpage">329</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1977&pages=325-329&author=J.+B.+Malickauthor=E.+Dorenauthor=A.+Barnett&title=Quipazine-induced+head-twitch+in+mice"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMalick%26aufirst%3DJ.%2BB.%26aulast%3DDoren%26aufirst%3DE.%26aulast%3DBarnett%26aufirst%3DA.%26atitle%3DQuipazine-induced%2520head-twitch%2520in%2520mice%26jtitle%3DPharmacol.%252C%2520Biochem.%2520Behav.%26date%3D1977%26volume%3D6%26spage%3D325%26epage%3D329" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Wadenberg, M. L. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hicks, P. B.</span><span> </span><span class="NLM_article-title">The conditioned avoidance response test re-evaluated: is it a sensitive test for the detection of potentially atypical antipsychotics?</span> <span class="citation_source-journal">Neurosci. Biobehav. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">851</span><span class="NLM_x">–</span> <span class="NLM_lpage">862</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=1999&pages=851-862&author=M.+L.+G.+Wadenbergauthor=P.+B.+Hicks&title=The+conditioned+avoidance+response+test+re-evaluated%3A+is+it+a+sensitive+test+for+the+detection+of+potentially+atypical+antipsychotics%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWadenberg%26aufirst%3DM.%2BL.%2BG.%26aulast%3DHicks%26aufirst%3DP.%2BB.%26atitle%3DThe%2520conditioned%2520avoidance%2520response%2520test%2520re-evaluated%253A%2520is%2520it%2520a%2520sensitive%2520test%2520for%2520the%2520detection%2520of%2520potentially%2520atypical%2520antipsychotics%253F%26jtitle%3DNeurosci.%2520Biobehav.%2520Rev.%26date%3D1999%26volume%3D23%26spage%3D851%26epage%3D862" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Arnt, J.</span><span> </span><span class="NLM_article-title">Pharmacological specificity of conditioned avoidance response inhibition in rats: inhibition by neuroleptics and correlation to dopamine receptor blockade</span> <span class="citation_source-journal">Acta Pharmacol. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1982</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">321</span><span class="NLM_x">–</span> <span class="NLM_lpage">329</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Fjm401958n&amp;key=10.1111%2Fj.1600-0773.1982.tb01032.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Fjm401958n&amp;key=6129770" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Fjm401958n&amp;key=1%3ACAS%3A528%3ADyaL3sXmsFehug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=1982&pages=321-329&author=J.+Arnt&title=Pharmacological+specificity+of+conditioned+avoidance+response+inhibition+in+rats%3A+inhibition+by+neuroleptics+and+correlation+to+dopamine+receptor+blockade"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological specificity of conditioned avoidance response inhibition in rats:  inhibition by neuroleptics and correlation to dopamine receptor blockade</span></div><div class="casAuthors">Arnt, Joern</div><div class="citationInfo"><span class="NLM_cas:title">Acta Pharmacologica et Toxicologica</span>
        (<span class="NLM_cas:date">1982</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">321-9</span>CODEN:
                <span class="NLM_cas:coden">APTOA6</span>;
        ISSN:<span class="NLM_cas:issn">0001-6683</span>.
    </div><div class="casAbstract">The inhibitory effect of 36 neuroleptic compds. on conditioned avoidance response (CAR) and unconditioned escape response (UER) has been studied in rats.  All neuroleptics antagonized CAR in doses below those inhibiting UER and below those inducing catalepsy.  Stereospecificity was shown in 2 cases.  Significant correlation was found between CAR inhibitory and cataleptogenic potency.  Also inhibition of amphetamine-induced stereotypy, affinity to 3H-haloperidol binding in vitro, and clin. potency was significantly correlated to CAR inhibition.  CAR and UER inhibition induced by cis(Z)-flupentixol (I)  [53772-82-0] and haloperidol  [52-86-8] was attenuated by scopolamine, but was only weakly influenced by methysergide and prazosin.  Among a wide range of other CNS active compds. tested, CAR was inhibited by α1-adrenergic antagonists, benzodiazepines, a barbiturate, GABA agonists, morphine, and a serotonin agonist, but in doses inducing other motor disturbances.  Thus, CAR inhibition is a sensitive test for dopamine receptor antagonists.  However, addnl. α-adrenergic activity found for some neuroleptics (e.g. clozapine  [5786-21-0], chlorprothixene  [113-59-7]) may contribute to the CAR inhibitory potency.  Addnl. antimuscarinic activity of neuroleptics may moderately attenuate CAR inhibition whereas serotonin receptor blockade is of minor importance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcjmAjdj8YybVg90H21EOLACvtfcHk0ljyNBwHz6B2JA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3sXmsFehug%253D%253D&md5=3c6a8cdc6e90e5a481b017c61b84d39c</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1111%2Fj.1600-0773.1982.tb01032.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1600-0773.1982.tb01032.x%26sid%3Dliteratum%253Aachs%26aulast%3DArnt%26aufirst%3DJ.%26atitle%3DPharmacological%2520specificity%2520of%2520conditioned%2520avoidance%2520response%2520inhibition%2520in%2520rats%253A%2520inhibition%2520by%2520neuroleptics%2520and%2520correlation%2520to%2520dopamine%2520receptor%2520blockade%26jtitle%3DActa%2520Pharmacol.%2520Toxicol.%26date%3D1982%26volume%3D51%26spage%3D321%26epage%3D329" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Snyder, G. L.; Vanover, K. E.; Zhu, H.; Miller, D. B.; O’Callaghan, J. P.; Tomesch, J.; Li, P.; Zhang, Q.; Krishnan, V.; Hendrick, J. P.; Nestler, E. J.; Davis, R. E.; Wennogle, L. P.; Mates, S.</span> unpublished results.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Snyder%2C+G.+L.%3B+Vanover%2C+K.+E.%3B+Zhu%2C+H.%3B+Miller%2C+D.+B.%3B+O%E2%80%99Callaghan%2C+J.+P.%3B+Tomesch%2C+J.%3B+Li%2C+P.%3B+Zhang%2C+Q.%3B+Krishnan%2C+V.%3B+Hendrick%2C+J.+P.%3B+Nestler%2C+E.+J.%3B+Davis%2C+R.+E.%3B+Wennogle%2C+L.+P.%3B+Mates%2C+S.+unpublished+results."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dunpublished%26sid%3Dliteratum%253Aachs%26aulast%3DSnyder%26aufirst%3DG.%2BL." title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Snyder, G. L.; Vanover, K. E.</span><span> </span><span class="NLM_article-title">Intracellular signaling and approaches to the treatment of schizophrenia and associated cognitive impairment</span>.  <span class="citation_source-journal">Curr. Pharm. Des.</span><span class="NLM_month">December</span><span class="NLM_day">15</span>,<span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span>DOI: <span class="refDoi"> DOI: 10.2174/1381612819666131216115417</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Fjm401958n&amp;key=10.2174%2F1381612819666131216115417" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=G.+L.+Snyder&author=K.+E.+Vanover&title=Intracellular+signaling+and+approaches+to+the+treatment+of+schizophrenia+and+associated+cognitive+impairment&doi=10.2174%2F1381612819666131216115417"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.2174%2F1381612819666131216115417&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1381612819666131216115417%26sid%3Dliteratum%253Aachs%26aulast%3DSnyder%26aufirst%3DG.%2BL.%26atitle%3DIntracellular%2520signaling%2520and%2520approaches%2520to%2520the%2520treatment%2520of%2520schizophrenia%2520and%2520associated%2520cognitive%2520impairment%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2013%26doi%3D10.2174%2F1381612819666131216115417" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 33 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Andrew C. Flick, Carolyn A. Leverett, Hong X. Ding, Emma McInturff, Sarah J. Fink, Subham Mahapatra, Daniel W. Carney, Erick A. Lindsey, Jacob C. DeForest, Scott P. France, Simon Berritt, Simone V. Bigi-Botterill, Tony S. Gibson, Yiyang Liu, <span class="NLM_string-name hlFld-ContribAuthor">Christopher J. O’Donnell</span>. </span><span class="cited-content_cbyCitation_article-title">Synthetic Approaches to the New Drugs Approved during 2019. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (7)
                                     , 3604-3657. <a href="https://doi.org/10.1021/acs.jmedchem.1c00208" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00208</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00208&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00208%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSynthetic%252BApproaches%252Bto%252Bthe%252BNew%252BDrugs%252BApproved%252Bduring%252B2019%26aulast%3DFlick%26aufirst%3DAndrew%2BC.%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D03022021%26date%3D30032021%26volume%3D64%26issue%3D7%26spage%3D3604%26epage%3D3657" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Ronald L. Reyes, Miyu Sato, Tomohiro Iwai, <span class="NLM_string-name hlFld-ContribAuthor">Masaya Sawamura</span>. </span><span class="cited-content_cbyCitation_article-title">Asymmetric Synthesis of α-Aminoboronates via Rhodium-Catalyzed Enantioselective C(sp3)–H Borylation. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2020,</strong> <em>142 </em>
                                    (1)
                                     , 589-597. <a href="https://doi.org/10.1021/jacs.9b12013" title="DOI URL">https://doi.org/10.1021/jacs.9b12013</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jacs.9b12013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjacs.9b12013%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3DAsymmetric%252BSynthesis%252Bof%252B%2525CE%2525B1-Aminoboronates%252Bvia%252BRhodium-Catalyzed%252BEnantioselective%252BC%252528sp3%252529%2525E2%252580%252593H%252BBorylation%26aulast%3DReyes%26aufirst%3DRonald%2BL.%26date%3D2020%26date%3D2019%26date%3D2019%26date%3D07112019%26date%3D26122019%26date%3D10122019%26volume%3D142%26issue%3D1%26spage%3D589%26epage%3D597" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Zhiyang Lin, Yun Lan, <span class="NLM_string-name hlFld-ContribAuthor">Chuan Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Reductive Allylic Defluorinative Cross-Coupling Enabled by Ni/Ti Cooperative Catalysis. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2019,</strong> <em>21 </em>
                                    (20)
                                     , 8316-8322. <a href="https://doi.org/10.1021/acs.orglett.9b03102" title="DOI URL">https://doi.org/10.1021/acs.orglett.9b03102</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.9b03102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.9b03102%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DReductive%252BAllylic%252BDefluorinative%252BCross-Coupling%252BEnabled%252Bby%252BNi%25252FTi%252BCooperative%252BCatalysis%26aulast%3DLin%26aufirst%3DZhiyang%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D30082019%26date%3D01102019%26volume%3D21%26issue%3D20%26spage%3D8316%26epage%3D8322" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Xudong Cao, Yifang Zhang, Yin Chen, Yinli Qiu, Minquan Yu, Xiangqing Xu, Xin Liu, Bi-Feng Liu, Liangren Zhang, <span class="NLM_string-name hlFld-ContribAuthor">Guisen Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and Biological Evaluation of Fused Tricyclic Heterocycle Piperazine (Piperidine) Derivatives As Potential Multireceptor Atypical Antipsychotics. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (22)
                                     , 10017-10039. <a href="https://doi.org/10.1021/acs.jmedchem.8b01096" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01096</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01096&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01096%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Band%252BBiological%252BEvaluation%252Bof%252BFused%252BTricyclic%252BHeterocycle%252BPiperazine%252B%252528Piperidine%252529%252BDerivatives%252BAs%252BPotential%252BMultireceptor%252BAtypical%252BAntipsychotics%26aulast%3DCao%26aufirst%3DXudong%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D12072018%26date%3D09112018%26date%3D01112018%26volume%3D61%26issue%3D22%26spage%3D10017%26epage%3D10039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Paul  Czodrowski</span> and <span class="hlFld-ContribAuthor ">Wolf-Guido  Bolick</span>  . </span><span class="cited-content_cbyCitation_article-title">OCEAN: Optimized Cross rEActivity estimatioN. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2016,</strong> <em>56 </em>
                                    (10)
                                     , 2013-2023. <a href="https://doi.org/10.1021/acs.jcim.6b00067" title="DOI URL">https://doi.org/10.1021/acs.jcim.6b00067</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.6b00067&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.6b00067%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DOCEAN%25253A%252BOptimized%252BCross%252BrEActivity%252BestimatioN%26aulast%3DCzodrowski%26aufirst%3DPaul%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D11022016%26date%3D26092016%26date%3D24102016%26volume%3D56%26issue%3D10%26spage%3D2013%26epage%3D2023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">H. Keith  Chenault</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of Pyrrolidones and Caprolactams by Ring Modification or
              Multi‐component Ring‐Forming
              Reaction. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 191-238. <a href="https://doi.org/10.1002/9781119468769.hpcbm003" title="DOI URL">https://doi.org/10.1002/9781119468769.hpcbm003</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9781119468769.hpcbm003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9781119468769.hpcbm003%26sid%3Dliteratum%253Aachs%26atitle%3DSynthesis%252Bof%252BPyrrolidones%252Band%252BCaprolactams%252Bby%252BRing%252BModification%252Bor%252BMulti%2525E2%252580%252590component%252BRing%2525E2%252580%252590Forming%252BReaction%26aulast%3DChenault%26aufirst%3DH.%2BKeith%26date%3D2021%26date%3D2021%26spage%3D191%26epage%3D238%26pub%3DWiley%26atitle%3DHandbook%252Bof%252BPyrrolidone%252Band%252BCaprolactam%252BBased%252BMaterials%26aulast%3DMusa%26aufirst%3DOsama%26date%3D2022%26date%3D2022%26volume%3D69" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Christoph U.  Correll</span>, <span class="hlFld-ContribAuthor ">Kimberly E.  Vanover</span>, <span class="hlFld-ContribAuthor ">Robert E.  Davis</span>, <span class="hlFld-ContribAuthor ">Richard  Chen</span>, <span class="hlFld-ContribAuthor ">Andrew  Satlin</span>, <span class="hlFld-ContribAuthor ">Sharon  Mates</span>. </span><span class="cited-content_cbyCitation_article-title">Safety and tolerability of lumateperone 42 mg: An open-label antipsychotic switch study in outpatients with stable schizophrenia. </span><span class="cited-content_cbyCitation_journal-name">Schizophrenia Research</span><span> <strong>2021,</strong> <em>228 </em>, 198-205. <a href="https://doi.org/10.1016/j.schres.2020.12.006" title="DOI URL">https://doi.org/10.1016/j.schres.2020.12.006</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.schres.2020.12.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.schres.2020.12.006%26sid%3Dliteratum%253Aachs%26jtitle%3DSchizophrenia%2520Research%26atitle%3DSafety%252Band%252Btolerability%252Bof%252Blumateperone%252B42%2525C2%2525A0mg%25253A%252BAn%252Bopen-label%252Bantipsychotic%252Bswitch%252Bstudy%252Bin%252Boutpatients%252Bwith%252Bstable%252Bschizophrenia%26aulast%3DCorrell%26aufirst%3DChristoph%2BU.%26date%3D2021%26volume%3D228%26spage%3D198%26epage%3D205" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Piotr  Stępnicki</span>, <span class="hlFld-ContribAuthor ">Magda  Kondej</span>, <span class="hlFld-ContribAuthor ">Oliwia  Koszła</span>, <span class="hlFld-ContribAuthor ">Justyna  Żuk</span>, <span class="hlFld-ContribAuthor ">Agnieszka A.  Kaczor</span>. </span><span class="cited-content_cbyCitation_article-title">Multi-targeted drug design strategies for the treatment of schizophrenia. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Drug Discovery</span><span> <strong>2021,</strong> <em>16 </em>
                                    (1)
                                     , 101-114. <a href="https://doi.org/10.1080/17460441.2020.1816962" title="DOI URL">https://doi.org/10.1080/17460441.2020.1816962</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/17460441.2020.1816962&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F17460441.2020.1816962%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Drug%2520Discovery%26atitle%3DMulti-targeted%252Bdrug%252Bdesign%252Bstrategies%252Bfor%252Bthe%252Btreatment%252Bof%252Bschizophrenia%26aulast%3DSt%25C4%2599pnicki%26aufirst%3DPiotr%26date%3D2021%26date%3D2020%26volume%3D16%26issue%3D1%26spage%3D101%26epage%3D114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gretchen L.  Snyder</span>, <span class="hlFld-ContribAuthor ">Kimberly E.  Vanover</span>, <span class="hlFld-ContribAuthor ">Robert E.  Davis</span>, <span class="hlFld-ContribAuthor ">Peng  Li</span>, <span class="hlFld-ContribAuthor ">Allen  Fienberg</span>, <span class="hlFld-ContribAuthor ">Sharon  Mates</span>. </span><span class="cited-content_cbyCitation_article-title">A review of the pharmacology and clinical profile of lumateperone for the treatment of schizophrenia. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 253-276. <a href="https://doi.org/10.1016/bs.apha.2020.09.001" title="DOI URL">https://doi.org/10.1016/bs.apha.2020.09.001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/bs.apha.2020.09.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fbs.apha.2020.09.001%26sid%3Dliteratum%253Aachs%26atitle%3DA%252Breview%252Bof%252Bthe%252Bpharmacology%252Band%252Bclinical%252Bprofile%252Bof%252Blumateperone%252Bfor%252Bthe%252Btreatment%252Bof%252Bschizophrenia%26aulast%3DSnyder%26aufirst%3DGretchen%2BL.%26date%3D2021%26spage%3D253%26epage%3D276%26pub%3DElsevier%26atitle%3DA%252BTribute%252Bto%252BPaul%252BGreengard%252B%2525281925-2019%252529%26date%3D2021%26volume%3D90" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alveena Batool  Syed</span>, <span class="hlFld-ContribAuthor ">James Robert  Brašić</span>. </span><span class="cited-content_cbyCitation_article-title">The role of lumateperone in the treatment of schizophrenia. </span><span class="cited-content_cbyCitation_journal-name">Therapeutic Advances in Psychopharmacology</span><span> <strong>2021,</strong> <em>11 </em>, 204512532110340. <a href="https://doi.org/10.1177/20451253211034019" title="DOI URL">https://doi.org/10.1177/20451253211034019</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1177/20451253211034019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1177%2F20451253211034019%26sid%3Dliteratum%253Aachs%26jtitle%3DTherapeutic%2520Advances%2520in%2520Psychopharmacology%26atitle%3DThe%252Brole%252Bof%252Blumateperone%252Bin%252Bthe%252Btreatment%252Bof%252Bschizophrenia%26aulast%3DSyed%26aufirst%3DAlveena%2BBatool%26date%3D2021%26date%3D2021%26volume%3D11%26spage%3D204512532110340" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shuo  Yuan</span>, <span class="hlFld-ContribAuthor ">Bin  Yu</span>, <span class="hlFld-ContribAuthor ">Hong-Min  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">New drug approvals for 2019: Synthesis and clinical applications. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>205 </em>, 112667. <a href="https://doi.org/10.1016/j.ejmech.2020.112667" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112667</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112667&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112667%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DNew%252Bdrug%252Bapprovals%252Bfor%252B2019%25253A%252BSynthesis%252Band%252Bclinical%252Bapplications%26aulast%3DYuan%26aufirst%3DShuo%26date%3D2020%26volume%3D205%26spage%3D112667" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Marianna  Mazza</span>, <span class="hlFld-ContribAuthor ">Giuseppe  Marano</span>, <span class="hlFld-ContribAuthor ">Gianandrea  Traversi</span>, <span class="hlFld-ContribAuthor ">Gabriele  Sani</span>, <span class="hlFld-ContribAuthor ">Luigi  Janiri</span>. </span><span class="cited-content_cbyCitation_article-title">Evidence on the New Drug Lumateperone (ITI-007) for Psychiatric and Neurological Disorders. </span><span class="cited-content_cbyCitation_journal-name">CNS & Neurological Disorders - Drug Targets</span><span> <strong>2020,</strong> <em>19 </em>
                                    (4)
                                     , 243-247. <a href="https://doi.org/10.2174/1871527319666200601145653" title="DOI URL">https://doi.org/10.2174/1871527319666200601145653</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1871527319666200601145653&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1871527319666200601145653%26sid%3Dliteratum%253Aachs%26jtitle%3DCNS%2520%2526%2520Neurological%2520Disorders%2520-%2520Drug%2520Targets%26atitle%3DEvidence%252Bon%252Bthe%252BNew%252BDrug%252BLumateperone%252B%252528ITI-007%252529%252Bfor%252BPsychiatric%252Band%252BNeurological%252BDisorders%26aulast%3DMazza%26aufirst%3DMarianna%26date%3D2020%26volume%3D19%26issue%3D4%26spage%3D243%26epage%3D247" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Teresa  Sánchez-Gutiérrez</span>, <span class="hlFld-ContribAuthor ">Elisa  Rodríguez-Toscano</span>, <span class="hlFld-ContribAuthor ">Cloe  Llorente</span>, <span class="hlFld-ContribAuthor ">Elena  de la Serna</span>, <span class="hlFld-ContribAuthor ">Carmen  Moreno</span>, <span class="hlFld-ContribAuthor ">Gisela  Sugranyes</span>, <span class="hlFld-ContribAuthor ">Soledad  Romero</span>, <span class="hlFld-ContribAuthor ">Ana  Calvo</span>, <span class="hlFld-ContribAuthor ">Immaculada  Baeza</span>, <span class="hlFld-ContribAuthor ">Vanessa  Sánchez-Gistau</span>, <span class="hlFld-ContribAuthor ">Ana  Espliego</span>, <span class="hlFld-ContribAuthor ">Josefina  Castro-Fornieles</span>, <span class="hlFld-ContribAuthor ">Dolores  Moreno</span>. </span><span class="cited-content_cbyCitation_article-title">Neuropsychological, clinical and environmental predictors of severe mental disorders in offspring of patients with schizophrenia. </span><span class="cited-content_cbyCitation_journal-name">European Archives of Psychiatry and Clinical Neuroscience</span><span> <strong>2020,</strong> <em>270 </em>
                                    (6)
                                     , 739-748. <a href="https://doi.org/10.1007/s00406-019-01044-7" title="DOI URL">https://doi.org/10.1007/s00406-019-01044-7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00406-019-01044-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00406-019-01044-7%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Archives%2520of%2520Psychiatry%2520and%2520Clinical%2520Neuroscience%26atitle%3DNeuropsychological%25252C%252Bclinical%252Band%252Benvironmental%252Bpredictors%252Bof%252Bsevere%252Bmental%252Bdisorders%252Bin%252Boffspring%252Bof%252Bpatients%252Bwith%252Bschizophrenia%26aulast%3DS%25C3%25A1nchez-Guti%25C3%25A9rrez%26aufirst%3DTeresa%26date%3D2020%26date%3D2019%26volume%3D270%26issue%3D6%26spage%3D739%26epage%3D748" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zizhen  Yin</span>, <span class="hlFld-ContribAuthor ">Wenfei  Hu</span>, <span class="hlFld-ContribAuthor ">Wei  Zhang</span>, <span class="hlFld-ContribAuthor ">Hiroyuki  Konno</span>, <span class="hlFld-ContribAuthor ">Hiroki  Moriwaki</span>, <span class="hlFld-ContribAuthor ">Kunisuke  Izawa</span>, <span class="hlFld-ContribAuthor ">Jianlin  Han</span>, <span class="hlFld-ContribAuthor ">Vadim A.  Soloshonok</span>. </span><span class="cited-content_cbyCitation_article-title">Tailor-made amino acid-derived pharmaceuticals approved by the FDA in 2019. </span><span class="cited-content_cbyCitation_journal-name">Amino Acids</span><span> <strong>2020,</strong> <em>52 </em>
                                    (9)
                                     , 1227-1261. <a href="https://doi.org/10.1007/s00726-020-02887-4" title="DOI URL">https://doi.org/10.1007/s00726-020-02887-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00726-020-02887-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00726-020-02887-4%26sid%3Dliteratum%253Aachs%26jtitle%3DAmino%2520Acids%26atitle%3DTailor-made%252Bamino%252Bacid-derived%252Bpharmaceuticals%252Bapproved%252Bby%252Bthe%252BFDA%252Bin%252B2019%26aulast%3DYin%26aufirst%3DZizhen%26date%3D2020%26date%3D2020%26volume%3D52%26issue%3D9%26spage%3D1227%26epage%3D1261" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Haibo  Mei</span>, <span class="hlFld-ContribAuthor ">Attila Márió  Remete</span>, <span class="hlFld-ContribAuthor ">Yupiao  Zou</span>, <span class="hlFld-ContribAuthor ">Hiroki  Moriwaki</span>, <span class="hlFld-ContribAuthor ">Santos  Fustero</span>, <span class="hlFld-ContribAuthor ">Lorand  Kiss</span>, <span class="hlFld-ContribAuthor ">Vadim A.  Soloshonok</span>, <span class="hlFld-ContribAuthor ">Jianlin  Han</span>. </span><span class="cited-content_cbyCitation_article-title">Fluorine-containing drugs approved by the FDA in 2019. </span><span class="cited-content_cbyCitation_journal-name">Chinese Chemical Letters</span><span> <strong>2020,</strong> <em>31 </em>
                                    (9)
                                     , 2401-2413. <a href="https://doi.org/10.1016/j.cclet.2020.03.050" title="DOI URL">https://doi.org/10.1016/j.cclet.2020.03.050</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.cclet.2020.03.050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.cclet.2020.03.050%26sid%3Dliteratum%253Aachs%26jtitle%3DChinese%2520Chemical%2520Letters%26atitle%3DFluorine-containing%252Bdrugs%252Bapproved%252Bby%252Bthe%252BFDA%252Bin%252B2019%26aulast%3DMei%26aufirst%3DHaibo%26date%3D2020%26volume%3D31%26issue%3D9%26spage%3D2401%26epage%3D2413" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pankhuri  Vyas</span>, <span class="hlFld-ContribAuthor ">Brian Jaeho  Hwang</span>, <span class="hlFld-ContribAuthor ">James Robert  Brašić</span>. </span><span class="cited-content_cbyCitation_article-title">An evaluation of lumateperone tosylate for the treatment of schizophrenia. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Pharmacotherapy</span><span> <strong>2020,</strong> <em>21 </em>
                                    (2)
                                     , 139-145. <a href="https://doi.org/10.1080/14656566.2019.1695778" title="DOI URL">https://doi.org/10.1080/14656566.2019.1695778</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/14656566.2019.1695778&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F14656566.2019.1695778%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Pharmacotherapy%26atitle%3DAn%252Bevaluation%252Bof%252Blumateperone%252Btosylate%252Bfor%252Bthe%252Btreatment%252Bof%252Bschizophrenia%26aulast%3DVyas%26aufirst%3DPankhuri%26date%3D2020%26date%3D2019%26volume%3D21%26issue%3D2%26spage%3D139%26epage%3D145" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Steve  Pedrini</span>, <span class="hlFld-ContribAuthor ">Mike  Morici</span>, <span class="hlFld-ContribAuthor ">Ralph N.  Martins</span>. </span><span class="cited-content_cbyCitation_article-title">Current and Prospective Treatments for Alzheimer's Disease (and Other Neurodegenerative Diseases). </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2019,</strong>,, 391-442. <a href="https://doi.org/10.1002/9781119356752.ch14" title="DOI URL">https://doi.org/10.1002/9781119356752.ch14</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9781119356752.ch14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9781119356752.ch14%26sid%3Dliteratum%253Aachs%26atitle%3DCurrent%252Band%252BProspective%252BTreatments%252Bfor%252BAlzheimer%252527s%252BDisease%252B%252528and%252BOther%252BNeurodegenerative%252BDiseases%252529%26aulast%3DPedrini%26aufirst%3DSteve%26date%3D2019%26date%3D2019%26spage%3D391%26epage%3D442%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%252C%2520Ltd%26atitle%3DNeurodegeneration%252Band%252BAlzheimer%252527s%252BDisease%26aulast%3DN.%2BMartins%26aufirst%3DRalph%26date%3D2019%26volume%3D55" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Satbir  Mor</span>, <span class="hlFld-ContribAuthor ">Suchita  Sindhu</span>. </span><span class="cited-content_cbyCitation_article-title">Convenient and efficient synthesis of novel 11
              H
              -benzo[5,6][1,4]thiazino[3,4-
              a
              ]isoindol-11-ones derived from 2-bromo-(2/3-substitutedphenyl)-1
              H
              -indene-1,3(2
              H
              )-diones. </span><span class="cited-content_cbyCitation_journal-name">RSC Advances</span><span> <strong>2019,</strong> <em>9 </em>
                                    (23)
                                     , 12784-12792. <a href="https://doi.org/10.1039/C9RA02403D" title="DOI URL">https://doi.org/10.1039/C9RA02403D</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9RA02403D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9RA02403D%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Advances%26atitle%3DConvenient%252Band%252Befficient%252Bsynthesis%252Bof%252Bnovel%252B11%252BH%252B-benzo%25255B5%25252C6%25255D%25255B1%25252C4%25255Dthiazino%25255B3%25252C4-%252Ba%252B%25255Disoindol-11-ones%252Bderived%252Bfrom%252B2-bromo-%2525282%25252F3-substitutedphenyl%252529-1%252BH%252B-indene-1%25252C3%2525282%252BH%252B%252529-diones%26aulast%3DMor%26aufirst%3DSatbir%26date%3D2019%26date%3D2019%26volume%3D9%26issue%3D23%26spage%3D12784%26epage%3D12792" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sneha H.  Meshram</span>, <span class="hlFld-ContribAuthor ">Tungana  Ramesh</span>, <span class="hlFld-ContribAuthor ">Jagadeesh Babu  Nanubolu</span>, <span class="hlFld-ContribAuthor ">Ajay Kumar  Srivastava</span>, <span class="hlFld-ContribAuthor ">Bhaskar Rao  Adari</span>, <span class="hlFld-ContribAuthor ">Nivedita  Sahu</span>. </span><span class="cited-content_cbyCitation_article-title">Green synthesis of enantiopure quinoxaline alcohols using
              
                Daucus carota
              . </span><span class="cited-content_cbyCitation_journal-name">Chirality</span><span> <strong>2019,</strong> <em>31 </em>
                                    (4)
                                     , 312-320. <a href="https://doi.org/10.1002/chir.23057" title="DOI URL">https://doi.org/10.1002/chir.23057</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/chir.23057&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fchir.23057%26sid%3Dliteratum%253Aachs%26jtitle%3DChirality%26atitle%3DGreen%252Bsynthesis%252Bof%252Benantiopure%252Bquinoxaline%252Balcohols%252Busing%252BDaucus%252Bcarota%26aulast%3DMeshram%26aufirst%3DSneha%2BH.%26date%3D2019%26date%3D2019%26volume%3D31%26issue%3D4%26spage%3D312%26epage%3D320" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kimberly E.  Vanover</span>, <span class="hlFld-ContribAuthor ">Robert E.  Davis</span>, <span class="hlFld-ContribAuthor ">Yun  Zhou</span>, <span class="hlFld-ContribAuthor ">Weiguo  Ye</span>, <span class="hlFld-ContribAuthor ">James R.  Brašić</span>, <span class="hlFld-ContribAuthor ">Lorena  Gapasin</span>, <span class="hlFld-ContribAuthor ">Jelena  Saillard</span>, <span class="hlFld-ContribAuthor ">Michal  Weingart</span>, <span class="hlFld-ContribAuthor ">Robert E.  Litman</span>, <span class="hlFld-ContribAuthor ">Sharon  Mates</span>, <span class="hlFld-ContribAuthor ">Dean F.  Wong</span>. </span><span class="cited-content_cbyCitation_article-title">Dopamine D2 receptor occupancy of lumateperone (ITI-007): a Positron Emission Tomography Study in patients with schizophrenia. </span><span class="cited-content_cbyCitation_journal-name">Neuropsychopharmacology</span><span> <strong>2019,</strong> <em>44 </em>
                                    (3)
                                     , 598-605. <a href="https://doi.org/10.1038/s41386-018-0251-1" title="DOI URL">https://doi.org/10.1038/s41386-018-0251-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41386-018-0251-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41386-018-0251-1%26sid%3Dliteratum%253Aachs%26jtitle%3DNeuropsychopharmacology%26atitle%3DDopamine%252BD2%252Breceptor%252Boccupancy%252Bof%252Blumateperone%252B%252528ITI-007%252529%25253A%252Ba%252BPositron%252BEmission%252BTomography%252BStudy%252Bin%252Bpatients%252Bwith%252Bschizophrenia%26aulast%3DVanover%26aufirst%3DKimberly%2BE.%26date%3D2019%26date%3D2018%26volume%3D44%26issue%3D3%26spage%3D598%26epage%3D605" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lei  Zhang</span>, <span class="hlFld-ContribAuthor ">Joseph  Hendrick</span>. </span><span class="cited-content_cbyCitation_article-title">The presynaptic D2 partial agonist lumateperone acts as a postsynaptic D2 antagonist. </span><span class="cited-content_cbyCitation_journal-name">Matters</span><span> <strong>2018,</strong> <em> </em><a href="https://doi.org/10.19185/matters.201712000006" title="DOI URL">https://doi.org/10.19185/matters.201712000006</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.19185/matters.201712000006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.19185%2Fmatters.201712000006%26sid%3Dliteratum%253Aachs%26jtitle%3DMatters%26atitle%3DThe%252Bpresynaptic%252BD2%252Bpartial%252Bagonist%252Blumateperone%252Bacts%252Bas%252Ba%252Bpostsynaptic%252BD2%252Bantagonist%26aulast%3DZhang%26aufirst%3DLei%26date%3D2018%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xi  Mao</span>, <span class="hlFld-ContribAuthor ">Tao  Tong</span>, <span class="hlFld-ContribAuthor ">Senbao  Fan</span>, <span class="hlFld-ContribAuthor ">Liting  Fang</span>, <span class="hlFld-ContribAuthor ">Jingyi  Wu</span>, <span class="hlFld-ContribAuthor ">Xiaoxia  Wang</span>, <span class="hlFld-ContribAuthor ">Honglan  Kang</span>, <span class="hlFld-ContribAuthor ">Xin  Lv</span>. </span><span class="cited-content_cbyCitation_article-title">One-pot synthesis of thiazino[2,3,4-hi]indole derivatives through a tandem oxidative coupling/heteroannulation process. </span><span class="cited-content_cbyCitation_journal-name">Chemical Communications</span><span> <strong>2017,</strong> <em>53 </em>
                                    (34)
                                     , 4718-4721. <a href="https://doi.org/10.1039/C7CC00992E" title="DOI URL">https://doi.org/10.1039/C7CC00992E</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C7CC00992E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC7CC00992E%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Communications%26atitle%3DOne-pot%252Bsynthesis%252Bof%252Bthiazino%25255B2%25252C3%25252C4-hi%25255Dindole%252Bderivatives%252Bthrough%252Ba%252Btandem%252Boxidative%252Bcoupling%25252Fheteroannulation%252Bprocess%26aulast%3DMao%26aufirst%3DXi%26date%3D2017%26date%3D2017%26volume%3D53%26issue%3D34%26spage%3D4718%26epage%3D4721" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rui  Wang</span>, <span class="hlFld-ContribAuthor ">Ruo-Xing  Jin</span>, <span class="hlFld-ContribAuthor ">Zi-Yang  Qin</span>, <span class="hlFld-ContribAuthor ">Kang-Jie  Bian</span>, <span class="hlFld-ContribAuthor ">Xi-Sheng  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Novel and facile synthesis of 1-benzazepines via copper-catalyzed oxidative C(sp
              3
              )–H/C(sp
              2
              )–H cross-coupling. </span><span class="cited-content_cbyCitation_journal-name">Chemical Communications</span><span> <strong>2017,</strong> <em>53 </em>
                                    (90)
                                     , 12229-12232. <a href="https://doi.org/10.1039/C7CC07027F" title="DOI URL">https://doi.org/10.1039/C7CC07027F</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C7CC07027F&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC7CC07027F%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Communications%26atitle%3DNovel%252Band%252Bfacile%252Bsynthesis%252Bof%252B1-benzazepines%252Bvia%252Bcopper-catalyzed%252Boxidative%252BC%252528sp%252B3%252B%252529%2525E2%252580%252593H%25252FC%252528sp%252B2%252B%252529%2525E2%252580%252593H%252Bcross-coupling%26aulast%3DWang%26aufirst%3DRui%26date%3D2017%26date%3D2017%26volume%3D53%26issue%3D90%26spage%3D12229%26epage%3D12232" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Priya  Bawa</span>, <span class="hlFld-ContribAuthor ">Priyamvada  Pradeep</span>, <span class="hlFld-ContribAuthor ">Pradeep  Kumar</span>, <span class="hlFld-ContribAuthor ">Yahya E.  Choonara</span>, <span class="hlFld-ContribAuthor ">Girish  Modi</span>, <span class="hlFld-ContribAuthor ">Viness  Pillay</span>. </span><span class="cited-content_cbyCitation_article-title">Multi-target therapeutics for neuropsychiatric and neurodegenerative disorders. </span><span class="cited-content_cbyCitation_journal-name">Drug Discovery Today</span><span> <strong>2016,</strong> <em>21 </em>
                                    (12)
                                     , 1886-1914. <a href="https://doi.org/10.1016/j.drudis.2016.08.001" title="DOI URL">https://doi.org/10.1016/j.drudis.2016.08.001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.drudis.2016.08.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.drudis.2016.08.001%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Discovery%2520Today%26atitle%3DMulti-target%252Btherapeutics%252Bfor%252Bneuropsychiatric%252Band%252Bneurodegenerative%252Bdisorders%26aulast%3DBawa%26aufirst%3DPriya%26date%3D2016%26volume%3D21%26issue%3D12%26spage%3D1886%26epage%3D1914" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Robert E.  Davis</span>, <span class="hlFld-ContribAuthor ">Christoph U.  Correll</span>. </span><span class="cited-content_cbyCitation_article-title">ITI-007 in the treatment of schizophrenia: from novel pharmacology to clinical outcomes. </span><span class="cited-content_cbyCitation_journal-name">Expert Review of Neurotherapeutics</span><span> <strong>2016,</strong> <em>16 </em>
                                    (6)
                                     , 601-614. <a href="https://doi.org/10.1080/14737175.2016.1174577" title="DOI URL">https://doi.org/10.1080/14737175.2016.1174577</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/14737175.2016.1174577&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F14737175.2016.1174577%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Review%2520of%2520Neurotherapeutics%26atitle%3DITI-007%252Bin%252Bthe%252Btreatment%252Bof%252Bschizophrenia%25253A%252Bfrom%252Bnovel%252Bpharmacology%252Bto%252Bclinical%252Boutcomes%26aulast%3DDavis%26aufirst%3DRobert%2BE.%26date%3D2016%26date%3D2016%26volume%3D16%26issue%3D6%26spage%3D601%26epage%3D614" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jeffrey A.  Lieberman</span>, <span class="hlFld-ContribAuthor ">Robert E.  Davis</span>, <span class="hlFld-ContribAuthor ">Christoph U.  Correll</span>, <span class="hlFld-ContribAuthor ">Donald C.  Goff</span>, <span class="hlFld-ContribAuthor ">John M.  Kane</span>, <span class="hlFld-ContribAuthor ">Carol A.  Tamminga</span>, <span class="hlFld-ContribAuthor ">Sharon  Mates</span>, <span class="hlFld-ContribAuthor ">Kimberly E.  Vanover</span>. </span><span class="cited-content_cbyCitation_article-title">ITI-007 for the Treatment of Schizophrenia: A 4-Week Randomized, Double-Blind, Controlled Trial. </span><span class="cited-content_cbyCitation_journal-name">Biological Psychiatry</span><span> <strong>2016,</strong> <em>79 </em>
                                    (12)
                                     , 952-961. <a href="https://doi.org/10.1016/j.biopsych.2015.08.026" title="DOI URL">https://doi.org/10.1016/j.biopsych.2015.08.026</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.biopsych.2015.08.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.biopsych.2015.08.026%26sid%3Dliteratum%253Aachs%26jtitle%3DBiological%2520Psychiatry%26atitle%3DITI-007%252Bfor%252Bthe%252BTreatment%252Bof%252BSchizophrenia%25253A%252BA%252B4-Week%252BRandomized%25252C%252BDouble-Blind%25252C%252BControlled%252BTrial%26aulast%3DLieberman%26aufirst%3DJeffrey%2BA.%26date%3D2016%26volume%3D79%26issue%3D12%26spage%3D952%26epage%3D961" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gang  Liu</span>, <span class="hlFld-ContribAuthor ">Xuechun  Sun</span>, <span class="hlFld-ContribAuthor ">Ling  Chen</span>, <span class="hlFld-ContribAuthor ">Yueci  Wu</span>, <span class="hlFld-ContribAuthor ">Jing  Han</span>, <span class="hlFld-ContribAuthor ">Jie  Chen</span>, <span class="hlFld-ContribAuthor ">Hongmei  Deng</span>, <span class="hlFld-ContribAuthor ">Min  Shao</span>, <span class="hlFld-ContribAuthor ">Hui  Zhang</span>, <span class="hlFld-ContribAuthor ">Weiguo  Cao</span>. </span><span class="cited-content_cbyCitation_article-title">Facile synthesis of quinoxaline annulated perfluoroalkylated benzoazepine derivatives. </span><span class="cited-content_cbyCitation_journal-name">RSC Advances</span><span> <strong>2016,</strong> <em>6 </em>
                                    (110)
                                     , 108154-108157. <a href="https://doi.org/10.1039/C6RA22727A" title="DOI URL">https://doi.org/10.1039/C6RA22727A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C6RA22727A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC6RA22727A%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Advances%26atitle%3DFacile%252Bsynthesis%252Bof%252Bquinoxaline%252Bannulated%252Bperfluoroalkylated%252Bbenzoazepine%252Bderivatives%26aulast%3DLiu%26aufirst%3DGang%26date%3D2016%26date%3D2016%26volume%3D6%26issue%3D110%26spage%3D108154%26epage%3D108157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ling  Huang</span>, <span class="hlFld-ContribAuthor ">Wenjun  Zhang</span>, <span class="hlFld-ContribAuthor ">Xiaohua  Zhang</span>, <span class="hlFld-ContribAuthor ">Lei  Yin</span>, <span class="hlFld-ContribAuthor ">Bangyin  Chen</span>, <span class="hlFld-ContribAuthor ">Jinchun  Song</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and pharmacological evaluation of piperidine (piperazine)-substituted benzoxazole derivatives as multi-target antipsychotics. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2015,</strong> <em>25 </em>
                                    (22)
                                     , 5299-5305. <a href="https://doi.org/10.1016/j.bmcl.2015.09.045" title="DOI URL">https://doi.org/10.1016/j.bmcl.2015.09.045</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2015.09.045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2015.09.045%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DSynthesis%252Band%252Bpharmacological%252Bevaluation%252Bof%252Bpiperidine%252B%252528piperazine%252529-substituted%252Bbenzoxazole%252Bderivatives%252Bas%252Bmulti-target%252Bantipsychotics%26aulast%3DHuang%26aufirst%3DLing%26date%3D2015%26volume%3D25%26issue%3D22%26spage%3D5299%26epage%3D5305" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Robert E.  Davis</span>, <span class="hlFld-ContribAuthor ">Kimberly E.  Vanover</span>, <span class="hlFld-ContribAuthor ">Yun  Zhou</span>, <span class="hlFld-ContribAuthor ">James R.  Brašić</span>, <span class="hlFld-ContribAuthor ">Maria  Guevara</span>, <span class="hlFld-ContribAuthor ">Blanca  Bisuna</span>, <span class="hlFld-ContribAuthor ">Weiguo  Ye</span>, <span class="hlFld-ContribAuthor ">Vanessa  Raymont</span>, <span class="hlFld-ContribAuthor ">William  Willis</span>, <span class="hlFld-ContribAuthor ">Anil  Kumar</span>, <span class="hlFld-ContribAuthor ">Lorena  Gapasin</span>, <span class="hlFld-ContribAuthor ">D. Ronald  Goldwater</span>, <span class="hlFld-ContribAuthor ">Sharon  Mates</span>, <span class="hlFld-ContribAuthor ">Dean F.  Wong</span>. </span><span class="cited-content_cbyCitation_article-title">ITI-007 demonstrates brain occupancy at serotonin 5-HT2A and dopamine D2 receptors and serotonin transporters using positron emission tomography in healthy volunteers. </span><span class="cited-content_cbyCitation_journal-name">Psychopharmacology</span><span> <strong>2015,</strong> <em>232 </em>
                                    (15)
                                     , 2863-2872. <a href="https://doi.org/10.1007/s00213-015-3922-1" title="DOI URL">https://doi.org/10.1007/s00213-015-3922-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00213-015-3922-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00213-015-3922-1%26sid%3Dliteratum%253Aachs%26jtitle%3DPsychopharmacology%26atitle%3DITI-007%252Bdemonstrates%252Bbrain%252Boccupancy%252Bat%252Bserotonin%252B5-HT2A%252Band%252Bdopamine%252BD2%252Breceptors%252Band%252Bserotonin%252Btransporters%252Busing%252Bpositron%252Bemission%252Btomography%252Bin%252Bhealthy%252Bvolunteers%26aulast%3DDavis%26aufirst%3DRobert%2BE.%26date%3D2015%26date%3D2015%26volume%3D232%26issue%3D15%26spage%3D2863%26epage%3D2872" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wei  Peng</span>, <span class="hlFld-ContribAuthor ">Fei  Ding</span>. </span><span class="cited-content_cbyCitation_article-title">Biomolecular recognition of antagonists by α 7 nicotinic acetylcholine receptor: Antagonistic mechanism and structure–activity relationships studies. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Pharmaceutical Sciences</span><span> <strong>2015,</strong> <em>76 </em>, 119-132. <a href="https://doi.org/10.1016/j.ejps.2015.05.005" title="DOI URL">https://doi.org/10.1016/j.ejps.2015.05.005</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejps.2015.05.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejps.2015.05.005%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Pharmaceutical%2520Sciences%26atitle%3DBiomolecular%252Brecognition%252Bof%252Bantagonists%252Bby%252B%2525CE%2525B1%252B7%252Bnicotinic%252Bacetylcholine%252Breceptor%25253A%252BAntagonistic%252Bmechanism%252Band%252Bstructure%2525E2%252580%252593activity%252Brelationships%252Bstudies%26aulast%3DPeng%26aufirst%3DWei%26date%3D2015%26volume%3D76%26spage%3D119%26epage%3D132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jing-Wen  Yu</span>, <span class="hlFld-ContribAuthor ">Shuai  Mao</span>, <span class="hlFld-ContribAuthor ">Yong-Qiang  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Copper-catalyzed base-accelerated direct oxidation of C–H bond to synthesize benzils, isatins, and quinoxalines with molecular oxygen as terminal oxidant. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron Letters</span><span> <strong>2015,</strong> <em>56 </em>
                                    (12)
                                     , 1575-1580. <a href="https://doi.org/10.1016/j.tetlet.2015.02.019" title="DOI URL">https://doi.org/10.1016/j.tetlet.2015.02.019</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tetlet.2015.02.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tetlet.2015.02.019%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%2520Letters%26atitle%3DCopper-catalyzed%252Bbase-accelerated%252Bdirect%252Boxidation%252Bof%252BC%2525E2%252580%252593H%252Bbond%252Bto%252Bsynthesize%252Bbenzils%25252C%252Bisatins%25252C%252Band%252Bquinoxalines%252Bwith%252Bmolecular%252Boxygen%252Bas%252Bterminal%252Boxidant%26aulast%3DYu%26aufirst%3DJing-Wen%26date%3D2015%26volume%3D56%26issue%3D12%26spage%3D1575%26epage%3D1580" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Luisa-Sophie  Köster</span>, <span class="hlFld-ContribAuthor ">Maren  Carbon</span>, <span class="hlFld-ContribAuthor ">Christoph U  Correll</span>. </span><span class="cited-content_cbyCitation_article-title">Emerging drugs for schizophrenia: an update. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Emerging Drugs</span><span> <strong>2014,</strong> <em>19 </em>
                                    (4)
                                     , 511-531. <a href="https://doi.org/10.1517/14728214.2014.958148" title="DOI URL">https://doi.org/10.1517/14728214.2014.958148</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1517/14728214.2014.958148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1517%2F14728214.2014.958148%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Emerging%2520Drugs%26atitle%3DEmerging%252Bdrugs%252Bfor%252Bschizophrenia%25253A%252Ban%252Bupdate%26aulast%3DK%25C3%25B6ster%26aufirst%3DLuisa-Sophie%26date%3D2014%26date%3D2014%26volume%3D19%26issue%3D4%26spage%3D511%26epage%3D531" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Olukayode  Abayomi</span>, <span class="hlFld-ContribAuthor ">Davide  Amato</span>, <span class="hlFld-ContribAuthor ">Candace  Bailey</span>, <span class="hlFld-ContribAuthor ">Byron  Bitanihirwe</span>, <span class="hlFld-ContribAuthor ">Lynneice  Bowen</span>, <span class="hlFld-ContribAuthor ">Shimon  Burshtein</span>, <span class="hlFld-ContribAuthor ">Alexis  Cullen</span>, <span class="hlFld-ContribAuthor ">Montserrat  Fusté</span>, <span class="hlFld-ContribAuthor ">Ana P.  Herrmann</span>, <span class="hlFld-ContribAuthor ">Babak  Khodaie</span>, <span class="hlFld-ContribAuthor ">Sanja  Kilian</span>, <span class="hlFld-ContribAuthor ">Qortni A.  Lang</span>, <span class="hlFld-ContribAuthor ">Elizabeth E.  Manning</span>, <span class="hlFld-ContribAuthor ">Raffael  Massuda</span>, <span class="hlFld-ContribAuthor ">Milawaty  Nurjono</span>, <span class="hlFld-ContribAuthor ">Sarosh  Sadiq</span>, <span class="hlFld-ContribAuthor ">Teresa  Sanchez-Gutierrez</span>, <span class="hlFld-ContribAuthor ">Tamara  Sheinbaum</span>, <span class="hlFld-ContribAuthor ">Venkataram  Shivakumar</span>, <span class="hlFld-ContribAuthor ">Nicholas  Simon</span>, <span class="hlFld-ContribAuthor ">Anneliese  Spiteri-Staines</span>, <span class="hlFld-ContribAuthor ">Suttajit  Sirijit</span>, <span class="hlFld-ContribAuthor ">Nanna Gilliam  Toftdahl</span>, <span class="hlFld-ContribAuthor ">Sunali  Wadehra</span>, <span class="hlFld-ContribAuthor ">Yi  Wang</span>, <span class="hlFld-ContribAuthor ">Rebekah  Wigton</span>, <span class="hlFld-ContribAuthor ">Susan  Wright</span>, <span class="hlFld-ContribAuthor ">Sergey  Yagoda</span>, <span class="hlFld-ContribAuthor ">Yuliya  Zaytseva</span>, <span class="hlFld-ContribAuthor ">Anne  O'Shea</span>, <span class="hlFld-ContribAuthor ">Lynn E.  DeLisi</span>. </span><span class="cited-content_cbyCitation_article-title">The 4th Schizophrenia International Research Society Conference, 5–9 April 2014, Florence, Italy: A summary of topics and trends. </span><span class="cited-content_cbyCitation_journal-name">Schizophrenia Research</span><span> <strong>2014,</strong> <em>159 </em>
                                    (2-3)
                                     , e1-e22. <a href="https://doi.org/10.1016/j.schres.2014.08.032" title="DOI URL">https://doi.org/10.1016/j.schres.2014.08.032</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.schres.2014.08.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.schres.2014.08.032%26sid%3Dliteratum%253Aachs%26jtitle%3DSchizophrenia%2520Research%26atitle%3DThe%252B4th%252BSchizophrenia%252BInternational%252BResearch%252BSociety%252BConference%25252C%252B5%2525E2%252580%2525939%252BApril%252B2014%25252C%252BFlorence%25252C%252BItaly%25253A%252BA%252Bsummary%252Bof%252Btopics%252Band%252Btrends%26aulast%3DAbayomi%26aufirst%3DOlukayode%26date%3D2014%26volume%3D159%26issue%3D2-3%26spage%3De1%26epage%3De22" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-6/jm401958n/production/images/medium/jm-2013-01958n_0010.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-6/jm401958n/production/images/large/jm-2013-01958n_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401958n&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-6/jm401958n/production/images/medium/jm-2013-01958n_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-6/jm401958n/production/images/large/jm-2013-01958n_0002.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of representative antipsychotics and <b>5</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-6/jm401958n/production/images/large/jm-2013-01958n_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401958n&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-6/jm401958n/production/images/medium/jm-2013-01958n_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-6/jm401958n/production/images/large/jm-2013-01958n_0003.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-6/jm401958n/production/images/large/jm-2013-01958n_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401958n&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) NaNO<sub>2</sub>, HOAc, 0–5 °C, 60–80%; (b) Zn, HOAc, 10 °C; (c) ethyl 4-oxopiperidine-1-carboxylate, HOAc, HCl, 100 °C, 40–60% (two steps); (d) NaBH<sub>3</sub>CN, TFA, rt, 85–95%; (e) R<sub>2</sub>X, K<sub>2</sub>CO<sub>3</sub> or NaH, 80–95%; (f) borane, THF, reflux, then 6N HCl, reflux, 85–95%; (g) KOH, <sup><i>n</i></sup>BuOH, reflux, 90–99%; (h) 4-chloro-1-(4-fluorophenyl)butan-1-one, NEt<sub>3</sub>, dioxane, toluene, reflux, 50–70%; (i) chiral HPLC separation, 30–45%.</p></p></figure><figure data-id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-6/jm401958n/production/images/medium/jm-2013-01958n_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-6/jm401958n/production/images/large/jm-2013-01958n_0004.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-6/jm401958n/production/images/large/jm-2013-01958n_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401958n&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) 4-piperidone monohydrate hydrochloride, HCl, EtOH, reflux, 6 h, 76%; (b) TFA, Et<sub>3</sub>SiH, rt, 19 h, 83%; (c) ethyl chloroformate, NEt<sub>3</sub>, THF, rt, 1 h, 84%; (d) benzophenone imine, Pd<sub>2</sub>(dba)<sub>3</sub>, NaOBu<sup><i>t</i></sup>, BINAP, toluene, 105 °C, 93%; (e) ethyl bromoacetate, Na<sub>2</sub>CO<sub>3</sub>, KI, acetone, reflux, 16 h; (f) 2N HCl, THF, rt, 1.5 h, 73% (two steps); (g) MeI, K<sub>2</sub>CO<sub>3</sub>, acetone, 109 °C, 6 h, 99%; (h) BH<sub>3</sub>-THF, THF, reflux, 3 h, 99%; (i) KOH, <sup><i>n</i></sup>BuOH, 120 °C, 3 h, 99%; (j) R<sub>3</sub>X, NEt<sub>3</sub>, dioxane, toluene, reflux, 50–70%; (k) chiral HPLC separation, 30–45%.</p></p></figure><figure data-id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-6/jm401958n/production/images/medium/jm-2013-01958n_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-6/jm401958n/production/images/large/jm-2013-01958n_0005.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 3. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-6/jm401958n/production/images/large/jm-2013-01958n_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401958n&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) 4-piperidone hydrochloride monohydrate or azepan-4-one, HCl, EtOH, reflux, 50–80%; (b) TFA, NaBH<sub>3</sub>CN or Et<sub>3</sub>SiH, 80–95%; (c) Boc<sub>2</sub>O, aq NaOH, dioxane, rt, 80–90%; (d) chiral HPLC separation, 30–45%; (e) TFA, CH<sub>2</sub>Cl<sub>2</sub>, rt, 90–99%.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i49">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_38350" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_38350" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 40 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Wickelgren, I.</span><span> </span><span class="NLM_article-title">A new route to treating schizophrenia?</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">281</span><span class="NLM_x">, </span> <span class="NLM_fpage">1264</span><span class="NLM_x">–</span> <span class="NLM_lpage">1265</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=281&publication_year=1998&pages=1264-1265&author=I.+Wickelgren&title=A+new+route+to+treating+schizophrenia%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWickelgren%26aufirst%3DI.%26atitle%3DA%2520new%2520route%2520to%2520treating%2520schizophrenia%253F%26jtitle%3DScience%26date%3D1998%26volume%3D281%26spage%3D1264%26epage%3D1265" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Marino, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knutsen, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, M.</span><span> </span><span class="NLM_article-title">Emerging opportunities for antipsychotic drug discovery in the postgenomic era</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">1077</span><span class="NLM_x">–</span> <span class="NLM_lpage">1107</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm701094q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=1077-1107&author=M.+J.+Marinoauthor=L.+J.+Knutsenauthor=M.+Williams&title=Emerging+opportunities+for+antipsychotic+drug+discovery+in+the+postgenomic+era"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1021%2Fjm701094q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm701094q%26sid%3Dliteratum%253Aachs%26aulast%3DMarino%26aufirst%3DM.%2BJ.%26aulast%3DKnutsen%26aufirst%3DL.%2BJ.%26aulast%3DWilliams%26aufirst%3DM.%26atitle%3DEmerging%2520opportunities%2520for%2520antipsychotic%2520drug%2520discovery%2520in%2520the%2520postgenomic%2520era%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D1077%26epage%3D1107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Remington, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agid, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foussias, G.</span><span> </span><span class="NLM_article-title">Schizophrenia as a disorder of too little dopamine: implications for symptoms and treatment</span> <span class="citation_source-journal">Expert Rev. Neurother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">589</span><span class="NLM_x">–</span> <span class="NLM_lpage">607</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm401958n&amp;key=10.1586%2Fern.10.191" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm401958n&amp;key=21469931" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm401958n&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktlyqtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=589-607&author=G.+Remingtonauthor=O.+Agidauthor=G.+Foussias&title=Schizophrenia+as+a+disorder+of+too+little+dopamine%3A+implications+for+symptoms+and+treatment"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Schizophrenia as a disorder of too little dopamine: implications for symptoms and treatment</span></div><div class="casAuthors">Remington, Gary; Agid, Ofer; Foussias, George</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Neurotherapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">589-607</span>CODEN:
                <span class="NLM_cas:coden">ERNXAR</span>;
        ISSN:<span class="NLM_cas:issn">1473-7175</span>.
    
            (<span class="NLM_cas:orgname">Expert Reviews Ltd.</span>)
        </div><div class="casAbstract">A review.  Antipsychotics represent the first effective therapy for schizophrenia, with their benefits linked to dopamine D2 blockade.  Schizophrenia was soon identified as a hyperdopaminergic disorder, and antipsychotics proved to be reasonably effective in controlling pos. symptoms.  However, over the years, schizophrenia has been reconceptualized more broadly, now defined as a heterogeneous disorder with multiple symptom domains.  Neg. and cognitive features, not particularly responsive to antipsychotic therapy, have taken on increased importance -- current thinking suggests that these domains predate the onset of pos. symptoms and are more closely tied to functional outcome.  That they are better understood in the context of decreased dopamine activity suggests that schizophrenia may fundamentally represent a hypodopaminergic disorder.  This shift in thinking has important theor. implications from the standpoint of etiol. and pathophysiol., but also clin. in terms of treatment and drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKxDPNplr2yrVg90H21EOLACvtfcHk0libTJW2quZR4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktlyqtbo%253D&md5=65a8003827406d9e7ba57f1a60222940</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1586%2Fern.10.191&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252Fern.10.191%26sid%3Dliteratum%253Aachs%26aulast%3DRemington%26aufirst%3DG.%26aulast%3DAgid%26aufirst%3DO.%26aulast%3DFoussias%26aufirst%3DG.%26atitle%3DSchizophrenia%2520as%2520a%2520disorder%2520of%2520too%2520little%2520dopamine%253A%2520implications%2520for%2520symptoms%2520and%2520treatment%26jtitle%3DExpert%2520Rev.%2520Neurother.%26date%3D2011%26volume%3D11%26spage%3D589%26epage%3D607" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Kim, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maneen, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stahl, S. M.</span><span> </span><span class="NLM_article-title">Building a better antipsychotic: receptor targets for the treatment of multiple symptom dimensions of schizophrenia</span> <span class="citation_source-journal">Neurotherapeutics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">78</span><span class="NLM_x">–</span> <span class="NLM_lpage">85</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2009&pages=78-85&author=D.+H.+Kimauthor=M.+J.+Maneenauthor=S.+M.+Stahl&title=Building+a+better+antipsychotic%3A+receptor+targets+for+the+treatment+of+multiple+symptom+dimensions+of+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DD.%2BH.%26aulast%3DManeen%26aufirst%3DM.%2BJ.%26aulast%3DStahl%26aufirst%3DS.%2BM.%26atitle%3DBuilding%2520a%2520better%2520antipsychotic%253A%2520receptor%2520targets%2520for%2520the%2520treatment%2520of%2520multiple%2520symptom%2520dimensions%2520of%2520schizophrenia%26jtitle%3DNeurotherapeutics%26date%3D2009%26volume%3D6%26spage%3D78%26epage%3D85" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Muench, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamer, A. M.</span><span> </span><span class="NLM_article-title">Adverse effects of antipsychotic medications</span> <span class="citation_source-journal">Am. Fam. Physician</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">81</span><span class="NLM_x">, </span> <span class="NLM_fpage">617</span><span class="NLM_x">–</span> <span class="NLM_lpage">622</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm401958n&amp;key=20187598" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm401958n&amp;key=1%3ACAS%3A280%3ADC%252BC3c7ktlynsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2010&pages=617-622&author=J.+Muenchauthor=A.+M.+Hamer&title=Adverse+effects+of+antipsychotic+medications"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Adverse effects of antipsychotic medications</span></div><div class="casAuthors">Muench John; Hamer Ann M</div><div class="citationInfo"><span class="NLM_cas:title">American family physician</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">617-22</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The use of antipsychotic medications entails a difficult trade-off between the benefit of alleviating psychotic symptoms and the risk of troubling, sometimes life-shortening adverse effects.  There is more variability among specific antipsychotic medications than there is between the first- and second-generation antipsychotic classes.  The newer second-generation antipsychotics, especially clozapine and olanzapine, generally tend to cause more problems relating to metabolic syndrome, such as obesity and type 2 diabetes mellitus.  Also, as a class, the older first-generation antipsychotics are more likely to be associated with movement disorders, but this is primarily true of medications that bind tightly to dopaminergic neuroreceptors, such as haloperidol, and less true of medications that bind weakly, such as chlorpromazine.  Anticholinergic effects are especially prominent with weaker-binding first-generation antipsychotics, as well as with the second-generation antipsychotic clozapine.  All antipsychotic medications are associated with an increased likelihood of sedation, sexual dysfunction, postural hypotension, cardiac arrhythmia, and sudden cardiac death.  Primary care physicians should understand the individual adverse effect profiles of these medications.  They should be vigilant for the occurrence of adverse effects, be willing to adjust or change medications as needed (or work with psychiatric colleagues to do so), and be prepared to treat any resulting medical sequelae.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTKTaXFsO12OOIHSmpohpd0fW6udTcc2eaVS38PBTc9FLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3c7ktlynsQ%253D%253D&md5=2bac8b3c75c7610f7d59f5a34b296723</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMuench%26aufirst%3DJ.%26aulast%3DHamer%26aufirst%3DA.%2BM.%26atitle%3DAdverse%2520effects%2520of%2520antipsychotic%2520medications%26jtitle%3DAm.%2520Fam.%2520Physician%26date%3D2010%26volume%3D81%26spage%3D617%26epage%3D622" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Meltzer, H. Y.</span><span> </span><span class="NLM_article-title">Clozapine: balancing safety with superior antipsychotic efficacy</span> <span class="citation_source-journal">Clin. Schizophrenia Relat. Psychoses</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">134</span><span class="NLM_x">–</span> <span class="NLM_lpage">144</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Fjm401958n&amp;key=10.3371%2FCSRP.6.3.5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm401958n&amp;key=1%3ACAS%3A280%3ADC%252BC38bps1Ghsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2012&pages=134-144&author=H.+Y.+Meltzer&title=Clozapine%3A+balancing+safety+with+superior+antipsychotic+efficacy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Clozapine: balancing safety with superior antipsychotic efficacy</span></div><div class="casAuthors">Meltzer Herbert Y</div><div class="citationInfo"><span class="NLM_cas:title">Clinical schizophrenia & related psychoses</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">134-44</span>
        ISSN:<span class="NLM_cas:issn">1935-1232</span>.
    </div><div class="casAbstract">Clozapine is often referred to as the gold standard for the treatment of schizophrenia and yet has also been described as the most underutilized treatment for schizophrenia supported by solid evidence-based medicine.  In 2008, it was used to treat only 4.4% of patients with schizophrenia in the U.S., which is ~10-20% of those with approved indications for clozapine for which there is no alternative of equal efficacy.  Its use is much higher in Scandinavian countries and China.  The primary indications for clozapine are: 1) treatment-resistant schizophrenia or schizoaffective disorder, defined as persistent moderate to severe delusions or hallucinations despite two or more clinical trials with other antipsychotic drugs; and, 2) patients with schizophrenia or schizoaffective disorder who are at high risk for suicide.  Concerns over a number of safety considerations are responsible for much of the underutilization of clozapine: 1) agranulocytosis; 2) metabolic side effects; and, 3) myocarditis.  These side effects can be detected, prevented, minimized and treated, but there will be a very small number of fatalities.  Nevertheless, clozapine has been found in two large epidemiologic studies to have the lowest mortality of any antipsychotic drug, mainly due to its very large effect to reduce the risk for suicide.  Other reasons for limited use of clozapine include the extra effort entailed in monitoring white blood cell counts to detect granulocytopenia or agranulocytosis and, possibly, minimal efforts to market it now that it is largely generic.  Awareness of the benefits and risks of clozapine is essential for increasing the use of this lifesaving agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRaC8eLy6C7ZGmbXvSEQle5fW6udTcc2eaVS38PBTc9FLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38bps1Ghsw%253D%253D&md5=ea71630fe3a2fae86f0c2a18180e0cb5</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.3371%2FCSRP.6.3.5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3371%252FCSRP.6.3.5%26sid%3Dliteratum%253Aachs%26aulast%3DMeltzer%26aufirst%3DH.%2BY.%26atitle%3DClozapine%253A%2520balancing%2520safety%2520with%2520superior%2520antipsychotic%2520efficacy%26jtitle%3DClin.%2520Schizophrenia%2520Relat.%2520Psychoses%26date%3D2012%26volume%3D6%26spage%3D134%26epage%3D144" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Fakra, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azorin, J. M.</span><span> </span><span class="NLM_article-title">Clozapine for the treatment of schizophrenia</span> <span class="citation_source-journal">Expert Opin. Pharmacother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">1923</span><span class="NLM_x">–</span> <span class="NLM_lpage">1935</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm401958n&amp;key=10.1517%2F14656566.2012.709235" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm401958n&amp;key=22803789" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm401958n&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1WltbnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=1923-1935&author=E.+Fakraauthor=J.+M.+Azorin&title=Clozapine+for+the+treatment+of+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">for the treatment of schizophrenia</span></div><div class="casAuthors">Fakra, Eric; Azorin, Jean-Michel</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Pharmacotherapy</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1923-1935</span>CODEN:
                <span class="NLM_cas:coden">EOPHF7</span>;
        ISSN:<span class="NLM_cas:issn">1465-6566</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Despite considerable progress in the pharmacol. treatment of schizophrenia, about 30% of patients are minimally responsive to antipsychotics and there is still an excessively high rate of mortality in schizophrenia patients. , a D2-5HT2 antagonist, was the first antipsychotic to demonstrate efficacy in treatment-resistant patients, and to be assocd. with the lowest risk of death.Areas covered: The pharmacodynamics, pharmacokinetics, clin. efficacy, safety and cost-effectiveness of clozapine are covered in this article, based on a literature review (PubMed) from 1975 to 2012.  Pivotal, as well as supporting, randomized controlled trials are reviewed, along with observational and/or naturalistic safety studies.  This review of clozapine will allow the reader to det. the place for clozapine in the schizophrenia treatment landscape.  Expert opinion: Studies conducted so far suggest that clozapine is the treatment of choice for schizophrenic patients who are refractory to treatment, display violent behaviors, or who are at high risk of suicide.  However, it is also the antipsychotic with the worst side effect profile, the highest risk of complications, and the most difficult to prescribe.  Experience with clozapine should therefore be included in the education of future physicians.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-DXVoDDm74LVg90H21EOLACvtfcHk0ljhFUNWRmrc1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1WltbnM&md5=c1b548b4020dae15d89d48cec36b9cc8</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1517%2F14656566.2012.709235&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14656566.2012.709235%26sid%3Dliteratum%253Aachs%26aulast%3DFakra%26aufirst%3DE.%26aulast%3DAzorin%26aufirst%3DJ.%2BM.%26atitle%3DClozapine%2520for%2520the%2520treatment%2520of%2520schizophrenia%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2012%26volume%3D13%26spage%3D1923%26epage%3D1935" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Schmidt, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sorensen, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kehne, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carr, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palfreyman, M. G.</span><span> </span><span class="NLM_article-title">The role of 5-HT<sub>2A</sub> receptors in antipsychotic activity</span> <span class="citation_source-journal">Life Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">2209</span><span class="NLM_x">–</span> <span class="NLM_lpage">2222</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=1995&pages=2209-2222&author=C.+J.+Schmidtauthor=S.+M.+Sorensenauthor=J.+H.+Kehneauthor=A.+A.+Carrauthor=M.+G.+Palfreyman&title=The+role+of+5-HT2A+receptors+in+antipsychotic+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSchmidt%26aufirst%3DC.%2BJ.%26aulast%3DSorensen%26aufirst%3DS.%2BM.%26aulast%3DKehne%26aufirst%3DJ.%2BH.%26aulast%3DCarr%26aufirst%3DA.%2BA.%26aulast%3DPalfreyman%26aufirst%3DM.%2BG.%26atitle%3DThe%2520role%2520of%25205-HT2A%2520receptors%2520in%2520antipsychotic%2520activity%26jtitle%3DLife%2520Sci.%26date%3D1995%26volume%3D56%26spage%3D2209%26epage%3D2222" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Sorensen, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kehne, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fadayel, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Humphreys, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sullivan, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, V. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, C. J.</span><span> </span><span class="NLM_article-title">Characterization of the 5-HT2 receptor antagonist MDL 100907 as a putative atypical antipsychotic: behavioral, electrophysiological and neurochemical studies</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">266</span><span class="NLM_x">, </span> <span class="NLM_fpage">684</span><span class="NLM_x">–</span> <span class="NLM_lpage">691</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Fjm401958n&amp;key=8102646" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Fjm401958n&amp;key=1%3ACAS%3A528%3ADyaK2cXitlelug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=266&publication_year=1993&pages=684-691&author=S.+M.+Sorensenauthor=J.+H.+Kehneauthor=G.+M.+Fadayelauthor=T.+M.+Humphreysauthor=C.+K.+Sullivanauthor=V.+L.+Taylorauthor=C.+J.+Schmidt&title=Characterization+of+the+5-HT2+receptor+antagonist+MDL+100907+as+a+putative+atypical+antipsychotic%3A+behavioral%2C+electrophysiological+and+neurochemical+studies"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of the 5-HT2 receptor antagonist MDL 100907 as a putative atypical antipsychotic: Behavioral, electrophysiological and neurochemical studies</span></div><div class="casAuthors">Sorensen, Stephen M.; Kehne, John H.; Fadayel, Gina M.; Humphreys, Teresa M.; Ketteler, Herbert J.; Sullivan, Christine K.; Taylor, Vicki L.; Schmidt, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">266</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">684-91</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    </div><div class="casAbstract">Progress toward understanding the role of the 5-hydroxytryptamine (5-HT)2 receptor in the therapy for schizophrenia has been hampered by the lack of high selective antagonists.  The authors now report on the effects of MDL 100,907 [R(+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenylethyl)]-4-piperidinemethanol], a highly selective and potent 5-HT2 receptor antagonist, in behavioral, electrophysiol. and neurochem. models of antipsychotic activity and extrapyramidal side-effect liability.  In mice, MDL 100,907 blocked amphetamine-stimulated locomotion at doses that did not significantly affect apomorphine-stimulated climbing behavior.  Neither MDL 100,907 nor clozapine reduced apomorphine-induced stereotypies or produced catalepsy in rats.  MDL 100,907 blocked the slowing of ventral tegmental area (A10) dopaminergic neurons by amphetamine but, like clozapine, produced only small increases in the no. of active substantia nigra zona compacta (A9) and A10 dopamine neurons after acute administration.  When administered chronically, MDL 100,907 and clozapine selectively reduced the no. of spontaneously active A10 neurons, whereas haloperidol reduced activity in both the A9 and A10 regions.  Consistent with their acute effect on A9 and A10 activity, neither MDL 100,907 nor clozapine increased dopamine metab. in the striatum or nucleus accumbens, whereas acute haloperidol accelerated dopamine turnover in both regions.  The administration of the dopamine uptake blocker amfonelic acid with haloperidol produced a massive increase in DA metab. characteristic of typical antipsychotics.  In contrast, MDL 100,907 and clozapine were without effect on dopamine turnover when given in the presence of amfonelic acid.  These data indicate that MDL 100,907 has a clozapine-like profile of potential antipsychotic activity with low extrapyramidal side-effect liability.  The receptor selectivity of MDL 100,907 and the proposed regulation of dopaminergic function by 5-HT2 receptors support the conclusion that further clin. evaluation of selective 5-HT2 antagonists as antipsychotic agents is warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwBFqMWvGTiLVg90H21EOLACvtfcHk0lisZnPT38vd8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXitlelug%253D%253D&md5=5519667c5d7e79ee2132247738de91a7</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSorensen%26aufirst%3DS.%2BM.%26aulast%3DKehne%26aufirst%3DJ.%2BH.%26aulast%3DFadayel%26aufirst%3DG.%2BM.%26aulast%3DHumphreys%26aufirst%3DT.%2BM.%26aulast%3DSullivan%26aufirst%3DC.%2BK.%26aulast%3DTaylor%26aufirst%3DV.%2BL.%26aulast%3DSchmidt%26aufirst%3DC.%2BJ.%26atitle%3DCharacterization%2520of%2520the%25205-HT2%2520receptor%2520antagonist%2520MDL%2520100907%2520as%2520a%2520putative%2520atypical%2520antipsychotic%253A%2520behavioral%252C%2520electrophysiological%2520and%2520neurochemical%2520studies%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1993%26volume%3D266%26spage%3D684%26epage%3D691" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Kehne, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baron, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carr, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaney, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elands, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feldman, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frrank, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Giersbergen, P. L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mccloskey, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mccarty, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poirot, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Senyah, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siegel, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Widmaier, C.</span><span> </span><span class="NLM_article-title">Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100907 as a potent 5-HT<sub>2A</sub> antagonist with a favorable CNS safety profile</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">277</span><span class="NLM_x">, </span> <span class="NLM_fpage">968</span><span class="NLM_x">–</span> <span class="NLM_lpage">981</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Fjm401958n&amp;key=8627580" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm401958n&amp;key=1%3ACAS%3A528%3ADyaK28XivFeht7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=1996&pages=968-981&author=J.+H.+Kehneauthor=B.+M.+Baronauthor=A.+A.+Carrauthor=S.+F.+Chaneyauthor=J.+Elandsauthor=D.+J.+Feldmanauthor=R.+A.+Frrankauthor=P.+L.+M.+van+Giersbergenauthor=T.+C.+Mccloskeyauthor=M.+P.+Johnsonauthor=D.+R.+Mccartyauthor=M.+Poirotauthor=Y.+Senyahauthor=B.+W.+Siegelauthor=C.+Widmaier&title=Preclinical+characterization+of+the+potential+of+the+putative+atypical+antipsychotic+MDL+100907+as+a+potent+5-HT2A+antagonist+with+a+favorable+CNS+safety+profile"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100,907 as a potent 5-HT2A antagonist with a favorable CNS safety profile</span></div><div class="casAuthors">Kehne, John H.; Baron, Bruce M.; Carr, Albert A.; Chaney, Stephen F.; Elands, Jack; Feldman, Daniel J.; Frank, Robert A.; Van Giersbergen, Paul L. M.; McCloskey, Timothy C.; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">277</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">968-981</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">In preclin. studies, [R-(+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol] (MDL 100,907), a putative atypical antipsychotic, was characterized in vitro as a potent and selective ligand for the serotonin2A (5-HT2A) receptor and was evaluated in vitro and in vivo as a potent 5-HT2A receptor antagonist.  Furthermore, MDL 100,907's potential CNS safety profile and selectivity as a potential antipsychotic agent were evaluated and compared with benchmark compds.  MDL 100,907 demonstrated low nanomolar or subnanomolar binding in vitro at the 5-HT2A receptor and showed a > 100-fold sepn. from all other receptors measured.  MDL 100,907 has subnanomolar potency as a 5-HT2A antagonist in vitro in reversing 5-HT-stimulated inositol phosphate accumulation in NIH 3T3 cells transfected with the rat 5-HT2A receptor.  In vivo, MDL 100,907 potently inhibited 5-methoxy-N,N-dimethyltryptamine-induced head twitches in mice or 5-hydroxytrypophan-induced head twitched in rats.  In vivo functional tests in mice revealed a > 500-fold sepn. between doses that produced 5-HT2A antagonism and doses that produced α1-adrenergic or striatal D2 antagonism.  Using inhibition of D-amphetamine-stimulated locomotion in mice as a measure of potential antipsychotic efficacy, MDL 100,907 showed a superior CNS safety index relative to the ref. compds., haloperidol, clozapine, risperidone,ritanserin, and amperozide, in each of five tests for side effect potential, including measures of ataxia, general depressant effects, α1-adrenergic antagonism, striatal D2 receptor antagonism, and muscle relaxation.  MDL 100,907 did not antagonize apomorphine-induced stereotypies in rats, suggesting that it potentially lacks extrapyramidal side effect liability.  MDL 100,907 showed selectivity as a potential antipsychotic in that it lacked consistent activity in selected rodent models of anticonvulsant, anti-depressant, analgesic, or anxiolytic activity.  In summary, these preclin. data indicate that MDL 100,907 is a potent and selective ligand at the 5-HT2A receptor.  MDL 100,907's potent 5-HT2A antagonist activity might account for its activity in preclin. models of antipsychotic potential.  Ongoing clin. evaluation with MDL 100,907 will test the hypothesis that 5-HT2A receptor antagonism is sufficient for antipsychotic activity in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqravKtRD4ZLbVg90H21EOLACvtfcHk0lisZnPT38vd8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XivFeht7s%253D&md5=01a7031bf3ef86ac47fe60ac14493a64</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKehne%26aufirst%3DJ.%2BH.%26aulast%3DBaron%26aufirst%3DB.%2BM.%26aulast%3DCarr%26aufirst%3DA.%2BA.%26aulast%3DChaney%26aufirst%3DS.%2BF.%26aulast%3DElands%26aufirst%3DJ.%26aulast%3DFeldman%26aufirst%3DD.%2BJ.%26aulast%3DFrrank%26aufirst%3DR.%2BA.%26aulast%3Dvan%2BGiersbergen%26aufirst%3DP.%2BL.%2BM.%26aulast%3DMccloskey%26aufirst%3DT.%2BC.%26aulast%3DJohnson%26aufirst%3DM.%2BP.%26aulast%3DMccarty%26aufirst%3DD.%2BR.%26aulast%3DPoirot%26aufirst%3DM.%26aulast%3DSenyah%26aufirst%3DY.%26aulast%3DSiegel%26aufirst%3DB.%2BW.%26aulast%3DWidmaier%26aufirst%3DC.%26atitle%3DPreclinical%2520characterization%2520of%2520the%2520potential%2520of%2520the%2520putative%2520atypical%2520antipsychotic%2520MDL%2520100907%2520as%2520a%2520potent%25205-HT2A%2520antagonist%2520with%2520a%2520favorable%2520CNS%2520safety%2520profile%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1996%26volume%3D277%26spage%3D968%26epage%3D981" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">De Paulis, T.</span><span> </span><span class="NLM_article-title">M-100907 (Aventis)</span> <span class="citation_source-journal">Curr. Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">123</span><span class="NLM_x">–</span> <span class="NLM_lpage">132</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2001&pages=123-132&author=T.+De+Paulis&title=M-100907+%28Aventis%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BPaulis%26aufirst%3DT.%26atitle%3DM-100907%2520%2528Aventis%2529%26jtitle%3DCurr.%2520Opin.%2520Invest.%2520Drugs%26date%3D2001%26volume%3D2%26spage%3D123%26epage%3D132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Buckley, P. F.</span><span> </span><span class="NLM_article-title">Olanzapine: a critical review of recent literature</span> <span class="citation_source-journal">Expert Opin. Pharmacother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">2077</span><span class="NLM_x">–</span> <span class="NLM_lpage">2089</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Fjm401958n&amp;key=10.1517%2F14656566.6.12.2077" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Fjm401958n&amp;key=16197360" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Fjm401958n&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFCjsbjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2005&pages=2077-2089&author=P.+F.+Buckley&title=Olanzapine%3A+a+critical+review+of+recent+literature"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Olanzapine: a critical review of recent literature</span></div><div class="casAuthors">Buckley, Peter F.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Pharmacotherapy</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2077-2089</span>CODEN:
                <span class="NLM_cas:coden">EOPHF7</span>;
        ISSN:<span class="NLM_cas:issn">1465-6566</span>.
    
            (<span class="NLM_cas:orgname">Ashley Publications Ltd.</span>)
        </div><div class="casAbstract">The purpose of this review is to critically review the current literature on olanzapine with an emphasis on emergent themes and key findings in the use of this agent for the treatment of mood disorders and schizophrenia.  New information continues to emerge on the impact of olanzapine on schizo-phrenia and on aspects of the course of mood disorders.  There are also continued efforts to understand, predict and manage the side-effect risk with olanzapine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquFaBBxEa2sbVg90H21EOLACvtfcHk0lisZnPT38vd8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFCjsbjL&md5=7a8d254ff01b11854b8af9e93acb80a5</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1517%2F14656566.6.12.2077&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14656566.6.12.2077%26sid%3Dliteratum%253Aachs%26aulast%3DBuckley%26aufirst%3DP.%2BF.%26atitle%3DOlanzapine%253A%2520a%2520critical%2520review%2520of%2520recent%2520literature%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2005%26volume%3D6%26spage%3D2077%26epage%3D2089" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Worrel, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marken, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beckman, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruehter, V. L.</span><span> </span><span class="NLM_article-title">Atypical antipsychotic agents: a critical review</span> <span class="citation_source-journal">Am. J. Health Syst. Pharm.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">238</span><span class="NLM_x">–</span> <span class="NLM_lpage">255</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2000&pages=238-255&author=J.+A.+Worrelauthor=P.+A.+Markenauthor=S.+E.+Beckmanauthor=V.+L.+Ruehter&title=Atypical+antipsychotic+agents%3A+a+critical+review"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWorrel%26aufirst%3DJ.%2BA.%26aulast%3DMarken%26aufirst%3DP.%2BA.%26aulast%3DBeckman%26aufirst%3DS.%2BE.%26aulast%3DRuehter%26aufirst%3DV.%2BL.%26atitle%3DAtypical%2520antipsychotic%2520agents%253A%2520a%2520critical%2520review%26jtitle%3DAm.%2520J.%2520Health%2520Syst.%2520Pharm.%26date%3D2000%26volume%3D57%26spage%3D238%26epage%3D255" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Meltzer, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsubara, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. C.</span><span> </span><span class="NLM_article-title">The ratios of serotonin2 and dopamine2 affinities differentiate atypical antipsychotic drugs</span> <span class="citation_source-journal">Psychopharmacol. Bull.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">390</span><span class="NLM_x">–</span> <span class="NLM_lpage">392</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Fjm401958n&amp;key=2576319" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm401958n&amp;key=1%3ACAS%3A528%3ADyaK3cXhsFWmu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=1989&pages=390-392&author=H.+Y.+Meltzerauthor=S.+Matsubaraauthor=J.+C.+Lee&title=The+ratios+of+serotonin2+and+dopamine2+affinities+differentiate+atypical+antipsychotic+drugs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs</span></div><div class="casAuthors">Meltzer, Herbert Y.; Matsubara, Shigehiro; Lee, Jar Chi</div><div class="citationInfo"><span class="NLM_cas:title">Psychopharmacology Bulletin</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">390-2</span>CODEN:
                <span class="NLM_cas:coden">PSYBB9</span>;
        ISSN:<span class="NLM_cas:issn">0048-5764</span>.
    </div><div class="casAbstract">Atypical antipsychotic drugs such as clozapine, fluperlapine, and melperone produce weak catalepsy in rodents, and minimal extrapyramidal symptoms and serum prolactin elevations in humans, compared to typical antipsychotic drugs such as haloperidol.  The biol. basis for these differences has been attributed to relatively weak blockade at D2 dopamine (DA) receptors, various effects at D1 receptors, or potent serotonin2 (5-HT2) antagonism, although other possibilities exist.  To clarify the relative importance of actions of D1, D2, and 5-HT2 receptors for identification of candidate typical and atypical drugs, the authors detd. the neg. log of the Ki (pKi) value of 21 typical and 17 atypical antipsychotic drugs for the striatal D1 and D2 and frontal cortex 5-HT2 receptors of rodent brain.  Cluster anal. identified that the 5-HT2/D2 ratio was the most successful means of utilizing this data to classify typical and atypical antipsychotic drugs correctly.  A 92% accuracy was achieved.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGos0Xqr2TSGcLVg90H21EOLACvtfcHk0lhTO6_nhU9Cfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXhsFWmu7Y%253D&md5=3f5c199f61ada18f6210532b086b0e13</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMeltzer%26aufirst%3DH.%2BY.%26aulast%3DMatsubara%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DJ.%2BC.%26atitle%3DThe%2520ratios%2520of%2520serotonin2%2520and%2520dopamine2%2520affinities%2520differentiate%2520atypical%2520antipsychotic%2520drugs%26jtitle%3DPsychopharmacol.%2520Bull.%26date%3D1989%26volume%3D25%26spage%3D390%26epage%3D392" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Oakley, N. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayes, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheehan, M. J.</span><span> </span><span class="NLM_article-title">Effect of typical and atypical neuroleptics on the behavioural consequences of activation by muscimol of mesolimbic and nigro-striatal dopaminergic pathways in the rat</span> <span class="citation_source-journal">Psychopharmocology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">204</span><span class="NLM_x">–</span> <span class="NLM_lpage">208</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Fjm401958n&amp;key=10.1007%2FBF02244310" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Fjm401958n&amp;key=1686655" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=1991&pages=204-208&author=N.+R.+Oakleyauthor=A.+G.+Hayesauthor=M.+J.+Sheehan&title=Effect+of+typical+and+atypical+neuroleptics+on+the+behavioural+consequences+of+activation+by+muscimol+of+mesolimbic+and+nigro-striatal+dopaminergic+pathways+in+the+rat"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1007%2FBF02244310&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF02244310%26sid%3Dliteratum%253Aachs%26aulast%3DOakley%26aufirst%3DN.%2BR.%26aulast%3DHayes%26aufirst%3DA.%2BG.%26aulast%3DSheehan%26aufirst%3DM.%2BJ.%26atitle%3DEffect%2520of%2520typical%2520and%2520atypical%2520neuroleptics%2520on%2520the%2520behavioural%2520consequences%2520of%2520activation%2520by%2520muscimol%2520of%2520mesolimbic%2520and%2520nigro-striatal%2520dopaminergic%2520pathways%2520in%2520the%2520rat%26jtitle%3DPsychopharmocology%26date%3D1991%26volume%3D105%26spage%3D204%26epage%3D208" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Reynolds, G. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirk, S. L.</span><span> </span><span class="NLM_article-title">Metabolic side effects of antipsychotic drug treatment—pharmacological mechanisms</span> <span class="citation_source-journal">Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">125</span><span class="NLM_x">, </span> <span class="NLM_fpage">169</span><span class="NLM_x">–</span> <span class="NLM_lpage">179</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Fjm401958n&amp;key=10.1016%2Fj.pharmthera.2009.10.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Fjm401958n&amp;key=19931306" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Fjm401958n&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFyiu77E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2010&pages=169-179&author=G.+P.+Reynoldsauthor=S.+L.+Kirk&title=Metabolic+side+effects+of+antipsychotic+drug+treatment%E2%80%94pharmacological+mechanisms"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolic side effects of antipsychotic drug treatment - pharmacological mechanisms</span></div><div class="casAuthors">Reynolds, Gavin P.; Kirk, Shona L.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">169-179</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Obesity and metabolic syndrome, with increased risk of eventual cardiovascular disease and type II diabetes, are significant problems for patients receiving antipsychotic drugs and are likely contribute to their decreased life expectancy.  Several drug-related mechanisms may contribute to these problems, including effects both influencing food intake and on glucose and lipid metab.  The metabolic consequences of different antipsychotic drugs vary substantially; these variations reflect differences in receptor pharmacol. and provide clues as to the underlying pharmacol. mechanisms.  The two drugs with the greatest effects on body wt., olanzapine and clozapine, also have high affinity for the 5-HT2C and histamine H1 receptors, which implicate these receptors in antipsychotic-induced wt. gain, while peripheral M3 muscarinic receptor antagonism as well as central 5-HT2C effects may contribute to obesity-independent diabetes.  Other receptor mechanisms may have additive or synergistic effects; dopamine D2 receptor antagonism can enhance 5-HT2C-mediated effects on food intake, as well as influencing lipid and glucose metab. via disinhibition of prolactin secretion.  Pharmacogenetic assocns. of drug-induced wt. gain with 5-HT2C receptor and leptin gene polymorphisms, among others, have provided further clues.  Elevated leptin secretion in the absence of a decrease in food intake indicates drug-induced leptin insensitivity in the hypothalamus.  The minimal wt. gain seen with ziprasidone and aripiprazole may reflect their having further pharmacol. effects that protect against changes in food intake and related metabolic factors.  Understanding the pharmacol. of metabolic consequences of current antipsychotic drug treatment is clearly the key to developing improved pharmacotherapies that avoid these problematic and limiting adverse effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqt7JyuRcCdILVg90H21EOLACvtfcHk0lhTO6_nhU9Cfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFyiu77E&md5=548d49d2cca697e4405549be6ba0dd6f</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2009.10.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2009.10.010%26sid%3Dliteratum%253Aachs%26aulast%3DReynolds%26aufirst%3DG.%2BP.%26aulast%3DKirk%26aufirst%3DS.%2BL.%26atitle%3DMetabolic%2520side%2520effects%2520of%2520antipsychotic%2520drug%2520treatment%25E2%2580%2594pharmacological%2520mechanisms%26jtitle%3DPharmacol.%2520Ther.%26date%3D2010%26volume%3D125%26spage%3D169%26epage%3D179" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Deng, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weston-Green, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, X. F.</span><span> </span><span class="NLM_article-title">The role of histaminergic H1 and H3 receptors in food intake: a mechanism for atypical antipsychotic-induced weight gain?</span> <span class="citation_source-journal">Prog. Neuro-Psychopharmacol. Biol. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">4</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Fjm401958n&amp;key=10.1016%2Fj.pnpbp.2009.11.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Fjm401958n&amp;key=19922755" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm401958n&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjsl2kuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2010&pages=1-4&author=C.+Dengauthor=K.+Weston-Greenauthor=X.+F.+Huang&title=The+role+of+histaminergic+H1+and+H3+receptors+in+food+intake%3A+a+mechanism+for+atypical+antipsychotic-induced+weight+gain%3F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">The role of histaminergic H1 and H3 receptors in food intake: A mechanism for atypical antipsychotic-induced weight gain?</span></div><div class="casAuthors">Deng, Chao; Weston-Green, Katrina; Huang, Xu-Feng</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Neuro-Psychopharmacology & Biological Psychiatry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-4</span>CODEN:
                <span class="NLM_cas:coden">PNPPD7</span>;
        ISSN:<span class="NLM_cas:issn">0278-5846</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Atypical antipsychotics such as olanzapine and clozapine are effective at treating the multiple domains of schizophrenia, with a low risk of extra-pyramidal side-effects.  However a major downfall to their use is metabolic side-effects particularly wt. gain/obesity, which occurs by unknown mechanisms.  The present paper explores the potential candidature of histaminergic neurotransmission in the mechanisms of atypical antipsychotic-induced wt. gain, with a focus on the histaminergic H1 and H3 receptors.  Olanzapine and clozapine have a high affinity for the H1 receptor, and meta-analyses show a strong correlation between risk of wt. gain and H1 receptor affinity.  In addn., olanzapine treatment decreases H1 receptor binding and mRNA expression in the rat hypothalamus.  Furthermore, a complex role is emerging for the histamine H3 receptor in the control of hunger.  The H3 receptor is a pre-synaptic autoreceptor that inhibits the synthesis and release of histamine, and a heteroreceptor that inhibits other neurotransmitters such as serotonin (5-HT), noradrenaline (NA) and acetylcholine (ACh), which are also implicated in the regulation of food intake.  Thus, the H3 receptor is in a prime position to regulate food intake, both through its control of histamine and its influence on other feeding pathways.  We proposed that a mechanism for atypical antipsychotic-induced wt. gain may be partly through the H3 receptor, as a drug-induced decrease in H1 receptor activity may decrease histamine tone through the H3 autoreceptors, compounding the wt. gain problem.  In addn., atypical antipsychotics may affect food intake by influencing 5-HT, NA and ACh release via interactions with the H3 heteroreceptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRPtyjEiBxobVg90H21EOLACvtfcHk0liUECC8UqLsYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjsl2kuw%253D%253D&md5=8ee52c313f7e12534d2cf4016f06b6b4</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.pnpbp.2009.11.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pnpbp.2009.11.009%26sid%3Dliteratum%253Aachs%26aulast%3DDeng%26aufirst%3DC.%26aulast%3DWeston-Green%26aufirst%3DK.%26aulast%3DHuang%26aufirst%3DX.%2BF.%26atitle%3DThe%2520role%2520of%2520histaminergic%2520H1%2520and%2520H3%2520receptors%2520in%2520food%2520intake%253A%2520a%2520mechanism%2520for%2520atypical%2520antipsychotic-induced%2520weight%2520gain%253F%26jtitle%3DProg.%2520Neuro-Psychopharmacol.%2520Biol.%2520Psychiatry%26date%3D2010%26volume%3D34%26spage%3D1%26epage%3D4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Kirk, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glazebrook, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grayson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neill, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reynolds, G. P.</span><span> </span><span class="NLM_article-title">Olanzapine-induced weight gain in the rat: role of 5-HT<sub>2C</sub> and histamine H<sub>1</sub> receptors</span> <span class="citation_source-journal">Psychopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">207</span><span class="NLM_x">, </span> <span class="NLM_fpage">119</span><span class="NLM_x">–</span> <span class="NLM_lpage">125</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=207&publication_year=2009&pages=119-125&author=S.+L.+Kirkauthor=J.+Glazebrookauthor=B.+Graysonauthor=J.+C.+Neillauthor=G.+P.+Reynolds&title=Olanzapine-induced+weight+gain+in+the+rat%3A+role+of+5-HT2C+and+histamine+H1+receptors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKirk%26aufirst%3DS.%2BL.%26aulast%3DGlazebrook%26aufirst%3DJ.%26aulast%3DGrayson%26aufirst%3DB.%26aulast%3DNeill%26aufirst%3DJ.%2BC.%26aulast%3DReynolds%26aufirst%3DG.%2BP.%26atitle%3DOlanzapine-induced%2520weight%2520gain%2520in%2520the%2520rat%253A%2520role%2520of%25205-HT2C%2520and%2520histamine%2520H1%2520receptors%26jtitle%3DPsychopharmacology%26date%3D2009%26volume%3D207%26spage%3D119%26epage%3D125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Rajagopalan, P.</span><span> </span><span class="NLM_article-title">Pyridopyrrolobenzoxazine</span>. (Endo Laboratories, Inc.). U.S. Patent 4,013,652, <span class="NLM_month">March</span><span class="NLM_day">22</span>,<span class="NLM_x"> </span><span class="NLM_year">1977</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1977&author=P.+Rajagopalan&title=Pyridopyrrolobenzoxazine"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DRajagopalan%26aufirst%3DP.%26atitle%3DPyridopyrrolobenzoxazine%26date%3D1977" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Rajagopalan, P.</span><span> </span><span class="NLM_article-title"> Pyridopyrrolobenzheterocycles for combating depression</span>. (Endo Laboratories, Inc.). U.S. Patent 3,914,421, <span class="NLM_month">October</span><span class="NLM_day">21</span>,<span class="NLM_x"> </span><span class="NLM_year">1975</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1975&author=P.+Rajagopalan&title=+Pyridopyrrolobenzheterocycles+for+combating+depression"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DRajagopalan%26aufirst%3DP.%26atitle%3D%2520Pyridopyrrolobenzheterocycles%2520for%2520combating%2520depression%26date%3D1975" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Rajagopalan, P.</span><span> </span><span class="NLM_article-title"><i>cis</i>- and <i>trans</i>-Octahydropyridopyrrolobenzheterocycles</span>. (E. I. Du Pont De Nemours and Co.). U.S. Patent 4,219,550, <span class="NLM_month">August</span><span class="NLM_day">26</span>,<span class="NLM_x"> </span><span class="NLM_year">1980</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1980&author=P.+Rajagopalan&title=cis-+and+trans-Octahydropyridopyrrolobenzheterocycles"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DRajagopalan%26aufirst%3DP.%26atitle%3Dcis-%2520and%2520trans-Octahydropyridopyrrolobenzheterocycles%26date%3D1980" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Lee, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robichaud, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boyle, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robertson, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fitzgerald, L. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McElroy, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Largent, B. L.</span><span> </span><span class="NLM_article-title">Novel, highly potent, selective 5-HT<sub>2A</sub>/D<sub>2</sub> receptor antagonists as potential atypical antipsychotics</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">767</span><span class="NLM_x">–</span> <span class="NLM_lpage">770</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2003&pages=767-770&author=T.+Leeauthor=A.+J.+Robichaudauthor=K.+E.+Boyleauthor=Y.+Luauthor=D.+W.+Robertsonauthor=K.+J.+Millerauthor=L.+W.+Fitzgeraldauthor=J.+F.+McElroyauthor=B.+L.+Largent&title=Novel%2C+highly+potent%2C+selective+5-HT2A%2FD2+receptor+antagonists+as+potential+atypical+antipsychotics"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DT.%26aulast%3DRobichaud%26aufirst%3DA.%2BJ.%26aulast%3DBoyle%26aufirst%3DK.%2BE.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DRobertson%26aufirst%3DD.%2BW.%26aulast%3DMiller%26aufirst%3DK.%2BJ.%26aulast%3DFitzgerald%26aufirst%3DL.%2BW.%26aulast%3DMcElroy%26aufirst%3DJ.%2BF.%26aulast%3DLargent%26aufirst%3DB.%2BL.%26atitle%3DNovel%252C%2520highly%2520potent%252C%2520selective%25205-HT2A%252FD2%2520receptor%2520antagonists%2520as%2520potential%2520atypical%2520antipsychotics%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2003%26volume%3D13%26spage%3D767%26epage%3D770" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Wolfe, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sadighi, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singer, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchwald, S. L.</span><span> </span><span class="NLM_article-title">An ammonia equivalent for the palladium-catalyzed amination of aryl halides and triflates</span> <span class="citation_source-journal">Tetrahedron. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">6367</span><span class="NLM_x">–</span> <span class="NLM_lpage">6370</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Fjm401958n&amp;key=10.1016%2FS0040-4039%2897%2901465-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Fjm401958n&amp;key=1%3ACAS%3A528%3ADyaK2sXlvFGns7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=1997&pages=6367-6370&author=J.+P.+Wolfeauthor=J.+Ahmanauthor=J.+P.+Sadighiauthor=R.+A.+Singerauthor=S.+L.+Buchwald&title=An+ammonia+equivalent+for+the+palladium-catalyzed+amination+of+aryl+halides+and+triflates"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">An ammonia equivalent for the palladium-catalyzed amination of aryl halides and triflates</span></div><div class="casAuthors">Wolfe, John P.; Ahman, Jens; Sadighi, Joseph P.; Singer, Robert A.; Buchwald, Stephen L.</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron Letters</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">6367-6370</span>CODEN:
                <span class="NLM_cas:coden">TELEAY</span>;
        ISSN:<span class="NLM_cas:issn">0040-4039</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Com. available benzophenone imine serves as a convenient NH3 equiv. in the Pd-catalyzed amination of aryl halides and triflates.  The benzophenone imine adducts can be cleaved directly to the corresponding primary anilines by catalytic hydrogenation or treatment with hydroxylamine hydrochloride or a catalytic amt. of HCl in wet THF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXMgy_yfX_ubVg90H21EOLACvtfcHk0liUECC8UqLsYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXlvFGns7k%253D&md5=a460a4291911fcf3da1c7f6f61a1c38b</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2FS0040-4039%2897%2901465-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0040-4039%252897%252901465-2%26sid%3Dliteratum%253Aachs%26aulast%3DWolfe%26aufirst%3DJ.%2BP.%26aulast%3DAhman%26aufirst%3DJ.%26aulast%3DSadighi%26aufirst%3DJ.%2BP.%26aulast%3DSinger%26aufirst%3DR.%2BA.%26aulast%3DBuchwald%26aufirst%3DS.%2BL.%26atitle%3DAn%2520ammonia%2520equivalent%2520for%2520the%2520palladium-catalyzed%2520amination%2520of%2520aryl%2520halides%2520and%2520triflates%26jtitle%3DTetrahedron.%2520Lett.%26date%3D1997%26volume%3D38%26spage%3D6367%26epage%3D6370" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Welch, W. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harbert, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weissman, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koe, B. K.</span><span> </span><span class="NLM_article-title">Neuroleptics from the 4a, 9b-<i>cis</i>- and 4a, 9b-<i>trans</i>-2,3,4,4a,5,9b-hexahydro-1<i>H</i>-pyrido[4,3-<i>b</i>]indole series. 2</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1986</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">2093</span><span class="NLM_x">–</span> <span class="NLM_lpage">2099</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm00160a050" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=1986&pages=2093-2099&author=W.+M.+Welchauthor=C.+A.+Harbertauthor=A.+Weissmanauthor=B.+K.+Koe&title=Neuroleptics+from+the+4a%2C+9b-cis-+and+4a%2C+9b-trans-2%2C3%2C4%2C4a%2C5%2C9b-hexahydro-1H-pyrido%5B4%2C3-b%5Dindole+series.+2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fjm00160a050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00160a050%26sid%3Dliteratum%253Aachs%26aulast%3DWelch%26aufirst%3DW.%2BM.%26aulast%3DHarbert%26aufirst%3DC.%2BA.%26aulast%3DWeissman%26aufirst%3DA.%26aulast%3DKoe%26aufirst%3DB.%2BK.%26atitle%3DNeuroleptics%2520from%2520the%25204a%252C%25209b-cis-%2520and%25204a%252C%25209b-trans-2%252C3%252C4%252C4a%252C5%252C9b-hexahydro-1H-pyrido%255B4%252C3-b%255Dindole%2520series.%25202%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1986%26volume%3D29%26spage%3D2093%26epage%3D2099" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Fitzgerald, L. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conklin, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krause, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patterson, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iyer, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kostich, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Largent, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartig, P. R.</span><span> </span><span class="NLM_article-title">High-affinity agonist binding correlates with efficacy (intrinsic activity) at the human serotonin 5-HT<sub>2A</sub> and 5-HT<sub>2C</sub> receptors: evidence favoring the ternary complex and two-state models of agonist action</span> <span class="citation_source-journal">J. Neurochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">2127</span><span class="NLM_x">–</span> <span class="NLM_lpage">2134</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Fjm401958n&amp;key=10.1046%2Fj.1471-4159.1999.0722127.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Fjm401958n&amp;key=10217294" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Fjm401958n&amp;key=1%3ACAS%3A528%3ADyaK1MXis12ltLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=1999&pages=2127-2134&author=L.+W.+Fitzgeraldauthor=D.+S.+Conklinauthor=C.+M.+Krauseauthor=A.+P.+Marshallauthor=J.+P.+Pattersonauthor=D.+P.+Tranauthor=G.+Iyerauthor=W.+A.+Kostichauthor=B.+L.+Largentauthor=P.+R.+Hartig&title=High-affinity+agonist+binding+correlates+with+efficacy+%28intrinsic+activity%29+at+the+human+serotonin+5-HT2A+and+5-HT2C+receptors%3A+evidence+favoring+the+ternary+complex+and+two-state+models+of+agonist+action"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">High-affinity agonist binding correlates with efficacy (intrinsic activity) at the human serotonin 5-HT2A and 5-HT2C receptors: evidence favoring the ternary complex and two-state models of agonist action</span></div><div class="casAuthors">Fitzgerald, Lawrence W.; Conklin, Deborah S.; Krause, Carol M.; Marshall, Anne P.; Patterson, John P.; Tran, David P.; Iyer, Geeta; Kostich, Walter A.; Largent, Brian L.; Hartig, Paul R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2127-2134</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Many modern models of receptor-G protein function assume that there is a direct relationship between high-affinity agonist binding and efficacy.  The validity of this assumption has been recently questioned for the serotonin 5-HT2A receptor.  The authors examd. the intrinsic activities of various ligands in activating phosphoinositide hydrolysis and measured their resp. binding affinities to the high- and low-affinity states of the 5-HT2C (VNV isoform) and 5-HT2A receptors.  Ligand binding affinities for the high-affinity state of the receptors were detd. using 1-(4-[125I]iodo-2,5-dimethoxyphenyl)-2-aminopropane, whereas [3H]mesulergine and N-[3H]-methylspiperone were used, in the presence of excess guanine nucleotide [guanosine 5'-O-(3-thiotriphosphate)], to define binding to the low-affinity state of the 5-HT2C and 5-HT2A receptors, resp.  Antagonists labeled the high- and low-affinity states of each receptor with comparable affinities.  Previously identified inverse agonists of the 5-HT2C receptor behaved as silent antagonists in the authors' systems even when the receptor was over-expressed at a relatively high d.  In contrast, the ability of agonists to bind differentially to the high- and low-affinity states of the 5-HT2A and 5-HT2C receptors was highly correlated (R2 = 0.86 and 0.96, resp.) with their intrinsic activities.  These data suggest that high-affinity agonist states can account for agonist efficacy at human 5-HT2A or 5-HT2C receptors without the need for considering addnl. transition or active states of the receptor-ligand complex.  The procedure described herein may expedite drug discovery efforts by predicting intrinsic activities of ligands solely from ligand binding assays.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozA61mRFBtzbVg90H21EOLACvtfcHk0ljqJ7mKDFtYyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXis12ltLg%253D&md5=76a7600ee51a0dff38298d091640ffd7</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1046%2Fj.1471-4159.1999.0722127.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1471-4159.1999.0722127.x%26sid%3Dliteratum%253Aachs%26aulast%3DFitzgerald%26aufirst%3DL.%2BW.%26aulast%3DConklin%26aufirst%3DD.%2BS.%26aulast%3DKrause%26aufirst%3DC.%2BM.%26aulast%3DMarshall%26aufirst%3DA.%2BP.%26aulast%3DPatterson%26aufirst%3DJ.%2BP.%26aulast%3DTran%26aufirst%3DD.%2BP.%26aulast%3DIyer%26aufirst%3DG.%26aulast%3DKostich%26aufirst%3DW.%2BA.%26aulast%3DLargent%26aufirst%3DB.%2BL.%26aulast%3DHartig%26aufirst%3DP.%2BR.%26atitle%3DHigh-affinity%2520agonist%2520binding%2520correlates%2520with%2520efficacy%2520%2528intrinsic%2520activity%2529%2520at%2520the%2520human%2520serotonin%25205-HT2A%2520and%25205-HT2C%2520receptors%253A%2520evidence%2520favoring%2520the%2520ternary%2520complex%2520and%2520two-state%2520models%2520of%2520agonist%2520action%26jtitle%3DJ.%2520Neurochem.%26date%3D1999%26volume%3D72%26spage%3D2127%26epage%3D2134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Nelson, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucaites, V. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wainscott, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glennon, R. A.</span><span> </span><span class="NLM_article-title">Comparisons of hallucinogenic phenylisopropylamine binding affinities at cloned human 5-HT<sub>2A</sub>, 5-HT<sub>2B</sub> and 5-HT<sub>2C</sub> receptors</span> <span class="citation_source-journal">Naunyn-Schmiedeberg’s Arch. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">359</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">6</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Fjm401958n&amp;key=10.1007%2FPL00005315" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Fjm401958n&amp;key=9933142" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Fjm401958n&amp;key=1%3ACAS%3A528%3ADyaK1cXnvFalu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=359&publication_year=1999&pages=1-6&author=D.+L.+Nelsonauthor=V.+L.+Lucaitesauthor=D.+B.+Wainscottauthor=R.+A.+Glennon&title=Comparisons+of+hallucinogenic+phenylisopropylamine+binding+affinities+at+cloned+human+5-HT2A%2C+5-HT2B+and+5-HT2C+receptors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Comparisons of hallucinogenic phenylisopropylamine binding affinities at cloned human 5-HT2A, 5-HT2B and 5-HT2C receptors</span></div><div class="casAuthors">Nelson, D. L.; Lucaites, V. L.; Wainscott, D. B.; Glennon, R. A.</div><div class="citationInfo"><span class="NLM_cas:title">Naunyn-Schmiedeberg's Archives of Pharmacology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">359</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-6</span>CODEN:
                <span class="NLM_cas:coden">NSAPCC</span>;
        ISSN:<span class="NLM_cas:issn">0028-1298</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag</span>)
        </div><div class="casAbstract">Since the classical hallucinogens were initially reported to produce their behavioral effects via a 5-HT2 agonist mechanism (i.e., the 5-HT2 hypothesis of hallucinogen action), 5-HT2 receptors have been demonstrated to represent a family of receptors that consists of three distinct subpopulations: 5-HT2A, 5-HT2B, and 5-HT2C receptors.  Today, there is greater support for 5-HT2A than for 5-HT2C receptor involvement in the behavioral effects evoked by these agents.  However, with the recent discovery of 5-HT2B receptors, a new question arises: do classical hallucinogens bind at 5-HT2B receptors.  In the present study, the authors examd. and compared the binding of 17 phenylisopropylamines at human 5-HT2A, 5-HT2B, and 5-HT2C receptors.  Although there was a notable pos. correlation (r>0.9) between the affinities of the agents at all three populations of 5-HT2 receptors, structural modification resulted only in small differences in 5-HT2B receptor affinity such that the range of affinities was only about 50-fold.  As with 5-HT2A and 5-HT2C receptor affinity, there is a significant correlation (r>0.9) between 5-HT2B receptor affinity and human hallucinogenic potency.  Nevertheless, given that 5-HT2A and 5-HT2A/2C antagonists - antagonists with low affinity for 5-HT2B receptors - have been previously shown to block the stimulus effects of phenylisopropylamine hallucinogens, it is likely that 5-HT2A receptors play a more prominent role than 5-HT2B and 5-HT2C receptors in mediating such effects despite the affinity of these agents for all three 5-HT2 receptor subpopulations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvcUJ72-JQ2LVg90H21EOLACvtfcHk0ljqJ7mKDFtYyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXnvFalu7k%253D&md5=0aa21959353f624601097271883a49de</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1007%2FPL00005315&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FPL00005315%26sid%3Dliteratum%253Aachs%26aulast%3DNelson%26aufirst%3DD.%2BL.%26aulast%3DLucaites%26aufirst%3DV.%2BL.%26aulast%3DWainscott%26aufirst%3DD.%2BB.%26aulast%3DGlennon%26aufirst%3DR.%2BA.%26atitle%3DComparisons%2520of%2520hallucinogenic%2520phenylisopropylamine%2520binding%2520affinities%2520at%2520cloned%2520human%25205-HT2A%252C%25205-HT2B%2520and%25205-HT2C%2520receptors%26jtitle%3DNaunyn-Schmiedeberg%25E2%2580%2599s%2520Arch.%2520Pharmacol.%26date%3D1999%26volume%3D359%26spage%3D1%26epage%3D6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Seo, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jung, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Son, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, W. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J.</span><span> </span><span class="NLM_article-title">Design and synthesis of novel arylpiperazine derivatives containing the imidazole core targeting 5-HT<sub>2A</sub> receptor and 5-HT transporter</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">6305</span><span class="NLM_x">–</span> <span class="NLM_lpage">6318</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm200682b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=6305-6318&author=H.+J.+Seoauthor=E.+J.+Parkauthor=M.+J.+Kimauthor=S.+Y.+Kangauthor=S.+H.+Leeauthor=H.+J.+Kimauthor=K.+N.+Leeauthor=M.+E.+Jungauthor=M.+Leeauthor=M.+S.+Kimauthor=E.+J.+Sonauthor=W.+K.+Parkauthor=J.+Kimauthor=J.+Lee&title=Design+and+synthesis+of+novel+arylpiperazine+derivatives+containing+the+imidazole+core+targeting+5-HT2A+receptor+and+5-HT+transporter"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fjm200682b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200682b%26sid%3Dliteratum%253Aachs%26aulast%3DSeo%26aufirst%3DH.%2BJ.%26aulast%3DPark%26aufirst%3DE.%2BJ.%26aulast%3DKim%26aufirst%3DM.%2BJ.%26aulast%3DKang%26aufirst%3DS.%2BY.%26aulast%3DLee%26aufirst%3DS.%2BH.%26aulast%3DKim%26aufirst%3DH.%2BJ.%26aulast%3DLee%26aufirst%3DK.%2BN.%26aulast%3DJung%26aufirst%3DM.%2BE.%26aulast%3DLee%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DM.%2BS.%26aulast%3DSon%26aufirst%3DE.%2BJ.%26aulast%3DPark%26aufirst%3DW.%2BK.%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DJ.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520novel%2520arylpiperazine%2520derivatives%2520containing%2520the%2520imidazole%2520core%2520targeting%25205-HT2A%2520receptor%2520and%25205-HT%2520transporter%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D6305%26epage%3D6318" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Ablordeppey, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Altundas, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bricker, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, X. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eyunni, S. E. V. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rothb, B. L.</span><span> </span><span class="NLM_article-title">Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">7291</span><span class="NLM_x">–</span> <span class="NLM_lpage">7301</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2008&pages=7291-7301&author=S.+Y.+Ablordeppeyauthor=R.+Altundasauthor=B.+Brickerauthor=X.+Y.+Zhuauthor=S.+E.+V.+K.+Eyunniauthor=T.+Jacksonauthor=A.+Khanauthor=B.+L.+Rothb&title=Identification+of+a+butyrophenone+analog+as+a+potential+atypical+antipsychotic+agent%3A+4-%5B4-%284-chlorophenyl%29-1%2C4-diazepan-1-yl%5D-1-%284-fluorophenyl%29butan-1-one"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAblordeppey%26aufirst%3DS.%2BY.%26aulast%3DAltundas%26aufirst%3DR.%26aulast%3DBricker%26aufirst%3DB.%26aulast%3DZhu%26aufirst%3DX.%2BY.%26aulast%3DEyunni%26aufirst%3DS.%2BE.%2BV.%2BK.%26aulast%3DJackson%26aufirst%3DT.%26aulast%3DKhan%26aufirst%3DA.%26aulast%3DRothb%26aufirst%3DB.%2BL.%26atitle%3DIdentification%2520of%2520a%2520butyrophenone%2520analog%2520as%2520a%2520potential%2520atypical%2520antipsychotic%2520agent%253A%25204-%255B4-%25284-chlorophenyl%2529-1%252C4-diazepan-1-yl%255D-1-%25284-fluorophenyl%2529butan-1-one%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2008%26volume%3D16%26spage%3D7291%26epage%3D7301" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Kroeze, W. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hufeisen, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Popadak, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Renock, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinberg, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ernsberger, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayathilake, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meltzer, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B. L.</span><span> </span><span class="NLM_article-title">H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs</span> <span class="citation_source-journal">Neuropsychopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">519</span><span class="NLM_x">–</span> <span class="NLM_lpage">526</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2003&pages=519-526&author=W.+K.+Kroezeauthor=S.+J.+Hufeisenauthor=B.+A.+Popadakauthor=S.+M.+Renockauthor=S.+Steinbergauthor=P.+Ernsbergerauthor=K.+Jayathilakeauthor=H.+Y.+Meltzerauthor=B.+L.+Roth&title=H1-histamine+receptor+affinity+predicts+short-term+weight+gain+for+typical+and+atypical+antipsychotic+drugs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKroeze%26aufirst%3DW.%2BK.%26aulast%3DHufeisen%26aufirst%3DS.%2BJ.%26aulast%3DPopadak%26aufirst%3DB.%2BA.%26aulast%3DRenock%26aufirst%3DS.%2BM.%26aulast%3DSteinberg%26aufirst%3DS.%26aulast%3DErnsberger%26aufirst%3DP.%26aulast%3DJayathilake%26aufirst%3DK.%26aulast%3DMeltzer%26aufirst%3DH.%2BY.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26atitle%3DH1-histamine%2520receptor%2520affinity%2520predicts%2520short-term%2520weight%2520gain%2520for%2520typical%2520and%2520atypical%2520antipsychotic%2520drugs%26jtitle%3DNeuropsychopharmacology%26date%3D2003%26volume%3D28%26spage%3D519%26epage%3D526" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Cahir, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">King, D. J.</span><span> </span><span class="NLM_article-title">Antipsychotics lack <i>α</i><sub>1A/B</sub> adrenoceptor subtype selectivity in the rat</span> <span class="citation_source-journal">Eur. Neuropsychopharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">231</span><span class="NLM_x">–</span> <span class="NLM_lpage">234</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Fjm401958n&amp;key=10.1016%2Fj.euroneuro.2004.10.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Fjm401958n&amp;key=15695070" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Fjm401958n&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVOqtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2005&pages=231-234&author=M.+Cahirauthor=D.+J.+King&title=Antipsychotics+lack+%CE%B11A%2FB+adrenoceptor+subtype+selectivity+in+the+rat"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Antipsychotics lack α1A/B adrenoceptor subtype selectivity in the rat</span></div><div class="casAuthors">Cahir, Marie; King, David J.</div><div class="citationInfo"><span class="NLM_cas:title">European Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">231-234</span>CODEN:
                <span class="NLM_cas:coden">EURNE8</span>;
        ISSN:<span class="NLM_cas:issn">0924-977X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The α1A- and α1B-adrenoceptor affinity of the typical (chlorpromazine, haloperidol, pimozide, thioridazine and trifluoperazine) and atypical (clozapine, olanzapine, quetiapine, risperidone and sertindole) antipsychotics was detd. by competition binding at α1A- and α1B-adrenoceptors in rat submaxillary gland and liver.  Although all antipsychotics bound to both subtypes with relatively high affinity (Kis<74 nM), none were selective (>10-fold).  Comparison with published dopamine D2 receptor affinities suggests that antipsychotic blockade of α1A- and/or α1B-adrenoceptors may contribute to the antipsychotic activity of all the atypical and several of the typical antipsychotics examd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodcoj8da0IV7Vg90H21EOLACvtfcHk0li4sSvax9i8jA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVOqtLs%253D&md5=3c07837debd93eca7c671ae4d732e08d</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.euroneuro.2004.10.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.euroneuro.2004.10.002%26sid%3Dliteratum%253Aachs%26aulast%3DCahir%26aufirst%3DM.%26aulast%3DKing%26aufirst%3DD.%2BJ.%26atitle%3DAntipsychotics%2520lack%2520%25CE%25B11A%252FB%2520adrenoceptor%2520subtype%2520selectivity%2520in%2520the%2520rat%26jtitle%3DEur.%2520Neuropsychopharmacol.%26date%3D2005%26volume%3D15%26spage%3D231%26epage%3D234" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Nourian, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mow, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muftic, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burek, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pedersen, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matz, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mulvany, M. J.</span><span> </span><span class="NLM_article-title">Orthostatic hypotensive effect of antipsychotic drugs in Wistar rats by in vivo and in vitro studies of alpha1-adrenoceptor function</span> <span class="citation_source-journal">Psychopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">199</span><span class="NLM_x">, </span> <span class="NLM_fpage">15</span><span class="NLM_x">–</span> <span class="NLM_lpage">27</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=199&publication_year=2008&pages=15-27&author=Z.+Nourianauthor=T.+Mowauthor=D.+Mufticauthor=S.+Burekauthor=M.+L.+Pedersenauthor=J.+Matzauthor=M.+J.+Mulvany&title=Orthostatic+hypotensive+effect+of+antipsychotic+drugs+in+Wistar+rats+by+in+vivo+and+in+vitro+studies+of+alpha1-adrenoceptor+function"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNourian%26aufirst%3DZ.%26aulast%3DMow%26aufirst%3DT.%26aulast%3DMuftic%26aufirst%3DD.%26aulast%3DBurek%26aufirst%3DS.%26aulast%3DPedersen%26aufirst%3DM.%2BL.%26aulast%3DMatz%26aufirst%3DJ.%26aulast%3DMulvany%26aufirst%3DM.%2BJ.%26atitle%3DOrthostatic%2520hypotensive%2520effect%2520of%2520antipsychotic%2520drugs%2520in%2520Wistar%2520rats%2520by%2520in%2520vivo%2520and%2520in%2520vitro%2520studies%2520of%2520alpha1-adrenoceptor%2520function%26jtitle%3DPsychopharmacology%26date%3D2008%26volume%3D199%26spage%3D15%26epage%3D27" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Ancoli-Israel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vanover, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiner, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Kammen, D. P.</span><span> </span><span class="NLM_article-title">Pimavanserin tartrate, a 5-HT<sub>2A</sub> receptor inverse agonist, increases slow wave sleep as measured by polysomnography in healthy adult volunteers</span> <span class="citation_source-journal">Sleep Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">134</span><span class="NLM_x">–</span> <span class="NLM_lpage">141</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Fjm401958n&amp;key=10.1016%2Fj.sleep.2010.10.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Fjm401958n&amp;key=21256805" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Fjm401958n&amp;key=1%3ACAS%3A280%3ADC%252BC3M7msVSgsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2011&pages=134-141&author=S.+Ancoli-Israelauthor=K.+E.+Vanoverauthor=D.+M.+Weinerauthor=R.+E.+Davisauthor=D.+P.+van+Kammen&title=Pimavanserin+tartrate%2C+a+5-HT2A+receptor+inverse+agonist%2C+increases+slow+wave+sleep+as+measured+by+polysomnography+in+healthy+adult+volunteers"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Pimavanserin tartrate, a 5-HT(2A) receptor inverse agonist, increases slow wave sleep as measured by polysomnography in healthy adult volunteers</span></div><div class="casAuthors">Ancoli-Israel Sonia; Vanover Kimberly E; Weiner David M; Davis Robert E; van Kammen Daniel P</div><div class="citationInfo"><span class="NLM_cas:title">Sleep medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">134-41</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVE:  Determine the effects of pimavanserin tartrate [ACP-103; N-(4-flurophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl)carbamide], a selective serotonin 5-HT(2A) receptor inverse agonist, on slow wave sleep (SWS), other sleep parameters, and attention/vigilance.  METHODS:  Forty-five healthy adults were randomized to pimavanserin (1, 2.5, 5, or 20 mg) or placebo in a double-blind fashion (n=9/group).  Pimavanserin or placebo was administered once daily in the morning for 13 consecutive days.  The effects of pimavanserin were measured after the first dose and again after 13 days.  Sleep parameters were measured by polysomnography.  Effects on attention/vigilance were measured by a continuous performance task.  RESULTS:  Compared to placebo, pimavanserin significantly increased SWS following single and multiple dose administration.  Pimavanserin also decreased number of awakenings.  PSG variables not affected by pimavanserin included sleep period time, total sleep time, sleep onset latency, number of stage shifts, total time awake, early morning wake, and microarousal index.  Changes in sleep architecture parameters, sleep profile parameters, and spectral power density parameters were consistent with a selective increase in SWS.  Pimavanserin did not adversely affect performance on the continuous performance test measured in the evening before or morning after polysomnography.  CONCLUSIONS:  These data suggest that pimavanserin selectively increases slow wave sleep and decreases awakenings, an effect that does not diminish with repeated administration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSDDABm1ytk_xpyrDyM_m9cfW6udTcc2eY5I0SHi6UxYbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3M7msVSgsA%253D%253D&md5=0d59959b886b750a8fd987595ebfbe29</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.sleep.2010.10.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.sleep.2010.10.004%26sid%3Dliteratum%253Aachs%26aulast%3DAncoli-Israel%26aufirst%3DS.%26aulast%3DVanover%26aufirst%3DK.%2BE.%26aulast%3DWeiner%26aufirst%3DD.%2BM.%26aulast%3DDavis%26aufirst%3DR.%2BE.%26aulast%3Dvan%2BKammen%26aufirst%3DD.%2BP.%26atitle%3DPimavanserin%2520tartrate%252C%2520a%25205-HT2A%2520receptor%2520inverse%2520agonist%252C%2520increases%2520slow%2520wave%2520sleep%2520as%2520measured%2520by%2520polysomnography%2520in%2520healthy%2520adult%2520volunteers%26jtitle%3DSleep%2520Med.%26date%3D2011%26volume%3D12%26spage%3D134%26epage%3D141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Porter, R. H. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benwell, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malcolm, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allen, N. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Revell, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheardown, M. J.</span><span> </span><span class="NLM_article-title">Functional characterization of agonists at recombinant human 5-HT<sub>2A</sub>, 5-HT<sub>2B</sub> and 5-HT<sub>2C</sub> receptors in CHO-K1 cells</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">128</span><span class="NLM_x">, </span> <span class="NLM_fpage">13</span><span class="NLM_x">–</span> <span class="NLM_lpage">20</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Fjm401958n&amp;key=10.1038%2Fsj.bjp.0702751" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Fjm401958n&amp;key=10498829" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Fjm401958n&amp;key=1%3ACAS%3A528%3ADyaK1MXmt1Squrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=1999&pages=13-20&author=R.+H.+P.+Porterauthor=K.+R.+Benwellauthor=H.+Lamauthor=C.+S.+Malcolmauthor=N.+H.+Allenauthor=D.+F.+Revellauthor=D.+R.+Adamsauthor=M.+J.+Sheardown&title=Functional+characterization+of+agonists+at+recombinant+human+5-HT2A%2C+5-HT2B+and+5-HT2C+receptors+in+CHO-K1+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Functional characterization of agonists at recombinant human 5-HT2A, 5-HT2B and 5-HT2C receptors in CHO-K1 cells</span></div><div class="casAuthors">Porter, R. H. P.; Benwell, K. R.; Lamb, H.; Malcolm, C. S.; Allen, N. H.; Revell, D. F.; Adams, D. R.; Sheardown, M. J.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">128</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">13-20</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Stockton Press</span>)
        </div><div class="casAbstract">The goal of this study was to characterize the agonist pharmacol. of human 5-HT2A, 5-HT2B and 5-HT2C (VSV) receptors expressed in CHO-K1 (Chinese hamster ovary) cells.  We used a fluorometric imaging plate reader (FLIPR) which allows rapid detection of rises in intracellular calcium levels upon the addn. of agonists.  Stimulation of all three receptors by 5-HT caused a robust concn. dependent increase in intracellular calcium levels.  No such effect was obsd. from non-transfected control CHO-K1 cells.  The rank order of potency of agonists at the different receptor subtypes varied.  Tryptamines, BW-723C86, d-norfenfluramine, Ro 60-0175 and LSD exhibited the following rank order of potency; 5-HT2B>5-HT2C>5-HT2A.  Piperazines such as m-chlorophenylpiperazine (mCPP), ORG-12962, MK-212 and also ORG-37684 exhibited a rank order of potency of 5-HT2C>5-HT2B>5-HT2A.  The phenylisopropylamines DOI and DOB had a rank order of 5-HT2A>5-HT2B>5-HT2C.  Many agonists tested had partial agonist actions when compared to 5-HT, and a wide range of relative efficacies were exhibited, which was cell line dependent.  For example, mCPP had a relative efficacy of 65% at 5-HT2C receptors but <25% at either 5-HT2A or 5-HT2B receptors.  Interpretation of literature values of functional assays using different cell lines, different receptor expression levels and different receptor isoforms, is complex.  Species differences and the previous use of antagonist radioligands to characterize agonist potency in binding assays emphasizes the importance of studying agonists in the same expt. using the same assay conditions and parental cell lines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgNDFqRrlEtbVg90H21EOLACvtfcHk0lj9Ap65-HoZNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXmt1Squrg%253D&md5=ff33f4122999f10960865e75161179ca</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjp.0702751&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjp.0702751%26sid%3Dliteratum%253Aachs%26aulast%3DPorter%26aufirst%3DR.%2BH.%2BP.%26aulast%3DBenwell%26aufirst%3DK.%2BR.%26aulast%3DLam%26aufirst%3DH.%26aulast%3DMalcolm%26aufirst%3DC.%2BS.%26aulast%3DAllen%26aufirst%3DN.%2BH.%26aulast%3DRevell%26aufirst%3DD.%2BF.%26aulast%3DAdams%26aufirst%3DD.%2BR.%26aulast%3DSheardown%26aufirst%3DM.%2BJ.%26atitle%3DFunctional%2520characterization%2520of%2520agonists%2520at%2520recombinant%2520human%25205-HT2A%252C%25205-HT2B%2520and%25205-HT2C%2520receptors%2520in%2520CHO-K1%2520cells%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D1999%26volume%3D128%26spage%3D13%26epage%3D20" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Conn, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanders-Bush, E.</span><span> </span><span class="NLM_article-title">Selective 5-HT-2 antagonists inhibit serotonin stimulated phosphatidylinositol metabolism in cerebral cortex</span> <span class="citation_source-journal">Neuropharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1984</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">993</span><span class="NLM_x">–</span> <span class="NLM_lpage">996</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=1984&pages=993-996&author=P.+J.+Connauthor=E.+Sanders-Bush&title=Selective+5-HT-2+antagonists+inhibit+serotonin+stimulated+phosphatidylinositol+metabolism+in+cerebral+cortex"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DConn%26aufirst%3DP.%2BJ.%26aulast%3DSanders-Bush%26aufirst%3DE.%26atitle%3DSelective%25205-HT-2%2520antagonists%2520inhibit%2520serotonin%2520stimulated%2520phosphatidylinositol%2520metabolism%2520in%2520cerebral%2520cortex%26jtitle%3DNeuropharmacology%26date%3D1984%26volume%3D23%26spage%3D993%26epage%3D996" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Koval, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kopein, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Purvanov, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katanaev, V. L.</span><span> </span><span class="NLM_article-title">Europium-labeled GTP as a general nonradioactive substitute for [<sup>35</sup>S]GTPγS in high-throughput G protein studies</span> <span class="citation_source-journal">Anal. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">397</span><span class="NLM_x">, </span> <span class="NLM_fpage">202</span><span class="NLM_x">–</span> <span class="NLM_lpage">207</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=397&publication_year=2010&pages=202-207&author=A.+Kovalauthor=D.+Kopeinauthor=V.+Purvanovauthor=V.+L.+Katanaev&title=Europium-labeled+GTP+as+a+general+nonradioactive+substitute+for+%5B35S%5DGTP%CE%B3S+in+high-throughput+G+protein+studies"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKoval%26aufirst%3DA.%26aulast%3DKopein%26aufirst%3DD.%26aulast%3DPurvanov%26aufirst%3DV.%26aulast%3DKatanaev%26aufirst%3DV.%2BL.%26atitle%3DEuropium-labeled%2520GTP%2520as%2520a%2520general%2520nonradioactive%2520substitute%2520for%2520%255B35S%255DGTP%25CE%25B3S%2520in%2520high-throughput%2520G%2520protein%2520studies%26jtitle%3DAnal.%2520Biochem.%26date%3D2010%26volume%3D397%26spage%3D202%26epage%3D207" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Malick, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doren, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barnett, A.</span><span> </span><span class="NLM_article-title">Quipazine-induced head-twitch in mice</span> <span class="citation_source-journal">Pharmacol., Biochem. Behav.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1977</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">325</span><span class="NLM_x">–</span> <span class="NLM_lpage">329</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1977&pages=325-329&author=J.+B.+Malickauthor=E.+Dorenauthor=A.+Barnett&title=Quipazine-induced+head-twitch+in+mice"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMalick%26aufirst%3DJ.%2BB.%26aulast%3DDoren%26aufirst%3DE.%26aulast%3DBarnett%26aufirst%3DA.%26atitle%3DQuipazine-induced%2520head-twitch%2520in%2520mice%26jtitle%3DPharmacol.%252C%2520Biochem.%2520Behav.%26date%3D1977%26volume%3D6%26spage%3D325%26epage%3D329" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Wadenberg, M. L. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hicks, P. B.</span><span> </span><span class="NLM_article-title">The conditioned avoidance response test re-evaluated: is it a sensitive test for the detection of potentially atypical antipsychotics?</span> <span class="citation_source-journal">Neurosci. Biobehav. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">851</span><span class="NLM_x">–</span> <span class="NLM_lpage">862</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=1999&pages=851-862&author=M.+L.+G.+Wadenbergauthor=P.+B.+Hicks&title=The+conditioned+avoidance+response+test+re-evaluated%3A+is+it+a+sensitive+test+for+the+detection+of+potentially+atypical+antipsychotics%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWadenberg%26aufirst%3DM.%2BL.%2BG.%26aulast%3DHicks%26aufirst%3DP.%2BB.%26atitle%3DThe%2520conditioned%2520avoidance%2520response%2520test%2520re-evaluated%253A%2520is%2520it%2520a%2520sensitive%2520test%2520for%2520the%2520detection%2520of%2520potentially%2520atypical%2520antipsychotics%253F%26jtitle%3DNeurosci.%2520Biobehav.%2520Rev.%26date%3D1999%26volume%3D23%26spage%3D851%26epage%3D862" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Arnt, J.</span><span> </span><span class="NLM_article-title">Pharmacological specificity of conditioned avoidance response inhibition in rats: inhibition by neuroleptics and correlation to dopamine receptor blockade</span> <span class="citation_source-journal">Acta Pharmacol. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1982</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">321</span><span class="NLM_x">–</span> <span class="NLM_lpage">329</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Fjm401958n&amp;key=10.1111%2Fj.1600-0773.1982.tb01032.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Fjm401958n&amp;key=6129770" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Fjm401958n&amp;key=1%3ACAS%3A528%3ADyaL3sXmsFehug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=1982&pages=321-329&author=J.+Arnt&title=Pharmacological+specificity+of+conditioned+avoidance+response+inhibition+in+rats%3A+inhibition+by+neuroleptics+and+correlation+to+dopamine+receptor+blockade"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological specificity of conditioned avoidance response inhibition in rats:  inhibition by neuroleptics and correlation to dopamine receptor blockade</span></div><div class="casAuthors">Arnt, Joern</div><div class="citationInfo"><span class="NLM_cas:title">Acta Pharmacologica et Toxicologica</span>
        (<span class="NLM_cas:date">1982</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">321-9</span>CODEN:
                <span class="NLM_cas:coden">APTOA6</span>;
        ISSN:<span class="NLM_cas:issn">0001-6683</span>.
    </div><div class="casAbstract">The inhibitory effect of 36 neuroleptic compds. on conditioned avoidance response (CAR) and unconditioned escape response (UER) has been studied in rats.  All neuroleptics antagonized CAR in doses below those inhibiting UER and below those inducing catalepsy.  Stereospecificity was shown in 2 cases.  Significant correlation was found between CAR inhibitory and cataleptogenic potency.  Also inhibition of amphetamine-induced stereotypy, affinity to 3H-haloperidol binding in vitro, and clin. potency was significantly correlated to CAR inhibition.  CAR and UER inhibition induced by cis(Z)-flupentixol (I)  [53772-82-0] and haloperidol  [52-86-8] was attenuated by scopolamine, but was only weakly influenced by methysergide and prazosin.  Among a wide range of other CNS active compds. tested, CAR was inhibited by α1-adrenergic antagonists, benzodiazepines, a barbiturate, GABA agonists, morphine, and a serotonin agonist, but in doses inducing other motor disturbances.  Thus, CAR inhibition is a sensitive test for dopamine receptor antagonists.  However, addnl. α-adrenergic activity found for some neuroleptics (e.g. clozapine  [5786-21-0], chlorprothixene  [113-59-7]) may contribute to the CAR inhibitory potency.  Addnl. antimuscarinic activity of neuroleptics may moderately attenuate CAR inhibition whereas serotonin receptor blockade is of minor importance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcjmAjdj8YybVg90H21EOLACvtfcHk0lj9Ap65-HoZNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3sXmsFehug%253D%253D&md5=3c6a8cdc6e90e5a481b017c61b84d39c</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1111%2Fj.1600-0773.1982.tb01032.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1600-0773.1982.tb01032.x%26sid%3Dliteratum%253Aachs%26aulast%3DArnt%26aufirst%3DJ.%26atitle%3DPharmacological%2520specificity%2520of%2520conditioned%2520avoidance%2520response%2520inhibition%2520in%2520rats%253A%2520inhibition%2520by%2520neuroleptics%2520and%2520correlation%2520to%2520dopamine%2520receptor%2520blockade%26jtitle%3DActa%2520Pharmacol.%2520Toxicol.%26date%3D1982%26volume%3D51%26spage%3D321%26epage%3D329" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Snyder, G. L.; Vanover, K. E.; Zhu, H.; Miller, D. B.; O’Callaghan, J. P.; Tomesch, J.; Li, P.; Zhang, Q.; Krishnan, V.; Hendrick, J. P.; Nestler, E. J.; Davis, R. E.; Wennogle, L. P.; Mates, S.</span> unpublished results.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Snyder%2C+G.+L.%3B+Vanover%2C+K.+E.%3B+Zhu%2C+H.%3B+Miller%2C+D.+B.%3B+O%E2%80%99Callaghan%2C+J.+P.%3B+Tomesch%2C+J.%3B+Li%2C+P.%3B+Zhang%2C+Q.%3B+Krishnan%2C+V.%3B+Hendrick%2C+J.+P.%3B+Nestler%2C+E.+J.%3B+Davis%2C+R.+E.%3B+Wennogle%2C+L.+P.%3B+Mates%2C+S.+unpublished+results."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dunpublished%26sid%3Dliteratum%253Aachs%26aulast%3DSnyder%26aufirst%3DG.%2BL." title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Snyder, G. L.; Vanover, K. E.</span><span> </span><span class="NLM_article-title">Intracellular signaling and approaches to the treatment of schizophrenia and associated cognitive impairment</span>.  <span class="citation_source-journal">Curr. Pharm. Des.</span><span class="NLM_month">December</span><span class="NLM_day">15</span>,<span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span>DOI: <span class="refDoi"> DOI: 10.2174/1381612819666131216115417</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Fjm401958n&amp;key=10.2174%2F1381612819666131216115417" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=G.+L.+Snyder&author=K.+E.+Vanover&title=Intracellular+signaling+and+approaches+to+the+treatment+of+schizophrenia+and+associated+cognitive+impairment&doi=10.2174%2F1381612819666131216115417"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.2174%2F1381612819666131216115417&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1381612819666131216115417%26sid%3Dliteratum%253Aachs%26aulast%3DSnyder%26aufirst%3DG.%2BL.%26atitle%3DIntracellular%2520signaling%2520and%2520approaches%2520to%2520the%2520treatment%2520of%2520schizophrenia%2520and%2520associated%2520cognitive%2520impairment%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2013%26doi%3D10.2174%2F1381612819666131216115417" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i42"><a href="/doi/suppl/10.1021/jm401958n">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_83353"></div></div></div></div></div><hr /></hr><p class="last">Synthesis and analytical data of intermediates and final compounds not listed in the <a class="ref internalNav" href="#sec5">Experimental Section</a>, receptor profiling results, in vitro binding assays, and homology modeling and docking studies. This material is available free of charge via the Internet at <a class="extLink" href="http://pubs.acs.org">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm401958n/suppl_file/jm401958n_si_001.pdf">jm401958n_si_001.pdf (575.34 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm401958n&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2014.57.issue-6%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Fjm401958n%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm401958n" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                579KB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679921f9bef53d76","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
